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Background: Polypharmacy, the excessive use of prescription drugs, is a growing worldwide phenomenon, 
especially among older adults. There is no consensus among clinical communities regarding how many drugs 
are too many. In general, a threshold of five or more drugs is used to define polypharmacy because it has been 
shown to correlate with an increased risk of adverse effects and mortality. Polypharmacy exposes individuals to 
increased risk of adverse effects, drug interactions, and adverse clinical outcomes such as falls, frailty, and 
mortality.  This is a special challenge among older adults, who have less metabolic reserve and may be more 
susceptible to drug risks. Because public resources are often spent to provide or subsidize older adults' 
pharmaceutical treatments, polypharmacy is also a matter of appropriate management and rational use of public 
resources. These questions are especially relevant in the context of low-and middle-income countries, where the 
demands of rapidly growing aging populations pose significant burden on public health systems, but where 
scarce resources are divided between multiple sources of disease burden such as maternal-child conditions, 
infectious disease and other critical needs.  
 
Aims: In this study, we examine the occurrence of polypharmacy among older adults living in Sao Paulo, 
Brazil. We explore temporal trends in polypharmacy over a period of 10 years and geographic variations in the 
prevalence of polypharmacy across Sao Paulo's thirty administrative areas. We investigate the extent to which 
polypharmacy is associated with increased risk of drug-related problems in this context and we investigate 
possible determinants at the individual, community, and health system's levels.   
 
Methods: We combine individual-level data from a survey of older adults age 60 years and over living in the 
community in Sao Paulo (the SABE Study) with data from official government sources to implement multi-
level latent variable mixed-effects analytical models in order to estimate the association between polypharmacy 
and community and health systems factors while controlling for individual characteristics. 
 
Results: The prevalence of polypharmacy among Sao Paulo older adults doubled from 16% to 38% in the 10-
year period. Drug risk was frequent, and strongly associated with higher numbers of drugs per day. About two-
thirds of people with polypharmacy were exposed to some form of risk. Levels of inappropriateness among 




increase. Polypharmacy was associated with having greater number of chronic diseases, being in worse health, 
using greater levels of health services, being older, and being female. There was significant geographic variation 
in polypharmacy across areas. Individual characteristics explained most, about 25%, of the variation in drug 
utilization. At the health system level, polypharmacy was associated with Presence of hospitals, higher number 
of private pharmacies, and higher enrollment in the family health program after controlling for individual 
characteristics. Having private health insurance did not change the likelihood of polypharmacy, but living in an 
area with higher health insurance coverage greatly increased the likelihood of polypharmacy. Higher number of 
doctors in the public health system was associated with lower polypharmacy. Polypharmacy is likely a 
combination of patient preferences and health need, as well as provider practices, and the constraints and 
limitations of the health system where they interact.  
 
Conclusion: polypharmacy among older adults should be a matter of public health concern in Sao Paulo. 
Understanding that not all polypharmacy is driven by need is important in order to devise strategies to improve 
monitoring and provide opportunities for review and discontinuation of treatments. Policies to reduce drug risk 








It was a typical day in Hospital de Clinicas, the public hospital in Southern Brazil where I trained as a 
neurologist. Carmela was coming to see us for a long-standing hand tremor that made her life very challenging. 
Carmela was taking more than ten different drugs every day to treat a multitude of health problems. I found that 
Carmela's tremor was caused by one of the drugs she was taking, which she should stop immediately. Carmela 
was surprised and hesitant. She had been taking these drugs for many years. It was the first time in her life that a 
doctor said she should stop taking medications instead of prescribing more of them.  
 
Patients like Carmela were very common. In the booming Brazilian economy, with its thriving generic industry 
and its government programs providing improved access to medicines, patients like Carmela were increasingly 
able to access medications and unfortunately many of them got on polypharmacy regimens. Because of the 
fragmented medical care system, polypharmacy received little monitoring.  
 
Once I completed my clinical training I was working with a team of policy-makers at the state health 
administration championing appropriate access to medicines. The experience of patients like Carmela convinced 
me that increasing drug access without adequate monitoring was wasteful of health resources, provided an 
unnecessary financial burden on patients and families, and could lead to adverse outcomes. 
 
I came to the Doctoral program in International Health - Health Systems at Johns Hopkins committed to 
researching ways to safeguard sustainable and qualified access to medical treatment for individuals with chronic 
diseases in low- and middle-income countries. With this dissertation, my main goal is to contribute to clarifying 
the drivers and potential solutions of growing pharmaceutical use among older Brazilian adults. Ultimately, I 
hope this work contributes to inform public health policies aimed at mitigating the risk from polypharmacy and 
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1. CHAPTER I: INTRODUCTION AND BACKGROUND 
 
1.1 INTRODUCTION 
Polypharmacy, the excessive use of prescription drugs, is a growing worldwide phenomenon, especially among 
older adults. There is no consensus among clinical communities regarding how many drugs are too many. 
Clearly, there are patient circumstances that will determine the need for certain drugs. Studies have also shown 
that provider characteristics and the availability and type of health insurance can influence the number of drugs 
prescribed. In general, a threshold of five or more drugs is used because it has been shown to correlate with an 
increased risk of adverse effects and mortality. Polypharmacy exposes individuals to increased risk of drug-
related problems such as adverse effects and drug interactions, as well as adverse clinical outcomes such as falls, 
frailty, cognitive impairment and mortality.  This is a special challenge among older adults, who have less 
metabolic reserve and may be more susceptible to drug risks. Mismanagement of drug-related problems may 
result in more drugs being prescribed, compounding the risks without adding benefits. Depending on level and 
type of health insurance benefits, polypharmacy may use up financial resources, which can be especially 
burdensome for older adults, who generally have fixed incomes.  
 
Because public resources are often spent to provide older adults' drug treatments, polypharmacy is also a matter 
of appropriate management and rational use of public resources. These questions are especially relevant in the 
context of low-and middle-income countries (LMICs), where the demands of rapidly growing aging populations 
pose significant burden on public health systems, but where scarce resources are divided between multiple 
sources of disease burden such as maternal-child conditions, infectious disease and other critical needs.  
 
In this study, we examine the occurrence of polypharmacy among older adults living in Sao Paulo, Brazil. We 
explore temporal trends in polypharmacy over a period of 10 years (2000-2010) and geographic variations in the 
prevalence of polypharmacy across the thirty administrative areas of the city of Sao Paulo (sub-prefectures). We 
investigate the extent to which polypharmacy is associated with increased risk of drug-related problems in this 




determinants at the individual and at the community level, including societal and health system characteristics.  
The objective is to provide evidence to support public health decision-making to mitigate the growing problem 
of polypharmacy. Identifying the main drivers of this phenomenon is of key importance to policy-makers who 
may want to develop strategies to mitigate it. 
 
1.2 BACKGROUND 
1.2.1 Policy Problem: Polypharmacy 
 
There is evidence from multiple countries around the world that people are taking medicines more often and in 
progressively higher quantities. Although there is no consensus regarding how many drugs constitute 
polypharmacy, it has been demonstrated that the concomitant use of five or more drugs per day exposes 
individuals to substantial risks regardless of the specific drugs involved (Gnjidic et al., 2012; Langeard et al., 
2016). Each individual drug that is added to a regimen has been associated with 7% increase in the odds of falls, 
8% increase in the odds of disability, 13% increase in the odds of frailty and 9% increase in the odds of 
mortality (Gnjidic et al., 2012). Regimens of five or more have been found to be a sensitive and specific marker 
of increased risk of physical and cognitive impairments (Langeard et al., 2016). When the number of drugs per 
day reaches 10 or more it is usually considered excessive polypharmacy (Jyrkka, Enlund, Korhonen, Sulkava, & 
Hartikainen, 2009a).  
 
Polypharmacy may reflect the need to treat increasingly complex and multifactorial chronic conditions 
(Appleton, Abel, & Payne, 2014). Some diseases have multiple causative pathways and demand multiple drugs 
for their appropriate management. This is the case of cardiovascular disease, the most common cause of death of 
older adults in the world (Sepulveda & Murray, 2014). Other diseases occur in frequent combinations, each 
requiring a separate therapy (Aronson, 2004; Gurwitz, 2004).  
 
Polypharmacy has been associated with increased risk of adverse effects and drug interactions (Buck et al., 
2009; Doan, Zakrzewski-Jakubiak, Roy, Turgeon, & Tannenbaum, 2013; Routledge, O'Mahony, & Woodhouse, 
2004; Saedder, Lisby, Nielsen, Bonnerup, & Brock, 2015); clinical conditions such as frailty, falls, cognitive 




Hartikainen, 2011; Payne, Abel, Avery, Mercer, & Roland, 2014); avoidable hospitalizations, and increased 
mortality (Gomez et al., 2015; Richardson, Ananou, Lafortune, Brayne, & Matthews, 2011). Misdiagnosis of 
drug-induced problems may trigger the prescription of additional drugs instead of the discontinuation of the 
offending drug. The prescription of additional drugs to treat drug-induced conditions is called a prescription 
cascade and is a serious public health problem particularly associated with polypharmacy (Hunt, Kreiner, & 
Brody, 2012; Rochon & Gurwitz, 1997). 
 
High drug expenditures make polypharmacy a matter of concern for financial protection in health systems. 
Drugs tend to consume a significant proportion of household budgets (Cahir et al., 2010; Hovstadius & 
Petersson, 2013; Lima, Ribeiro, Acurcio Fde, Rozenfeld, & Klein, 2007; Lima-Costa, Barreto, & Giatti, 2003). 
Older adults tend to have lower incomes and tend to use more drugs, so the financial burden from drugs is of 
special concern among this population. In Brazil, drug expenditures among older adults amount to, on average, 
51% of the national minimal wage (Lima et al., 2007). Drug expenditures may deplete financial resources that 
older adults could otherwise use towards self-care, nutrition and other needs (Fang, Nicholas, & Silverman, 
2010).  
 
Polypharmacy also poses significant challenges to medication adherence and self-management. The chronic 
stress from taking drugs, disruptions to treatment adherence, and depletion of financial resources are non-drug-
related pathways through which polypharmacy may impact quality of life (Hovstadius & Petersson, 2011). 
  
Because public health resources are often employed to provide or subsidize pharmaceutical treatments for older 
adults, the growing use of polypharmacy among the older population is also a matter of concern to public health 
decision makers, as it poses questions about appropriate allocation of public health resources.  
 
 
1.2.2 Definition  
 
In this study we define polypharmacy as the use of five or more prescription or over-the-counter drugs per day. 






Most studies of polypharmacy include prescription and over-the-counter drugs in their analyses but do not 
include nutritional supplements, herbal, or homeopathic medicines. Our definition includes prescription and 
over-the-counter drugs that are both orally and topically administered (skin, ocular, otologic, or inhaled drugs). 
Our definition includes topical-use drugs because they add complexity to treatment regimens, and we assume 
these drugs can have systemic effects once they have been absorbed. 
 
We do not include does not include nutritional supplements, herbal, or homeopathic medicines in our analyses. 
These drugs are not standardized in terms of manufacturing practices and chemical composition, so that 
comparisons across these substances may not be reliable. We assume that the effect of polypharmacy was 
independent from herbal and homeopathic medicines.  
 
1.2.3 Inappropriate Polypharmacy 
 
All cases of polypharmacy are associated with increased drug-related risks because each drug adds a set of 
potential adverse effects and increases the risk of drug interactions (Buck et al., 2009; Doan et al., 2013; 
Saedder et al., 2015).  There are drugs and drug combinations, however, that are known to have a particularly 
undesirable risk profile. These drugs have been labeled "potentially inappropriate medications" or "potentially 
inappropriate prescriptions" (Fick et al., 2003).   
 
In our study we label as "inappropriate polypharmacy" the cases where an individual taking five or more drugs 
per day also meets at least one criterion for increased drug risk: a potentially inappropriate medication, a 
potential drug interaction, or increased risk of anticholinergic adverse effects. With this differentiation we aim to 
identify regimens that may be associated with higher risks than general cases of polypharmacy. Potentially 
inappropriate medications are drugs that should be avoided in all older individuals because they "pose 
unnecessarily high risk" (of adverse effects and drug-drug interactions) or are likely to be "ineffective" among 
this population (Fick et al., 2003). 1 There are additional drugs that are considered inappropriate only among 
                                                      
1 The definition of what constitutes an "older adult" varies across contexts. In developed countries it is usually accepted to be 65 years of 




persons with certain underlying medical conditions (Fick et al., 2003). However, these are outside of the scope 
of our study. In order to identify potentially inappropriate medications we use the 2012 update of the Beers 
Criteria, a tool that lists over a hundred drugs that should be avoided among older adults (American Geriatrics 
Society Beers Criteria Update Expert, 2012).2  All the tools used to define inappropriate polypharmacy in our 
study were developed specifically for the population of older adults and have been demonstrated to identify 
individuals at risk independently of whether any symptoms or signs have occurred. 
 
Drug interactions are defined as a situation in which there is a "clinically meaningful alteration in the effect of 
one drug as a result of co-administration of another (precipitant drug)" (Hines & Murphy, 2011).  Some drug 
interactions may be desirable, for example when the beneficial effects of a drug are enhanced by another. 
However, some interactions may reduce therapeutic effects or increase toxicity. Undesired drug interactions can 
have mild to severe clinical consequences, and their diagnosis is often challenging. A combination of drugs that 
is known to be associated with undesired effects is called a potential drug interaction and it is considered a 
matter of concern even if no symptoms have yet occurred (Hines & Murphy, 2011). In this study we use the 
Hines list, a tool that identifies seventeen drug combinations associated with increased risk of hospitalization or 
mortality among the elderly, to identify cases of potentially harmful DDIs (Hines & Murphy, 2011).  
 
Adverse drug effects are: "a response to a drug that is noxious and unintended and occurs at doses normally 
used for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function" 
(Edwards & Aronson, 2000). There are several mechanisms through which adverse effects occur. They may be 
dose-related (toxicity), non-dose-related (idiosyncratic), time- and dose-related (cumulative effects), time-
related (occurring some period after the use of the drug), withdrawal-related, or unexpected failure of the 
therapy (Davies, 1977; Edwards & Aronson, 2000). The severity of adverse effects can range from mild to very 
severe, including death.   
 
There is not one single definition of symptoms that constitute adverse effects. This is because what is considered 
an adverse effect in one context may be desirable in another. In this study we chose to focus on anticholinergic 
adverse effects. These symptoms are clinically diverse and can be very severe, especially among older 
                                                      




individuals. Also, anticholinergic adverse effects can be triggered by a wide variety of drugs used to treat 
diverse conditions and organ systems. 
 
Anticholinergic symptoms arise when drugs interfere with acetylcholine, a chemical messenger involved in 
many different pathways in most organ systems of the body. Examples of peripheral anticholinergic adverse 
effects are those related to reduce production of saliva and tears (dry eyes, dry mouth), or reduced movements of 
the gut and bladder (constipation, urinary retention). Examples of central anticholinergic adverse effects are 
somnolence, memory problems, confusion and inability to concentrate. Anticholinergic adverse effects may be 
very severe and may cause falls, severe cognitive decline, hallucinations, hospitalizations, and even death.  
 
In order to identify patients at risk for anticholinergic adverse effects in this study we utilize the Anticholinergic 
Risk Scale (ARS).  The ARS comprehends an extensive list of frequently used drugs that are assigned a score 
from zero (limited or no anticholinergic potential) to three (very strong anticholinergic potential) based on 
findings from the medical literature, from FDA records, and from the chemical activity on the anticholinergic 
receptor (Rudolph, Salow, Angelini, & McGlinchey, 2008). There are other tools to evaluate anticholinergic 
adverse effects, but we chose the ARS because it performs better to identify individuals at high risk of severe 
anticholinergic adverse effects such as impaired cognitive and functional performance (Pasina et al., 2013) 
 
1.2.4 Polypharmacy in Older Adults – Prevalence and Trends 
 
The growing pharmaceutical use among older adult populations has been more extensively documented in high-
income countries. Nevertheless, it may also be a concern for developing countries, whose populations are aging 
at a fast pace. In fact, growing use of pharmaceuticals may be of special concern for developing countries, 
because expanded access to medicines may not be accompanied by adequate drug regulations, monitoring and 
surveillance in these settings.  
 
Although the specific rates vary across studies, it is clear that a very high proportion of older adults take at least 
one medicine per day (Table 1.1). The prevalence of taking at least one medicine per day tends to be higher 




take at least one drug at a daily basis in Finland (Jyrkka et al., 2009a). The prevalence of polypharmacy varies 
across settings, age groups, and with different definitions of polypharmacy (different cutoff points and duration 
of the pharmaceutical use).  
 
In this section we focus on describing prevalence and trends in polypharmacy worldwide. We discuss the factors 
that may underlie these trends in later sections. 
 
Among persons age 65 and older, an estimated 29.5% took five drugs or more in France (an average rate 
between 1995 and 2004) (Bongue et al., 2009), 46% in Italy (Nobili et al., 2011), and 53% in the United States 
(Linton, Garber, Fagan, & Peterson, 2007). The prevalence of polypharmacy was 34% in Costa Rica among 
those 60 year-olds and over (Jiménez Herrera & Fernández Rojas, 2008). The rates of polypharmacy in studies 
from Asian countries stand out. In Korea as much as 86.4% of individuals 65 years and older took six drugs or 
more per day (Kim, Shin, Kim, & Park, 2014). In Taiwan, 81% of individuals 65 years and older in Taiwan took 
five or more drugs at some point during the last 12 months, and 32.5% were with polypharmacy for at least 6 
months of the year (Chan, Hao, & Wu, 2009).  
 
Excessive polypharmacy was present in 23% of older adults in Finland (Jyrkka et al., 2009a) and 38% in 
Taiwan (Chan et al., 2009)(both defined as ten or more drugs a day), and about 45% in Korea (defined as 11 or 
more drugs per day) (Kim et al., 2014)  
 
All studies that analyzed trends in drug use over time have found significant growth in the rates of 
polypharmacy (Table 1.1). Rates of change varied according to the population age, baseline values, and years 
studied.  Between 1990/91 and 1998/99 the rates of polypharmacy grew more than 30% among Finnish 
individuals aged 65 and over, from 19 to 25% (Linjakumpu et al., 2002). Between 2000 and 2010 there was over 
20% growth in polypharmacy rates among Italians of the same age group, from 42.8 to 52.7% (Franchi et al., 
2013). In Sweden, rates of growth in a period of three years were higher for excessive polypharmacy (15%) than 
for polypharmacy (4%), probably because of the markedly lower baseline prevalence of excessive 







Table 1.1 Studies that estimated point prevalence of polypharmacy among community-dwelling older adults 
Author, year Country  Year(s) 
data was 
collected 
Participants Prevalence Factors associated 
with polypharmacy 
Jyrkka, 2009 Finland 1998 Age ≥75 
N=535 
≥1 drug: 98%  
≥ 6 drugs: 57% 






Bongue, 2009 France 1995-2004 Age ≥65 
N>30,000 
≥1 drug: 84% 
≥5 drugs: 29.5% 
 
Chan, 2009 Taiwan 2001-2002 Age ≥651 
N=11,788 





≥5 drugs2:  32.5% 










Use of co-pays 
Jimenez-
Herrera, 2008 
Costa Rica 2004 Age ≥60 
N=2,820 
 
≥1 drug: 78.7% 




Place of residence 
(metropolitan area) 
Linton, 2015 USA 2004-2005 Age ≥65 
N>1.3 million 
≥1 drug: 77% 
≥5 drugs: 53% 
Female gender 
Qato, 2008 USA 2005-2006 Age 57-85 
N=2,976 
≥1 drug: 81% 
≥5 drugs: 29% 
Male gender 
Age 75-85 
Nobili, 2011 Italy 2005 Age ≥65 
N>1.8 million 
 
≥1 drug: 88% 
≥5 drugs: 46% 
Higher age 
Female gender 
Place of residence 
(clusters of higher 
prevalence) 
Kim, 2014 South 
Korea 
2010-2011 Age ≥65 
N>320,000 
 
≥6 drugs: 86.4% 









Notes: 1: not all the study population lived in the community. However, those living in the community had higher prevalence of 
polypharmacy than those institutionalized. All individuals had impairment in least one activity of daily living or an instrumental activity of 
daily living. 2: polypharmacy was the use of 5 or more drugs at any point of the year, and persistent polypharmacy was the use of 5 or more 







Table 1.2 Studies that estimated changes over time in prevalence of polypharmacy among older adults 
















≥5 drugs:  
19à25% 
avg. drugs 











88à 90.3%  
≥5 drugs:  
42.8 à 52.7% 
Higher age 
Female gender 
*Males had lower 
baseline prevalence 









76à 78%  
≥5 drugs:  
39.4 à 40.9% 
≥10 drugs:  
9.05 à 10.9% 
 
Higher age 
Men had greater 
rates of increase 
 
 
1.2.5 Polypharmacy in Older Adults - Geographic Variation  
 
Geographic variation analyses recognize that there may be significant differences in the prevalence of 
polypharmacy across areas at the subnational level. Geographic variation studies have helped identify the role of 
supply-side factors in influencing the utilization of polypharmacy (Table 1.3).  
 
Studies of geographic variations of polypharmacy at the small area/sub-national level have found differences in 
the prevalence of polypharmacy among older adults of up to 26% across areas (Franchi et al., 2013). In a same 
geographic area, polypharmacy rates tended to be highly correlated over time (Cashion et al., 2015; Franchi et 
al., 2013; Perry & Turner, 2001). Areas that stood out as clusters of high prevalence in a given year tended to 
remain the ones with highest prevalence even after a period of ten years – this was the case of Southern states in 






Table 1.3 Geographic variation studies of polypharmacy in older adults 







with higher rates of 
polypharmacy  









Higher age  
Female gender 
Higher income and 
education 
Southern region 
Number of physician 
visits was not 
associated when 




Sweden 2006 Entire population 














Poorer health of 
adult population (24-




education levels and 
higher number of 
doctors per 100,000 
population 









10% in 2000 
(0 - 10%) 
 
26.6% in 2010  
(0 - 26.6%) 
Strong correlation 
over time in 
prevalence for each 
area 2 
Low correlation with 
health status (deaths, 
hospitalization) 
Kim, 2014 South 
Korea 

























after controlling for 
gender, age, income, 
education, and 
comorbidities 
1: Chronic polypharmacy: "five or more drugs in 1 month for at least 6 months (consecutive or not) in a year". 2: the authors hypothesize 
that the correlation for the same area over time may be explained by some overlap in the patient population and/or by doctors maintaining 





1.2.6 Individual-Level Determinants of Polypharmacy  
 
Tables 1.1 and 1.2 display the studies that investigated the association between polypharmacy and individual 
characteristics. Gender was found to be associated with polypharmacy in virtually all studies, even after 
adjusting for confounders such as age and presence of chronic diseases. However, while most studies identified 
that females had more polypharmacy, some studies found that males were more likely to have polypharmacy 
(Chan et al., 2009; Kim et al., 2014; Qato et al., 2008). Interestingly, two of the studies that found higher 
prevalence of polypharmacy among males were from the Asian region (Chan et al., 2009; Kim et al., 2014). It is 
not clear why gender is associated with polypharmacy. Patterns of disease occurrence, care-seeking behavior, 
and beliefs and preferences related to acceptability of drug treatments are some of the underlying characteristics 
that could help explain the differences in polypharmacy observed across genders. Women are more likely to live 
to older ages and are more likely to have chronic diseases, including multi-comorbidities(Miilunpalo, Vuori, 
Oja, Pasanen, & Urponen, 1997). Women are more likely to seek care, and could also be more likely to accept 
and to adhere to pharmaceutical treatments, or even to self-medicate (Miilunpalo et al., 1997).  
 
Age was associated with polypharmacy across the multiple studies, even after adjusting for other variables. 
Because higher age is strongly associated with greater prevalence of chronic conditions, as well as higher rates 
of functional limitations, it is important to control for these conditions when investigating the association 
between age and polypharmacy. Some studies found that any increases in age were associated with greater 
polypharmacy (Franchi et al., 2013; Hovstadius, Astrand, & Petersson, 2010; Hovstadius, Hovstadius, et al., 
2010; Jiménez Herrera & Fernández Rojas, 2008; Linjakumpu et al., 2002; Nobili et al., 2011). Others found 
that specific age ranges, either at the middle or at the higher end of the age distribution, were most at risk 
(Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 2009b; Kim et al., 2014; Qato et al., 2008). One study 
found higher polypharmacy in the relatively younger age group (Chan et al., 2009).  
 
Poorer health was measured in different ways across studies: higher number of comorbidities (Chan et al., 2009; 
Jiménez Herrera & Fernández Rojas, 2008; Jyrkka et al., 2009b; Kim et al., 2014), worse perceived health status 
(Jyrkka et al., 2009b; Linjakumpu et al., 2002), and increased disability (Chan et al., 2009). All the different 
metrics of poor health were associated with greater polypharmacy. These results indicate that, from a population 




demand-side drivers of polypharmacy. Although it is not clear whether these factors act independently from 
each other or whether they may modify each other's associations.  
 
Other findings suggest that factors beyond the individual level may independently affect the likelihood of 
polypharmacy. Polypharmacy was associated with having supplemental private health insurance and higher 
health care utilization (Kim et al., 2014) and seeking a greater number of different health providers (Chan et al., 
2009). Place of residence (urban and metropolitan areas) was also an independent predictor of polypharmacy 
(Chan et al., 2009; Jiménez Herrera & Fernández Rojas, 2008). These findings suggest that characteristics at the 
community and the health system's levels may play an independent role in determining polypharmacy 
 
1.2.7 Community-Level Determinants of Polypharmacy  
 
At the community (area) level,3 the findings from the geographic variation studies (Table 1.3) were similar to 
the individual-level determinants described above (Tables 1.1 and 1.2). Communities with higher concentration 
of older adults (Hovstadius, Astrand, et al., 2010; Perry & Turner, 2001), with lower levels of health status 
(Cashion et al., 2015; Franchi et al., 2013; Hovstadius, Astrand, et al., 2010), and where a higher percentage of 
individuals were women (Cashion et al., 2015; Perry & Turner, 2001) tended to have greater polypharmacy. 
Most studies that investigated community-level characteristics utilized aggregated data only. Therefore, this 
evidence could simply reflect the aggregated experiences of the individuals living in a community. 
 
In addition, communities with higher income and education levels (Cashion et al., 2015; Perry & Turner, 2001) 
tended to have higher polypharmacy – although one study found that communities with higher education levels 
tended to have lower polypharmacy (Hovstadius, Astrand, et al., 2010). The instability of these and other factors 
suggests that other factors or pathways may be at play, and that studies that find these associations may be 
incomplete models of a more complex reality. When interpreting these findings is important to consider that 
these associations do not imply causation or underlying mechanisms. 
                                                      







1.2.8 Health Systems Determinants of Polypharmacy 
 
The association between polypharmacy and health systems factors was unclear in the studies that we reviewed 
(Table 1.3). The main health system factor investigated was the utilization of medical care (doctor visits). One 
study found a strong correlation between greater number of medical visits and polypharmacy, independently 
from individual factors (Kim et al., 2014). Another study did not find an association between polypharmacy and 
greater utilization of medical visits when controlling for individual factors (Perry & Turner, 2001).  The other 
health system characteristic examined was the number of doctors that worked in each area. Higher number of 
doctors was found to be correlated with lower polypharmacy (Hovstadius, Astrand, et al., 2010). We turn to the 
larger literature on geographic variation of health care utilization and health spending to identify the factors at 
the health system level that should be examined in order to better understand the supply-side drivers of 
polypharmacy.  
 
1.2.9 Health Systems Determinants of Health Care Utilization 
 
Significant geographic variations in health care utilization and spending have been demonstrated since the late 
1960’s (J. E. Wennberg, 2014; J. Wennberg & Gittelsohn, 1973). It has since become a consensus that 
geographic variations in health care utilization and spending are not entirely explained by population 
characteristics and underlying health needs (Medicine, 2013). Among older adults in the United States patient 
health status explained less than a third (29%) of area-level differences in total health spending (Zuckerman, 
Waidmann, Berenson, & Hadley, 2010). A study of patient preferences found that patient characteristics such as 
income and health explained 12% of the variation in spending; patient preferences explained an additional 5%. 
Added together, patient characteristics accounted for 17% of the variation (Baker, Bundorf, & Kessler, 2014).  
 
Studies have found that supply-side factors explained a larger proportion of the geographic variation in health 
care utilization and spending (Cutler, Skinner, Stern, & Wennberg, 2013; J. E. Wennberg, 2014; J. Wennberg & 
Gittelsohn, 1973; Zuckerman et al., 2010). Health systems factors such as the number of physicians, physician 




beneficiaries in the United States4 (Baker et al., 2014). Physician characteristics alone (physician beliefs, 
preferences and prescription patterns) explained 17% of variation in health spending in Medicare (Cutler et al., 
2013). Physician mix (the type of specialty) was found to be independently associated with service utilization, 
indicating patterns of supply-induced demand (J. Wennberg & Gittelsohn, 1973). Type of health insurance plans 
were not found to be associated with health utilization and spending (Medicine, 2013). 
 
A study of geographic variation in the use of psychiatric drugs in the United States found that 50-60% of the 
variation was explained by health systems factors: higher access to care (as measured by the number of 
physicians), higher insurance coverage, and pharmaceutical marketing efforts (as measured by dollars spent in 
advertising) (King & Essick, 2013). Studies of other, non-polypharmacy forms of drug utilization may help 
shine a light on what may be the relevant health systems factors that should be considered when investigating 
the determinants of polypharmacy. 
 
In addition, geographic variation analyses of non-polypharmacy health outcomes indicate that there is a lack of 
correlation between the availability of health services and underlying population health needs (J. Wennberg & 
Gittelsohn, 1973). There is also a lack of correlation between health services utilizations or expenditures and 
health outcomes (Medicine, 2013).  
 
1.2.10 Prevalence and Determinants of Inappropriate Polypharmacy in Older Adults 
 
Population-level studies have found that, as measured by the Beers Criteria, inappropriate drug utilization was 
present in 31.9% of older adults age 65 years and over in the United States (Texas) (Holmes, Luo, Kuo, 
Baillargeon, & Goodwin, 2013) As measured by clinically relevant drug-drug interactions, inappropriate drug 
utilization was present in 29% of older adults 75 years and over in Sweden (Johnell, Fastbom, Rosen, & 
Leimanis, 2007).  
 
The main determinant of inappropriateness is the higher number of concomitant drugs. As measured by the 
Beers Criteria, the occurrence of inappropriateness among individuals 65 years and older in Texas was 2.5 times 
                                                      




greater among persons taking 6-8 drugs and 4.4 times greater among persons taking 9 or more drugs as 
compared to persons taking 1-5 drugs, all other things being equal (Holmes et al., 2013). As measured by 
clinically relevant drug-drug interactions, the occurrence of inappropriateness among individuals age 75 years 
and older in Sweden was 4 times higher among persons taking 5-7 drugs and over 45 times higher among 
persons taking 11 or more drugs when compared to those taking 1-4 drugs (Johnell et al., 2007). Other factors 
such as higher age, female gender, low education levels, living alone, and higher number of physician visits 
have been independently associated with inappropriateness (Bongue et al., 2009).  
 
1.3 CONTEXT   
1.3.1 Rationale for Investigating Polypharmacy in Brazil  
 
Few investigations have explored the occurrence of polypharmacy among older adults in LMICs.  
Polypharmacy may be an unrecognized problem in these countries.  
 
Brazil presents a perfect storm for the occurrence of polypharmacy - its fast aging population has growing rates 
of chronic diseases, increasing the demand for medicines (A. Palloni & McEniry, 2007); its recent economic 
growth has led to rising income levels, increasing the ability to pay for medicines (Branco, 2010); several 
government programs have been put in place to expand access to generics (Dias & Romano-Lieber, 2006) and 
to provide medicines for those who cannot afford them (Secretaria de Políticas de Saúde, 2000); and people 
have increasingly resorted to judicial courts to request medicines not covered or not timely provided by 
government programs5 (J. Biehl, Amon, Socal, & Petryna, 2012, 2016). 
 
In fact, Brazil has become the sixth largest country-level pharmaceutical market in the world, as measured by 
total expenditures on drugs. At around US$ 200 per capita per year, Brazil has largest spending on drugs than 
countries such as China, which is the world's second country-level pharmaceutical market (Informatics, 2014).  
                                                      
5 The growing phenomenon of "judicialization of health" has grown markedly in Brazil in the last decade. Individuals resort to courts to 
request access to medicines regardless of coverage by government formularies. Based on the constitutional right to health, judges grant 





1.3.2 Prevalence and Determinants of Polypharmacy in Brazil 
 
There have been several studies investigating drug utilization and polypharmacy among older adults in Brazil, 
producing various prevalence estimates (Table 1.4). It is possible that the difference between studies may be 
explained at least in part by differences in source populations and sampling mechanisms. However, some true 
differences may be present.  
 
After we discuss the conflicting results from studies with various sampling mechanisms, below we reason that 
differences in polypharmacy rates estimated by two large population-based studies in Brazil may reflect true 
geographic variations. We hypothesize that this finding is likely to be explained by both demand- and supply 
side differences across areas, and we propose that further geographic variation analyses should be conducted in 
order to clarify the role of individual and geographic level factors in determining polypharmacy in Brazil. 
 
When identifying and selecting a sample of individuals to participate in a survey, it is important to ensure that 
all eligible individuals have the same opportunity to participate, and that those who do participate are not 
systematically different from those who do not. Studies with non-random sampling mechanisms may have 
biased results. Selecting individuals who are systematically different from the general population may also 
introduce bias. Individuals who are part of health programs (Flores & Mengue, 2005; Mosegui, Rozenfeld, 
Veras, & Vianna, 1999), who live in the closer proximity to a health program (Marin et al., 2008), or who are 
healthier than the general population (Flores & Mengue, 2005; Mosegui et al., 1999; Torres Faggiani et al., 
2007) may have systematically different factors determining their need and influencing access to polypharmacy 
as compared to the general population. Lastly, studies with very low sample sizes may have great levels of 
uncertainty around their estimates (Flores, 2005; Coelho-Filho, 2004; Torres-Fagiani, 2007; Marin, 2008).  
 
From the studies below (Table 1.4) it seems that studies that selected individuals in a non-randomize), studies 
that explicitly selected healthier individuals, and studies that selected individuals with greater access to care 
tended to find higher rates of polypharmacy than studies of the overall population (the highest rates of 




fourth highest rate as well = 25.2% in Marin, 2008). Studies with very low sample sizes did have great levels of 
uncertainty around their estimates  (Coelho Filho, Marcopito, & Castelo, 2004; Flores & Mengue, 2005; Marin 
et al., 2008; Torres Faggiani et al., 2007).  
 
In our assessment, only two of the reviewed studies were likely to have adequately estimated the prevalence of 
polypharmacy in the general population (Loyola Filho, Uchoa, Firmo Jde, & Lima-Costa, 2005; Loyola Filho, 
Uchoa, & Lima-Costa, 2006). These studies are highlighted in grey on Table 1.4 and have strikingly different 
prevalence estimates.   
 
Each of these studies examined the population of older adults aged 60 and over in a different Brazilian 
municipality. The two municipalities were located in the same state, about a mere 170 miles apart. While one of 
the studies implemented a multi-stage sampling process to ensure that its sample was representative of all older 
adults in the municipality (Loyola Filho et al., 2006), the other examined all persons aged 60 and over in the 
area (Loyola Filho et al., 2005).  
 
In the municipality with a large and predominantly urban population, the prevalence of polypharmacy among 
persons 60 years old and over was 14.3% in 2003 (Loyola Filho et al., 2006). In the municipality with the 
smaller and predominantly rural population, the prevalence of polypharmacy among persons 60 years old and 
over was 25.5% in 1997 (Loyola Filho et al., 2005).  
 
It is likely that the estimates reflect true differences in the prevalence of polypharmacy across geographic areas 
in Brazil. This finding poses a small-area-variation problem similar to differences in health service utilization 
identified in other settings (J. Wennberg & Gittelsohn, 1973). The expansive literature on geographic variation 
analyses of health care utilization6 indicates that most of the variation across areas tends to be explained by 
differences in supply-side factors such as physicians' preferences and prescription patterns. These factors should 
be further investigated in the Brazilian context. 
 
There is only one study that explored geographic variation in polypharmacy in Brazil (Coelho Filho et al., 
2004). This study analyzed three districts of a main Brazilian metropolitan area (Fortaleza, CE), selected 
                                                      




according to their income levels. The study found that the prevalence of polypharmacy was correlated with 
higher area-level income. However, the study did not control for other individual and area-level characteristics 
that may also affect polypharmacy.  
 
The individual-level factors that have been associated with polypharmacy in the Brazilian context have in 
general been similar to those identified in international studies: female gender, higher age, higher levels of 
chronic diseases, and higher access to health services (Carvalho, Pascom, Souza-Junior, Damacena, & 
Szwarcwald, 2005; Loyola Filho et al., 2005; Loyola Filho et al., 2006). There is uncertainty surrounding some 
characteristics such as marital status – polypharmacy was found to be more frequent among married individuals 
(Loyola Filho et al., 2006) but also among non-married individuals (Loyola Filho, Firmo, Uchoa, & Lima-
Costa, 2011) in different studies. Similarly, polypharmacy has been associated with higher (Loyola Filho et al., 
2011) and lower (Carvalho et al., 2005) schooling and income levels.  
 
Investigations that address a wide set of individual characteristics, and that assess the role of geographic-area 
factors while controlling for individual factors are greatly needed in order to further elucidate the determinants 
of polypharmacy in Brazil. 
 






Setting Study Population % Polypharmacy 
Mosegui  
1999 




Convenience sample of "University for 
Seniors" members with regular medical 
and pharmaceutical care.  















Random sample of not-bedridden, able-
to-inform seniors enrolled in a hospital-










Two-stage cluster random sample of 









Multistage systematic sample of seniors 
living in three districts of different socio-
economic status  
N=668 
8.9% 










2007 Marília, SP  Simple random sample of seniors living 




Note: Studies are presented in order of publication. All studies investigated individuals aged 60 years and over living in the community. All 
studies defined polypharmacy as the use of five or more medicines. Additional selection criteria were listed accordingly. N=number of 
people included in the study. Setting indicated by city, state. Polypharmacy defined as daily intake of five or more medicines. All studies 
were cross-sectional surveys. Data collection conducted by in-person interviews unless noted otherwise. 
 
 
1.3.3 Access to Medicines in the Brazilian Health System 
 
The Brazilian Unified Health Care System (Sistema Unico de Saude - SUS), created in 1988, covers the entire 
population, including the elderly. The system is mostly funded by taxation. The public health system provides 
comprehensive health care free of charge for the population, including medicines.  
 
The public health system it is the sole source of care for over 75% of the Brazilian population.  About 24% of 
the population – mostly the employed and those financially better off – have supplementary private health 
insurance (Viacava, Souza-Junior, & Szwarcwald, 2005).  Private health insurance provides access to private 
networks of hospitals and health providers that would otherwise be accessible only out-of-pocket. Private 
services typically offer faster access than in the public system.  
 
Private health insurance does not cover drugs for outpatient use in Brazil. Medicines must be purchased out-of-
pocket in private pharmacies. By regulation most "prescription" drugs can be purchased in the private market 
without a medical prescription. This includes most drugs to treat chronic diseases. Mental health treatments and 
controlled substances such as and antimicrobial agents are the exception, and their sales are strictly monitored.  
 
Drug provision in the public health system is limited to a national formulary. States, federal and local 
governments share the responsibilities of drug provision according to a tiered system. Cheaper medicines that 
treat common conditions belong to the “essential” or “basic” formulary and are supplied by municipalities. 
Higher-cost drugs that are used in more restricted situations are part of the “specialized” formulary and are 




HIV) are supplied by the federal government. (Secretaria de Políticas de Saúde, 2000). Drugs provided in the 
public system are dispensed only in public pharmacies and typically require medical prescriptions that must be 
current and must be issued by a public health service. 
 
Brazil has strong policies to increase access to medicines and reduce drug prices. Policies to incentivize the 
production of generic drugs were shown to have significantly reduced overall drug prices (Vieira & Zucchi, 
2006). Government programs also subsidize drugs to treat chronic diseases such as hypertension and diabetes 
that can be purchased at great discounts in participating private pharmacies (Pinto, Miranda, Emmerick, Costa, 
& Castro, 2010). In addition, based on the right to health established by the 1988 Constitution, individuals have 
increasingly used legal action against the government in order to obtain drugs that are either not part of 
government formularies or not provided in a timely or sustainable manner (J. Biehl, Socal, & Amon, 2016). 
These judicial pathways have further expanded access to medicines in the country in recent years.  
 
1.3.4 Sao Paulo - Population and Geographic Characteristics 
 
The city of Sao Paulo is a megalopolis of country-size proportions. Because of its large population, its 
administrative structure, and the heterogeneity across each of its areas, Sao Paulo provides one of the best 
settings in which to investigate the occurrence and the determinants of polypharmacy in Brazil.  
 
With about 12 million inhabitants Sao Paulo is the largest city in Brazil and one of the five largest cities in the 
world. If Sao Paulo were a country, it would represent the world’s 77th largest population, ahead of countries 
such as Belgium, Portugal, Greece, Sweden and Bolivia (Factbook, 2010). Sao Paulo is the most important 
business and financial center of Brazil and likely of the Southern Hemisphere. Sao Paulo generates 12% of the 
Brazilian GDP alone (Ribeiro, 2012). The city of Sao Paulo has a central government and is administratively 




Figure 1.1 Administrative Divisions of the City of Sao Paulo  
Source: Municipal Planning Secretariat of the City of Sao Paulo (SEMPLA) 
Each sub-prefecture has their own administration, which is responsible for all public works such as road 
maintenance, sanitation, and others. The provision of health services in the public health system is overseen by 
the central administration and managed locally by the sub-prefectures (Paulo & Pública, 2011). Sub-prefectures 
also have some role in the private health system, as they may issue commercial licenses for health facilities and 
pharmacies independently from the central administration. 
The demographic and socio-economic characteristics of Sao Paulo’s 31 sub-prefectures vary widely. While the 
more centrally located areas are densely populated and heavily urban, there are peripheral areas that have almost 
rural characteristics, such as large territories and smaller and more scattered populations. Figure 1.2 displays the 





Figure 1.2 Rural and urban characteristics of the city of Sao Paulo 
  
Note: brown-shaded areas represent areas with predominantly rural characteristics. Grey-shaded areas represent areas with predominantly 
urban characteristics. Lighter grey represents higher urbanization. Source: gestaourbana.prefeitura.sp.gov.br 
 
Socio-economic status and housing conditions vary significantly across the areas. An index of socio-economic 
status incorporating education, income, and the composition of households was developed by the city’s 
administration in order to identify the socio-economic differences across the multiple geographic areas (Paulo & 
Pública, 2011). The index was used to classify areas between predominantly poor, areas transitioning into 
middle class, areas predominantly of middle class, and areas predominantly rich.  
 
Figure 1.3 displays the distribution of the socio-economic index across the multiple geographic areas of Sao 
Paulo (darker colors indicate lower socio-economic status). In 2000, an estimated 28.9% of the population lived 
in predominantly poor areas; 31.1% lived in areas transitioning into the middle class; 28.6% lived in 
predominantly middle class areas; and 11.4% lived in predominantly rich areas (Paulo & Pública, 2011).  
 
Most individuals who live in predominantly poor areas or in areas transitioning into middle class rely 
exclusively on the public health system to obtain their care. In other words, most individuals living in 




average rate of depending exclusively on the public health system across the city of Sao Paulo was 55.6% in 
2009 (Paulo & Pública, 2011). This was lower than the Brazilian average of about 76% in 2003 (Viacava et al., 
2005).   
 
There is a great overlap between having private health insurance coverage and living in predominantly middle 
class or rich areas. Up to 70% of residents of predominantly rich areas have private health insurance. In 




Figure 1.3 Socio-economic status (left) and private insurance coverage (right) in Sao Paulo  
 
Note: Darker colors reflect worse conditions: lower socio-economic status (left) and lower health insurance coverage (right). Source: Atlas 






1.3.5 Sao Paulo – Health System Characteristics 
 
The largest proportion of health services in Sao Paulo is part of the private sector (91%, or 10,641 out of 11,653 
health services). Around 93% of the private health services are medical and dental clinics.  The public health 
system maintains 818 primary care facilities (basic health units and outpatient clinics) and 86 hospitals, as well 
as other health facilities such as diagnostic laboratories and others. There are 219 hospitals in Sao Paulo, with 
about 35,000 beds. About 50% of the total hospital beds are available to the public health system, either directly 
or via contracts.  However, only about 5% of the equipment for diagnostic imaging, 1.4% of the equipment for 
life support and 2.4% of the equipment for dental care is available to the public health system. The health 
workforce in Sao Paulo is composed of about 130,000 health professionals, of which over 28,000 are 
physicians. The public health system employs over 50,000 workers, of which over 8,000 are physicians and 
12,000 are nurses (Paulo & Pública, 2011).   
 
There is great heterogeneity in the distribution of health services across the Sao Paulo sub-prefectures. Private 
health services are highly concentrated in the central areas of the city. The distribution of private health services 
greatly overlaps with areas of higher socio-economic status and greater private health insurance coverage 
(Figure 1.4). The distribution of the public health services is less centralized and less correlated with area-level 
socio-economic status. The implementation of public health services has been at least to some extent intended to 
cover underserved areas with greater population health needs. Of the 115 primary care clinics opened between 
2005 and 2008 in Sao Paulo, the majority (51%, 59 clinics) was allocated to high need areas; other 45% (52 
clinics) were allocated to medium-need areas, and only 4 clinics (3.5%) were allocated to areas with low need 
(Figure 1.4) (Paulo & Pública, 2011).  
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Figure 1.4 Distribution of private (left) and public health services (right) in Sao Paulo 
 
Source: Atlas Sao Paulo, 2012. 
 
1.4 STUDY OBJECTIVES 
1.4.1 Overall Research Goal 
This study aims to contribute to the understanding of the phenomenon of polypharmacy among older adults in 
Brazil. Specifically, we aim to quantify and characterize the occurrence of polypharmacy and identify its risks 
(as measured by the occurrence of inappropriate polypharmacy) and its determinants.  
The ultimate goal of this research is to provide useful information to policy-makers that may want to understand 
whether polypharmacy is necessarily a problem among Brazilian older adults; what is the extent of the problem; 
and what are the main factors at the individual-, the community-, and at the health system level that may 




Policy makers need information that truly reflects the realities of the populations that they aim to serve. There is 
still a dearth of evidence with polypharmacy in Brazil. Specifically, its association with inappropriateness, and 
therefore its potential health risks, its time trends, and its community- and health systems determinants, are not 
yet fully understood.  
 
Particularities of access to medicines in the Brazilian context – private insurance plans not covering outpatient 
drugs; private purchase of prescription drugs not requiring official prescriptions; thriving governmental 
programs and policies to expand access to medicines; and the possibility of obtaining medicines through judicial 
pathways – suggest that findings from studies conducted elsewhere may not be generalizable to Brazil.  
 
1.4.2 Specific Research Aims  
 
Aim 1: To quantify and characterize the occurrence of polypharmacy among the Sao Paulo older adult 
population 
Sub-aims:  
1a. To measure the overall prevalence of polypharmacy in adults aged 60 years old and over in Sao 
Paulo in the years 2000, 2006 and 2010 
- To quantify which proportion of older adults are exposed to polypharmacy in each of the 
studied years 
 - To identify differences over time in the occurrence of polypharmacy among the population 
of older adults 
1b. To quantify the occurrence of inappropriate polypharmacy among those with polypharmacy, 
measuring:  
 - The types of risk,  
 - The levels of risk, and 
 - Differences over time 
1c. To identify which drug classes are most often part of polypharmacy regimens and which drugs or 





Aim 2: To identify individual- and community-level factors associated with polypharmacy and 
inappropriate polypharmacy in the Sao Paulo older adult population  
Sub-aims: 
2a. To document area-level variations in the prevalence of polypharmacy and inappropriate 
polypharmacy among the Sao Paulo older adult population 
2b. To analyze the association between polypharmacy and individual-level characteristics, as well as 
inappropriate polypharmacy and individual-level characteristics, 
2c. To analyze the association between polypharmacy and community-level characteristics, 
controlling for individual-level factors; and the association between inappropriate polypharmacy and 
community-level characteristics, controlling for individual-level factors 
  
Aim 3: To identify health systems factors associated with polypharmacy in the Sao Paulo older adult 
population  
Sub-aims: 
3a. To analyze the association between polypharmacy and health systems characteristics, controlling 
for individual and community-level factors 
 
3b. To quantify the extent to which health systems factors contribute to explaining geographic 
variations in polypharmacy in addition to the variation explained by individual- and community-level 
factors. 
Note 
It is important to mention that the cross-sectional structure of this study does not provide an adequate setting to 
examine causative relationships between the multiple factors that we describe and polypharmacy. We some 
times call the factors associated with polypharmacy as "determinants" in this text, mostly when: 1) there is 
theoretical basis supporting potential causal pathways; 2) there is evidence from other studies supporting causal 
pathways; 3) the conceptual framework indicates causal pathways; or 4) the factors represent potential policy 
targets that should be further explored. We reason that the direction of the relationships goes from these factors 
to polypharmacy. However, we acknowledge that this may not always hold true. We review this rationale and 





Our findings are intended to help inform future research and identify potential policy targets for further 
exploration. The findings of this study will be specific to the Sao Paulo older adult population. In Chapter 6 we 
discuss the full set of limitations as well as the generalizability of our study. While our results may not be 
directly generalizable to other Brazilian settings, they may help inform future studies and comparative analyses.  
 
1.5 CONCEPTUAL FRAMEWORK 
We draw from the conceptual framework of Societal and Individual Determinants of Medical Care Utilization 
developed by Andersen & Newman (1973) (Figure 5) (R. Andersen & Newman, 1973). In our study the 
outcome of interest – "health service utilization" – is the use of polypharmacy.  
 
Andersen and Newman's framework envisioned health services utilization as the result of a "sequence of 
conditions". At the individual level, the framework divided these conditions as predisposing conditions ("the 
predisposition of the individual to use services"), enabling conditions (the individual's "ability to secure 
services"), and illness level (the diagnoses, level of symptoms and disability perceived by the individual or 
ascertained by the health provider).  
 
At a broader level the framework identified determinants at the societal and health system's levels. The model 
assumed that societal and health systems determinants affected service utilization only via modifications on 
individual-level determinants. The possibility that societal and health systems factors might affect health 
services utilization independently from individual behavior and characteristics was not described.  
 
There are many alternative versions of the model, adapted to accommodate different levels of detail as well as 
different interconnections between the spheres of determinants. Of interest, one of the model's versions also 
developed in the 1970's included a set of population-level determinants that mirrored the individual-level 
conditions (Andersen, 1994). This version of the framework described population-level predisposing, enabling, 
and need (illness level) factors that affected health services utilization independently from their individual-level 




what in this study we called community-level determinants, and we will use the term “community determinants” 
to identify this set of factors in the conceptual framework.    
 
In our study, we use the same conceptual model developed by Andersen. We adapt the graphic display of 
Andersen’s conceptual model to, first, demonstrate that the type of service utilization (outcome) of interest in 
our study is polypharmacy. Second, we identify that polypharmacy may result in inappropriate polypharmacy. 
Third, we add a box to explicitly show the set of community determinants, divided in predisposing, enabling, 
and illness level. Fourth, we add solid arrows identifying the possible direct associations between community 
and health services system determinants and polypharmacy. Lastly, we use dashed arrows to identify the indirect 
associations between community and health services system determinants and polypharmacy that are mediated 
by individual-level factors (Figure 1.6). 
 
We identify the main aims of this study in Figure 1.7. In Aim 1 we are interested in estimating the association 
between polypharmacy and inappropriate polypharmacy (solid line). In Aim 2 we are interested in estimating 
the associations between individual determinants and polypharmacy (solid arrow), as well as the association 
between community determinants and polypharmacy after controlling for individual-level characteristics (solid 
line). In Aim 3 we are interested in estimating the association between health systems determinants and 
polypharmacy after controlling for individual-level characteristics (solid line). 
 
Because our analysis is limited to one single city we assume that societal determinants (technology and norms) 
are constant across areas. Examples of technology and norms of interest in the case of polypharmacy are 
pharmaceutical regulations, policies for access to medicines, and the types and brands of pharmaceuticals 






Figure 1.5!Andersen & Newman's societal and individual determinants of medical care utilization – Conceptual 
framework
 
Source: Andersen & Newman (1973) 




Source: adapted from Andersen & Newman (1973), based on Andersen (1995). Individual, Community and 
Health Systems Determinants Are Identified by Thick Boxes 
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Figure 1.7 Adapted conceptual framework identifying the study aims 
 
Source: adapted from Andersen & Newman (1973), based on Andersen (1995). 
A potential limitation of the proposed conceptual framework is that it does not comprehend all the relevant 
dimensions of access to care (Penchansky & Thomas, 1981; Peters et al., 2008). Access to care has been 
described as the combination of multiple disaggregated dimensions: availability, accessibility, accommodation, 
affordability, and acceptability of services. These dimensions are important in order to qualify the access to the 
health care resources that we investigated at the community level. It is especially important in order to 
understand potential mechanisms that are specific to the public or to the private health care systems in Brazil. 
We discuss these factors in greater detail in Chapter 6. We recommend that future studies should investigate 
these dimensions of pharmaceutical access in the Brazilian context, as they are likely to provide potential policy 




2. CHAPTER II: DESCRIPTION OF THE DATA SOURCES 
 
In this study we combine comprehensive information from older adults living in Sao Paulo with community and 
health systems characteristics of the Sao Paulo sub-prefectures. We use the same data sources for all three aims. 
The individual-level data was obtained through a household survey of older adults conducted in Sao Paulo in the 
years 2000, 2006 and 2010. Community and health systems information for each of the sub-prefectures was 
collected from publically available online databases or calculated from the survey data. Below we describe the 
data sources utilized in this study.   
 
 
2.1 INDIVIDUAL LEVEL DATA – THE SABE STUDY 
2.1.1 History and Motivation 
 
The SABE study (Saude, Bem Estar e Envelhecimento – Health, Wellbeing and Aging) was a survey originally 
carried out to investigate health conditions of older adults in large metropolitan areas of six Latin American 
countries: Brazil (Sao Paulo), Argentina (Buenos Aires), Chile (Santiago), Uruguay (Montevideo), Mexico 
(Mexico City), Cuba (Havana) and Barbados (Bridgetown). The survey was modeled after the United States 
Health and Retirement Study (HSR). In order to allow for cross-country comparisons, the questionnaires and 
methodologies were standardized using the questions and methodology from the HSR.  
 
A population-based multi-stage sampling framework was employed in order to ensure that the samples of 
individuals investigated in the SABE study were representative of the population of non-institutionalized older 
adults in each of the survey sites. A common questionnaire and standardized data collection procedures were 
adopted in order to facilitate cross-country comparisons. The methodology and findings from the SABE study 
were extensively published. A summary by the leading academic investigators provides an overview (A. Palloni 





The SABE study was an initiative of the Pan-American Organization in partnership with academic institutions 
in each of the participating countries. Universidade de Sao Paulo (USP) was the academic institution that 
implemented the SABE study in Brazil.  
 
 Data collection in the original SABE study was conducted between 1999 and 2000. In Sao Paulo over 2,000 
individuals were surveyed in their households. When participants were not able to inform the interviews were 
conducted with a proxy. The participants in the SABE study were distributed across most areas of the city of 
Sao Paulo (Figure 2.1).   
 
In 2006 a USP initiative provided the resources for a new wave of data collection. An attempt was made to 
locate and re-interview all individuals who had participated in the original SABE study. In addition, new 
participants were sampled to ensure that the study sample was representative of the population of non-
institutionalized older adults living in Sao Paulo in that period. Another wave of data collection repeating the 
same methodological structure was carried out in 2010. The survey questionnaire underwent minor 
modifications across the survey years. 
 
Whereas data from the first wave of the SABE study is publicly available (Inter-university Consortium for 
Political and Social Research) the two other waves of data are proprietary of USP. The SABE data included in 
the present study was obtained from USP and was utilized with their permission.  
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Figure 2.1!Distribution of SABE participants across the Sao Paulo geographic areas !
 
Note: Red dots identify areas with at least one observation in the original SABE study. Source: Palloni, 2000. 
2.1.2 Sampling Method  
The sampling process of the SABE survey in Sao Paulo was conducted in two stages. In the first stage, census 
tracts (primary sampling units) were selected from the 1996 Census master sampling frame. In this stage the 
probability of selection for each census tract was equal to its total number of households. Because each sub-
prefecture contained thousands of census tracts, the probability of selection was fairly random at the sub-
prefecture level. 
In the second stage, the census tracts were stratified according to the proportion of the heads of households who 
were illiterate. Within each stratum households were selected with equal probability (secondary sampling units). 




spouses. The study oversampled individuals above 75 years of age, selecting them through a separate, equal-
probability sampling process (Alberto Palloni & Peláez, 2000). When weighted by inverse selection probability 
weights, the final sample of the SABE survey is representative of the non-institutionalized population aged 60 
years and older living in the city of Sao Paulo in each year.  
 
2.1.3 Overview of Waves and Participants 
 
The final sample of the SABE survey constituted of 2,143 participants in 2000, 1,413 participants in 2006 and 
1,333 participants in 2010.  Out of the total 4,889 interviews conducted in the SABE study, 903 (18%) were 
carried out with a proxy. The total 4,889 interviews covered 3,777 different households. On average 1.78 
individuals participated per household. Overall 67.2% of households (n=2538) contributed with only one 
participant, and 96.9% of households (n=3661) contributed up to three participants. Less than 5% of the 
households contributed four or more participants. The maximum number of participants per household was 10 
in 2000, 7 in 2006 and 4 in 2010.   
 
Out of the total 4,889 participations in the SABE study 2,796 (57%) individuals participated in only one wave; 
1,408 (29%) participated in two waves; and 685 (14%) participated in the three survey waves.  
 
Death was the major reason why some individuals from the first wave were not reexamined in the second. At 
the second wave of data collection, in 2006, 1,115 individuals from the original cohort were reexamined, and 
298 new participants were included. Out of the 1,028 individuals without a follow-up, 649 (63%) had died. 
Other 178 (17%) refused to participate, 139 (14%) were not located, 51 (5%) had moved out of Sao Paulo and 
11 (1%) had been institutionalized. At the third wave of data collection, in 2010, a new 355 individuals were 
examined.  Other 430 members of the original cohort and 68 members of the second cohort were not 
reexamined in 2010, largely due to the same causes (Figure 2.2).   
 
The addition of new participants in each wave was implemented in order to ensure that the final sample in each 
wave was representative of the Sao Paulo older adult population when survey weights were applied to 
reconstruct the population. 
36 
Figure 2.2 The Sao Paulo SABE study – Participants and follow-up!
 
Source: Sao Paulo SABE database 
 
Because each sub-prefecture has thousands of census tracts, the likelihood of selection of each specific sub-
prefecture is fairly random. The selected SABE participants were distributed across 27 of the 31 sub-prefectures 
in 2000; 30 sub-prefectures in 2006; and 30 sub-prefectures in 2010 (Table 2.1).  
One of Sao Paulo sub-prefectures (Cidade Tiradentes) was not represented in any of the SABE study samples. 
Three sub-prefectures were not represented in 2000 but were represented in 2006 and 2010 (Ermelino 
Mattarazzo, Guaianases and Sao Mateus). Because our study depended on characteristics measured at the 
individual level, areas that had no participants were not included in our analyses.  
Each sub-prefecture that was represented in the SABE sample had on average 108 participants in 2000 (the 
minimum number of participants per area was 13 and the maximum was 182). In 2006, each sub-prefecture had 
on average 63.8 participants (minimum 5 and maximum 111 participants per area). In 2010, each sub-prefecture 




Table 2.1 Overview of SABE participants 
 
Source: Sao Paulo SABE database 
 
 
2.1.4 Data Collection and Variables 
 
The SABE study collected comprehensive information on participants’ demographic and socio-economic 
characteristics, current and past health conditions, and ongoing treatments. Most information was collected by 
self-report. Table 6 describes the individual-level characteristics collected in the SABE study that we will use in 
this analysis. 
 
Information on medicine use was collected via self-report and researchers directly checked pill bottles, cartons 
and blisters to confirm the information provided by the participant (Landry, 1988). All pharmaceutical products, 
including over-the-counter, herbal and homeopathic drugs, were recorded. Information on drug dosage or 
number of intakes a day was not collected.  
 
The SABE study recorded medicines using the Anatomical Therapeutic Chemical classification (ATC) 
developed by the World Health Organization (WHO). The WHO-ATC classification aims to operationalize drug 
utilization research and provide a "standard language" for "exchanging and comparing data on drug use at 
international, national or local levels" (WHO Collaborating Centre for Drug Statistics Methodology).  
 
The WHO-ATC classification indexes active ingredients of allopathic drugs using alphanumeric codes. In this 
classification, the drugs are first divided according to the organ or system in which they act (level 1), and then 
they are progressively subdivided according to therapeutic subgroup (level 2), pharmacological subgroup (level 
3), and chemical subgroup (level 4). The final level (level 5) identifies the specific drug (WHO Collaborating 
Centre for Drug Statistics Methodology). The WHO-ATC classification does not include products such as 
2000 2006 2010
Nr.$of$Areas 27 30 30
Nr.$participants 2,143 1,413 1,133
Participants.per.Area
Avg$(sd) 107.7$(48.5) 63.8$(26.2) 56.8$(21.7)




herbal and homeopathic preparations. In Chapter 3 we provide a more detailed description of the WHO-ATC 
classification including an example. 
  
We utilized the drug use information collected by the SABE study to generate two variables: polypharmacy, 
which we defined as the use of five or more drugs per day, and inappropriate polypharmacy, which we 
described as taking five or more drugs per day plus having at least one drug risk criterion. We identified each 
drug by its ATC code. In this investigation we focus on prescription and over-the-counter drugs only.  
 
We assessed drug risk in the SABE sample using three different tools: the Beers Criteria, to capture potentially 
inappropriate prescribing (American Geriatrics Society Beers Criteria Update Expert, 2012), the ARS scale, to 
capture anticholinergic adverse effects (Rudolph et al., 2008), and the Hines list to capture clinically relevant 
drug-drug interactions (Hines & Murphy, 2011). A person was considered as having inappropriate 
polypharmacy if they were using five or more prescription or over-the-counter drugs per day, and had at least 
one positive criterion for drug risk in any of these three tools. A more detailed description of each tool, as well 
as the methodology that we used for their implementation, are provided in Chapter 3. 
 
 
2.1.5 Main Covariates 
 
Demographic characteristics collected included age, gender, marital status (binary coded as married or in a civil 
union versus single, widowed or divorced), race (binary coded as white versus other), and religion (binary coded 
as catholic versus other). Socio-economic characteristics included years of schooling (number of school years 
completed; repeated grades were not considered), number of people who lived in the household, having children 
who were still alive (yes, no), having a caregiver (yes, no), and per capita income. Income was measured in 
Brazilian Reais. Participants were asked to inform their total income per month from all different sources 
(wages, investments, pensions, rent, remittances, etc.). Per capita monthly income was calculated by dividing 
the total reported income by the number of people that depended on the income as informed by the participants. 
 
Health care utilization characteristics included health insurance coverage status (having or not having private 
health insurance), number of physician visits in the last 12 months, and whether the participant underwent a 




characteristics included presence and type of chronic conditions, presence and type of symptoms, level of 
disability, and self-reported health status7. Information on chronic disease was obtained by asking participants if 
they were ever diagnosed by a doctor or nurse with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, neuropsychiatric disorders, cancer, osteoporosis, and arthritis. 
Positive responses were aggregated to obtain the number of chronic diseases reported by each participant. 
 
Information on symptoms was obtained by asking participants whether they experienced any of the following 
symptoms in the last 12 months: persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, 
tiredness or fatigue, nausea or vomiting, fecal or urinary incontinence. Positive responses were aggregated to 
obtain the number of symptoms reported by each participant. 
 
Information on disability was obtained by asking participants whether they had difficulties performing one or 
more activities of daily living: walking across a room, getting dressed, bathing, feeding, transferring to/from 
bed, using the toilet, preparing meals, dealing with money, transportation, grocery shopping, using the phone, 
light household chores, and heavy household chores. Positive responses were aggregated to obtain the level of 
disability reported by each participant. Self-reported health status was obtained by asking participants how they 
assessed their current health. Participants could choose from the following options: excellent, very good, good, 
regular, bad, or very bad health. The information provided by the participants was aggregated to create a binary 
variable “good” (excellent, very good, or good) versus “bad” (regular, bad or very bad) health status.   
 
Health behavior characteristics included smoking, alcohol, and self-medication habits. Smoking was classified 
as currently smoking versus not currently smoking. Alcohol use was classified as current alcohol use versus no 
current alcohol use. Self-medication information was obtained by asking who had issued the prescription for 
each of the drugs that a participant was using. If any of the drugs been started by the participant on their own 
will, or on recommendation from family members/ friends, without a prescription issued by a health provider, 
the information was recorded as self-medication. If all drugs were prescribed by a health professional, or if the 
person did not take any drugs, the information was recorded as no self-medication. 
 
                                                      
7 Some characteristics, especially clinical symptoms and health care utilization, may have been influenced by polypharmacy. We make 





Table 2.2 Selected individual-level characteristics from the SABE study: Variable type and definition 
Variable Type N Definition 
Drug Utilization    
Medicines count 4889 Number of prescriptions and over-the-count drugs in use 
     Medicines were coded using the WHO-ATC classification 
Polypharmacy binary 4889 Five or more prescription or over-the-counter drugs per 
day. Reference: zero to 4 drugs. 
Inappropriate 
Polypharmacy 
binary 4889 Five or more prescription or over-the-counter drugs per 
day, with at least one positive drug risk criterion8. 
Reference: any number of drugs with no risk criterion. 
Excessive 
Polypharmacy 
binary 4889 Ten or more prescription or over-the-counter drugs per 
day. Reference: zero to 4 drugs. 
    
Socio-Demographic    
Age count 4889 In years 
Gender binary 4889 Reference: males 
Marital status binary 4870 Married or in a civil union; reference: single, widowed or 
divorced 
Income continuous 4258 In Brazilian Reais (R$). Income from multiple sources 
(pensions, investments, wages, and others) was recorded. 
Per capita income was calculated by dividing the total 
reported income by the number of people that depended on 
the income as informed by the participants. 
Health Insurance binary  4886 Having private health insurance; reference: not having 
Health Status       
Chronic Diseases count  4889 Self-reported information on ever having been diagnosed 
by a doctor or nurse with one or more of the following 
conditions: hypertension, diabetes, heart disease, lung 
disease, stroke, cancer, psychiatric conditions, joint 
diseases, or osteoporosis. 
Level of symptoms count  4887 
Self-reported information on having experienced persistent 
chest pain, swelling of feet or ankles, dyspnea, dizziness or 
vertigo, tiredness or fatigue, nausea or vomiting, fecal or 
urinary incontinence in the last 12 months.  
Level of disability count  4888 
Self-reported information on having difficulty performing 
one or more activities of daily living: walking across a 
room, getting dressed, bathing, feeding, transferring 
to/from bed, using the toilet, preparing meals, dealing with 
money, transportation, grocery shopping, using the phone, 
light household chores, and heavy household chores.  
Health Utilization    
Medical visits  count 4484 Self-reported information of the number of medical visits 
in the last 12 months.  
                                                      
8 Drug risk criteria: Beers Criteria, Anticholinergic Risk Scale, and Hines list of clinically relevant drug-drug interactions. We describe these 




Preventative exam  binary 4609 Self-reported information on having undergone a 
preventative exam in the last 24 months. Mammogram for 
women or prostate exam for men. Reference group: no 
preventative exam.  
Behaviors      
Smoking  binary 4887 Reference: not currently smoking 
Alcohol  binary 4884 Reference: no current use of alcohol 
Source: SABE Study. 
 
Missing values were not a major problem in the SABE study. The characteristic with the most missing values 
was income, with 13% (n=631) missing values. The number of medical visits in the last 12 months was the 
second most frequently missing variable, with about 8% (n=406) of missingness. Having a preventative exam 
was the third with about 6% of missing values (n=280). All other variables had less than 5% missing values.  
 
In our analysis, we excluded individuals with missing information for any variable, except for the three 
variables with most missing values that we described above (income, medical visits in the last 12 months, and 
preventative care in the last 24 months). We dealt with missing values differently for each of these three 
variables. For individuals with missing income information (n=631; 13%) we imputed the average per capita 
income for the corresponding gender and year. We identified individuals with imputed values by an indicator 
variable that represented missing income. No association between polypharmacy and missing income was found 
across the multiple analyses.  
 
There were 348 individuals with missing values for medical visits in the last 12 months in 2000 (representing 
16% of the 2000 sample). Because the large number of missing values allowed us to check for a relationship 
between missingness and the outcome, we identified missing individuals in the 2000 sample by an indicator 
variable for missingness and included in them in the 2000 analyses. Because in the other waves the number of 
missing individuals was too low, it did not allow us to check for a relationship between missingness and the 
outcome, and so we dropped these individuals from the analyses. In 2000, missing information on medical visits 
was associated with 64% lower odds of polypharmacy (p<0.05) in that year. We discuss this finding in chapter 
4. Individuals with missing values for medical visits in the last 12 months in 2006 (N=54, 3.8% of the 2006 





There were 263 individuals (representing 19.7% of the 2010 sample) with missing values for preventative care 
in the last 24 months in 2010. Using the same rationale described for medical visits, these individuals were 
identified by an indicator variable for missingness and were included in the analyses for the year 2010, but not 
for 2000 and 2006. There was no association between missing information on preventative care in the last 24 
months and the odds of polypharmacy in 2010. Individuals with missing values in 2000 (N=14, 0.65% of the 
2000 sample) and 2006 (N=3, 0.21% of the 2006 sample) were not included in the regressions. 
 
 
2.2 GEOGRAPHIC LEVEL DATA 
2.2.1 Community Characteristics Calculated from the SABE Study Data 
 
To allow for estimation of contextual effects (Aim 2) we calculated some community-level characteristics using 
aggregated information from SABE study participants (Table 2.3). The participant-derived community 
characteristics were obtained for each sub-prefecture. Each characteristic was calculated as a weighted average 
of the participants living in that area. Importantly, each characteristic reflects the average of the characteristic 







Table 2.3 Community-level characteristics derived from the SABE Study  
Variable Definition 
Drug Utilization   
Polypharmacy % of individuals who were with polypharmacy 
Socio-Demographic 
Age Average age of the population in years 
Gender % of population who are females  
Marital status % of population who were married or in a civil union 
Income Average income in Brazilian Reais (R$) 
Health Insurance % of population with private health insurance 
Health Status    
Chronic Diseases Average number of chronic conditions per capita (conditions: hypertension, diabetes, 
heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or 
osteoporosis) 
Level of symptoms Average number of clinical symptoms per capita (symptoms: persistent chest pain, 
swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness or fatigue, nausea 
or vomiting, fecal or urinary incontinence in the last 12 months) 
Level of disability Average level of disability per capita (activities: walking across a room, getting 
dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, 
dealing with money, transportation, grocery shopping, using the phone, light 
household chores, and heavy household chores) 
Health Utilization 
Medical visits Average number of medical visits in the last 12 moths per capita 
Preventative exam % of the population who underwent a preventative exam in the last 24 months 
(women: mammogram; men: prostate exam). 
Behaviors   
Smoking % of population currently smoking 
Alcohol % of population currently using alcohol 
Note: Aggregated data from individuals 60 years old and over. Source: SABE database.  
 
 
2.2.2 Characteristics Obtained from Official Government Sources  
 
We obtained community characteristics (population composition, living conditions, health needs) and health 
systems characteristics (health resources and health utilization) for each sub-prefecture from publicly available 
government sources.  
 
We collected sub-prefecture information corresponding to the same time periods for which we had individual-
level information, i.e., years 2000, 2006 and 2010. When information from the same year was not available we 




characteristics, respectively, at the sub-prefectures level. It is important to mention that, unless noted, these 
characteristics reflect the entire population of each subprefecture (not only the population of older adults).  
Table 2.4 Community characteristics – Data availability and sources 
Indicator Year Source 
Reference Year 2000 2006 2010  
Population & Geography  
    Area in 1,000km² fixed 
  
Municipalities Database, IBGE 
Number of districts fixed 
  
Municipalities Database, IBGE 
Total number of residents 2000 
 




IBGE data, SEADE Foundation 
% female residents 2000 
 




Calculated from Census data 
% residents over age 60 2000 
 




Calculated from Census data 
% non-white residents 
  
2010 Brazil Demographic Census 
Number of births 2003 2006 2010 Infocidade online database 
% white newborns 2003 2006 2010 Infocidade online database 
Avg. nr. years of Schooling1 2000 
  
Brazil Demographic Census 
% illiterate inhabitants 2000 
 
2010 Brazil Demographic Census 
Average per capita income2 2000 
 
2010 Brazil Demographic Census 
Households & Living Conditions         
Total nr. households 2000 
 
2010 Brazil Demographic Census 
Avg. persons per household 2000 
 
2010 Brazil Demographic Census 
% suboptimal households   2000 
 
2010 Brazil Demographic Census 
%households treated water 2000 
 
2010 Brazil Demographic Census 
% households treated sewage 2000 
 
2010 Brazil Demographic Census 
Avg. nr. rural areas3  2000 
 
2010 Brazil Demographic Census 
Any rural areas 2000 
 
2010 Brazil Demographic Census 
Nr. areas occupied by slums 2000 2008 2011 Infocidade online database 
% allocated city tax 2005 2006 2010 Infocidade online database 
Total sales, new apartments 2000 2006 2010 Infocidade online database 
Illness Level         
All-cause mortality4 2000 2006 2010 Infocidade online database 
External-Cause  Mortality5 2000 2006 2010 Infocidade online database 
Notes: 1Heads of households only. 2In Brazilian Reais. 3Classification according to the census. 4Available for seniors and for the general 
population. 5Available for the general population. IBGE: Brazilian National Institute for Geography and Statistics (Instituto Brasileiro de 
Geografia e Estatística), SEADE: Sao Paulo State Data Analysis Foundation (Fundação Sistema Estadual de Análise de Dados), Infocidade: 






Table 2.5 Health systems characteristics – Data availability and sources 
Indicator Year Source 
Reference Year 2000 2006 2010 2010  
Health Professionals1 
    
  














CE info online database 









CE info online database 




CE info online database 
Health Facilities 
    
  
Pharmacies1 
   
2015 Ministry of Health 
Pharmacies2 
   
2016 Apontador.com 
Pharmacies, partners 
   
2015 Ministry of Health 
Primary care clinics1 2000 2006 2010 
 
Infocidade online database 
Urgent care clinics1 
   
2013 SP Health Secretariat 
Specialty clinics1 
   
2013 SP Health Secretariat 
Senior health clinics1 
   
2013 SP Health Secretariat 
Mental health clinics1 
   
2013 SP Health Secretariat 
Hospitals3 2000 2006 2010 
 
CE info online database 
Hospital beds3 2000 2006 2010 
 
CE info online database 




CE info online database 




CE info online database 
Health Services Utilization1 
    
  




CE info online database 
Nr. elective hospitalizations 2003 2006 2010 
 
CE info online database 
Nr. urgent hospitalizations  2003 2006 2010 
 
CE info online database 
Total nr. hospitalizations 2003 2006 2010 
 
CE info online database 




SEADE online database 




SEADE online database 




SEADE online database 




SEADE online database 




SEADE online database 
Notes: 1Public health system only. 2Private health System only. 3 Available for both public and private health systems. IBGE: Brazilian 
National Institute for Geography and Statistics (Instituto Brasileiro de Geografia e Estatística), SEADE: Sao Paulo State Data Analysis 
Foundation (Fundação Sistema Estadual de Análise de Dados), Infocidade: information portal of the Urban Development Secretariat of the 
Sao Paulo Municipality (Secretaria Municipal de Desenvolvimento Urbano).  
 
 
As can be seen from Table 2.4 and Table 2.5, some community and health systems characteristics were not 
available for the years  corresponding to the SABE study. When a variable did not correspond to the specific 
years of the SABE study, we either avoided using it altogether (e.g., urgente and specialized health clinics), or 






There were only two cases where we did data imputation for geographic-area variables. We interpolated the 
rural area indicator for 2006 assuming that areas with same rural/urban status in 2000 and 2010 were the same in 
2006 (see Chapter 5). We could only obtain current information on number of private pharmacies per area. We 
calculated quintiles of greater concentrations of private pharmacies per area and we assumed that an area 





3. CHAPTER III: PATTERNS OF DRUG UTILIZATION AND RISK 





Background: Pharmaceuticals can expose individuals to risks such as adverse effects and drug interactions. The 
possibility of risk tends to increase with each additional drug in a pharmaceutical regimen. Regimens of five or 
more drugs per day (polypharmacy) have been progressively frequent among older adults in Brazil. It is not 
clear whether all polypharmacy regimens are equally risky or what specific drugs or combinations of drugs are 
likely to cause greater risk in that population.  
 
Aims: This study aimed to quantify the occurrence of inappropriate polypharmacy among the older adult 
population in Sao Paulo, characterizing its trends over time and its association with presence and type of drug 
risk. We focus on the risk from drug adverse effects, not the actual occurrence of events. We aim to capture the 
harm that could be averted if measures such as early detection and improved monitoring had been in place.  
 
Methods: We used data from a household survey of older individuals age 60 years and older living in the 
community in the city of Sao Paulo, Brazil. We used three waves of this survey, collected in 2000, 2006, and 
2010, to investigate time trends. We used the pooled sample, a total of 4,889 observations, to investigate the 
presence of adverse effects, using the Anticholinergic Risk Scale (ARS); clinically relevant drug-drug-
interactions, using the Hines list; and inappropriate prescribing, using the Beers Criteria. Only prescription and 
over-the-counter drugs were examined.  
 
Results: Drug risk was frequent, and strongly associated with higher number of drugs per day. About two-thirds 
of people with polypharmacy were exposed to some form of risk. There were no drug or drug combinations 
driving most of the risk. Levels of inappropriateness among people with polypharmacy tended to decrease over 
time, but drug interactions and anticholinergic potential tended to increase. The composition of drug treatments 





Conclusions: The association between polypharmacy and drug risk should receive greater attention from public 
health decision-makers in Sao Paulo. Policies to reduce drug risk should target all older adults with 
polypharmacy. By introducing additional tools to capture additional dimensions of drug risk we empirically 
demonstrated the importance of a comprehensive drug risk assessment in population studies. Better tools that 
combine these and other dimensions of drug risk are necessary, especially to improve drug risk evaluations at 










3.1.1 Policy Problem: Assessing the Risk from Polypharmacy 
 
There is evidence that the use of pharmaceuticals is very frequent among older adults in Brazil (Loyola Filho et 
al., 2005; Marin et al., 2008). There is also evidence that use of pharmaceuticals is growing, both in frequency 
and in number of drugs, among this population. Polypharmacy, the use of multiple drugs per day, is a special 
case of drug utilization that has increased sharply in recent decades (Loyola Filho et al., 2011). 
 
The growing use of pharmaceuticals is a matter of public health concern. Even when prescribed correctly – for 
the right indication, at the right dose, and for the right duration – pharmaceuticals can expose individuals to 
unnecessary risk (Gomez et al., 2015). All drugs have potential adverse effects. Drugs may interact with each 
other increasing the risk of toxicity or treatment failure (Johnell & Klarin, 2007). The incorrect use of 
pharmaceuticals (such as non-adherence) may also increase the risk of complications (Simonson & Feinberg, 
2005). Although it is not possible to predict which specific individuals will develop harmful effects from 
specific drugs or combinations of drugs, it is possible to identify drugs or combinations that pose greater risk, 
and populations that are most vulnerable.  
 
The possibility of risk tends to increase with each additional drug in a pharmaceutical regimen. Regimens of 
five or more drugs per day have been associated with increased risk of frailty, falls, cognitive impairment, and 
mortality (Gnjidic et al., 2012). Therefore, a threshold of five or more drugs a day is generally used to define 
polypharmacy (Gnjidic et al., 2012).  
 
Older adults are especially vulnerable the risk of adverse drug effects, especially the risk from polypharmacy. 
Older adults tend to have more comorbidities and lower metabolic capacity, which may increase their sensitivity 
to drug effects and drug risks. Yet, they tend to be prescribed more drugs more often than the rest of the 





Drugs are a modifiable exposure. Identifying situations of greater risk is important in order to adjust therapeutic 
regimens before they occur, avoiding reductions in quality of life; or increased risk of hospitalizations, or even 
deaths from drugs. Identifying precisely what causes the increased risk is challenging in the case of 
polypharmacy. It is not clear whether all polypharmacy regimens are equally risky or what specific drugs or 
combinations of drugs are likely to cause greater risk.  
 
While clinicians may perform a case-by-case risk assessment for each patient with polypharmacy, policy makers 
face challenges regarding population-level decisions. Are all persons with polypharmacy a matter of concern? 
Or is the risk from polypharmacy mostly driven by specific drugs or drug classes that should themselves become 
the focus of attention?  
 
We focus on drug adverse effect potential, or the "chance of causing harm", not the actual occurrence of harm 
(Edwards & Aronson, 2000). We aim to capture the harm that could be averted if measures such as early 
detection and improved monitoring had been in place.  
 
Our ultimate goal is to inform public health decisions, primarily in the context of Sao Paulo. We aim to identify 
the magnitude of drug-related risks associated with polypharmacy among older adults and we aim to identify 
whether risk is most commonly related to polypharmacy in general or whether there are specific drugs and drug 
classes that are responsible for the increased the risk among that population. 
 
Because drug-related risks depend on drug selection, all factors involved in drug selection provide potential 
targets for policies to reduce drug risk at the population level. In this context, prescription patterns and provider 
preferences matter; therapeutic guidelines matter; levels of health care integration across providers matter; drug 
formularies matter; and broader acceptability of drugs and awareness of drug risks by the general public also 
matter. However, determining which of these factors is not the objective of this chapter. The objective of this 
chapter is to determine how to measure inappropriate polypharmacy. Later chapters will examine the factors 
associated with greater levels of inappropriate polypharmacy. 
 
If we find that polypharmacy is frequently associated with drug risk among Sao Paulo older adults, then it may 




drug risks, but also there could be cost savings to the public health system with lower purchase of drugs and 
with lower expenditures from treating complications such as hospitalization. 
 
If we find, for example, that most of the risk is associated with a specific drug or drug combination, then 
policies to reduce drug risk in older adults in Sao Paulo could focus on individuals exposed to those drugs and 
the reason why this is occurring. Policies could be put in place to identify individuals using these target drugs or 
drug combinations and provide them with safer alternatives, for example, or improve clinical monitoring. Or, 
drug formularies could be altered to promote safer drug choices and disincentivize the use of the problem drugs.   
 
If, on the other hand, we find that drug inappropriateness is associated with cases of polypharmacy in general, 
then policies may be put in place to improve monitoring of polypharmacy among older adults in Sao Paulo.  
 
3.1.2 Overview of Main Drug Risk Types 
 
There are different classifications of drug risk (Davies, 1977). Most classifications focus on risks that are 
associated with the chemical properties of a drug and its pharmacologic effects on the body. This is the case of 
adverse effects and drug interactions, for example.  
 
However, there are other forms of drug risk that arise not from the chemical properties of the drug itself, but 
from the process of treatment administration. The main examples are medication errors - when harmful clinical 
consequences arise from improper administration of a drug - and treatment burden - when there are losses of 
quality of life arising from the burden of maintaining multiple drug intakes a day. 
 
In this study, we will focus on risks associated with drugs' chemical properties. While both medication errors 
and treatment burden can be associated with polypharmacy, their assessment relies heavily on clinical judgment 
and requires extensive information about the drug (dosage, frequency of administration) and the circumstances 
of treatment administration. These factors greatly limit the possibility of assessing treatment burden and 
medication errors from secondary data. The investigation of the relationship between polypharmacy and 






3.1.3 Adverse Effects 
 
Adverse effects are probably the most commonly recognized type of drug risk. An adverse effect can be 
understood more broadly as any "adverse outcome that can be attributed to some action of a drug" (Edwards & 
Aronson, 2000). Adverse drug effects are a term interchangeable with adverse drug reactions. However, the 
term "adverse effects" is employed to reflect patients' perspective, while "adverse reactions" refers to the drug 
itself (Edwards & Aronson, 2000).  
 
A more specific definition of adverse effect is an "appreciably harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product” 
(Edwards & Aronson, 2000). 
 
Adverse effects can be classified according to their main underlying mechanism: dose-related (adverse effects 
that are triggered by higher doses of a drug, such as drug toxicity), non-dose related (idiosyncratic adverse 
effects), dose and time-related (chronic adverse effects), time-related (delayed or tardive adverse effects), 
withdrawal (adverse effects that are triggered by treatment discontinuation), and unexpected treatment failure 
(Davies, 1977).  
 
The type, frequency, and severity of adverse effects are specific to each drug. There have been diverse attempts 
at developing classification systems of adverse effects. An example is the World Health Organization’s Adverse 
Reaction Terminology (WHO Collaborating Centre for International Drug Monitoring). However, adverse 
effects classification systems are usually descriptive rather than predictive. These systems list the possible 
adverse effects associated with each drug. Their goal is to create a terminology that helps standardize reporting 
and recording of adverse effects (WHO Collaborating Centre for International Drug Monitoring)  Adverse effect 
classification systems do not help predict which types of patients are more likely to develop a particular adverse 





Tools that have been developed to predict the likelihood of adverse effects have focused on specific adverse 
effects or specific drug classes (Day, Wood, Dewey, & Bentall, 1995; Jung et al., 2005). However, there is not 
one single list of adverse effects that can be applied to examine all drugs being used by the general population. 
This is because what is an adverse effect in one case may be a desirable effect in another. For example, blood 
pressure-lowering effects may be the desired effect behind the prescription of anti-hypertensive. However, when 
a drug used to treat a different condition triggers hypotension, this may be undesired and harmful, representing 
an adverse effect. 
 
In this study we focus our adverse effects investigation on anticholinergic adverse effects. Anticholinergic 
adverse effects are more frequent among older adults. Anticholinergic adverse effects occur when drugs 
interfere with the actions of the neurotransmitter acetylcholine. Acetylcholine is involved in numerous 
biochemical pathways in the body. In the peripheral nervous system acetylcholine is responsible for involuntary 
muscle movement, secretion of saliva, tears, and others. The main peripheral anticholinergic adverse effects are 
dry mouth, dry eyes, constipation, and urinary retention. In the central nervous system, acetylcholine is involved 
in many processes associated with attention, memory and balance. The main central anticholinergic adverse 
effects are dizziness, falls, confusion, and memory loss. We chose anticholinergic adverse effects because these 
effects can greatly impact quality of life and can be very severe (associated with physical and cognitive decline, 
for example) (Cancelli, Beltrame, Gigli, & Valente, 2009; Pasina et al., 2013). 
 
A wide variety of drugs used to treat many different conditions can cause anticholinergic adverse effects. 
Therefore, the possibility of such effects is relevant to the entire population. Also, anticholinergic effects are 
rarely clinically desirable. This fact minimizes the possibility that a desirable effect might be misclassified as 
drug risk in our study.   
 
3.1.4 Drug-Drug Interactions 
 
Combinations of drugs can be riskier than each drugs taken in isolation. Drug-drug interactions (DDIs) occur 
when the effect of one drug is modified by the effect of another (Goldberg, Mabee, Chan, & Wong, 1996). DDIs 




excretion) or through pharmacodynamic interactions (when there is synergism or antagonism between drug 
effects) (Mallet, Spinewine, & Huang, 2007).  
 
DDIs are not necessarily negative. Some DDIs may be desirable if they result in enhanced beneficial effects 
from treatments – in cases of treatment synergy. Or, DDIs may not be clinically relevant – in some cases the 
effects of DDIs are negligible or not clinically noticeable. 
 
DDIs become a matter of concern when they result in a significant reduction of the therapeutic effect of a drug 
or in a significant increase in the risk of adverse effects. In these cases, DDIs may have very severe clinical 
outcomes, leading to hospitalizations and even death. An example of clinically relevant DDI is the combination 
of an anticoagulant agent such as warfarin with a non-selective non-steroid anti-inflammatory agent (NSAID) 
such as diclofenac. The NSAID increases the likelihood of erosions in the gastro-esophageal mucosa, and the 
anti-coagulant prevents clot formation. When taken together, these drugs may result in major gastrointestinal 
bleeding, which can have disastrous consequences (Hines & Murphy, 2011). 
 
In order to adequately assess the risk from DDIs it is important to have information on all drugs that are part of a 
therapeutic regimen, including prescription and over-the-counter drugs. The adequate detection of DDIs requires 
pairwise comparisons across all drugs in a regimen. It also requires a database where the evidence on drug 
combinations is regularly updated.  
 
The best tools for the detection of DDIs are usually automated, computer-based systems. Hence, DDIs are most 
commonly and most comprehensively examined where detection systems are embedded in electronic 
prescribing platforms, such as in hospitals and other in-patient settings. The downside of automated DDI 
detection systems, however, is that they may be excessively sensitive and produce alerts for DDIs that are not 
clinically relevant. Over time, the overflow of non-relevant DDI alerts may de-sensitize prescribers reducing the 







3.1.5 Inappropriate Prescribing 
 
There are multiple dimensions to consider a treatment "appropriate". To be considered "appropriate", a drug 
should be prescribed in the right dose for the right indication, in a timely manner, be efficacious, safe, cost-
effective, and respect patients’ preferences (Hanlon & Schmader, 2013; Hanlon et al., 1992). For the purposes of 
drug risk assessment, appropriateness may be defined as a treatment which benefits exceed its risks (Shelton, 
Fritsch, & Scott, 2000). 
 
Because of the increased vulnerabilities of older adults, many classifications of inappropriate prescribing have 
been developed specifically for that population. Inappropriateness may be an easier way to capture higher risk of 
adverse effects, as it specifies drugs that may pose greater risk for individuals based on their age or their 
underlying health conditions – in these circumstances, adverse effects have also been called "drug-age" or 
"drug-disease" interactions (Mallet et al., 2007).  
 
Inappropriate prescribing encompasses several aspects of the fit between need and drug selection, from 
overprescribing (toxic doses or duplicate therapies) to under prescribing (not prescribing a needed therapy).  
 
In this study we investigated the presence of three main drug risk categories: adverse effects, clinically relevant 
DDIs, and inappropriate prescribing. In order to measure each type of drug risk, we identified tools to assess 
drug risk from the medical literature. We discuss the tools in more detail below.  
 
3.1.6 Tools to Assess Drug Risk 
 
We screened our sample for adverse effects, potentially inappropriate prescribing, and potentially harmful drug-
drug interaction. We selected among the tools developed specifically for the older adult population.  
 
We selected tools that had been validated against significant clinical outcomes and that had been used in many 
references such as clinical studies or secondary data analysis. Although none of our selected tools had been 




(Davidoff et al., 2015; Lowry, Woodman, Soiza, & Mangoni, 2011; Pasina et al., 2013), including in Brazil 
(Baldoni Ade et al., 2014). 
 
All the tools that we chose have been developed and published in a time frame that suits the period of the data 
collection for the SABE study. This is particularly important because prescription patterns change over time, as 
drugs may enter or exit the market, so that tools that have been developed too long before a study may not 
include drugs newly available at the time of the study. Conversely, tools developed long after the completion of 
a study may not include drugs that might have been widely used at the time of data collection but might have 
become obsolete at the time of the tool development.  
 
3.1.7 Adverse Effects – Tool: Anticholinergic Risk Scale 
 
We used the Anticholinergic Risk Scale (ARS) to detect the potential for anticholinergic adverse effects. The 
ARS scale was developed specifically for the geriatric population (Rudolph et al., 2008). The ARS assesses the 
potential for adverse effects from a given therapeutic regimen, and so it is an efficient tool to evaluate the risk to 
which patients are exposed even before any symptoms or signs have occurred. 
 
The ARS has a list of frequently prescribed drugs and assigns a score to each drug according to their potential 
for anticholinergic adverse effects. Scores were defined by experts who reviewed chemical information 
(specifically, the dissociation constant for the cholinergic receptor (pKi), obtained from the National Institute of 
Mental Health psychoactive drug screening program), clinical information (rates of anticholinergic adverse 
effects when compared to placebo obtained from the Micromedex platform), and scientific evidence from peer-
reviewed medical literature (reports of anticholinergic adverse effects catalogued in the Medline database of the 
National Library of Medicine). Each drug received a score varying from 0 to 3, were 0 represented no 
anticholinergic potential, 1 represented moderate, 2 represented strong, and 3 represented very strong 
anticholinergic potential. An example of a drug with a score of 0 is the antibiotic amoxicillin. An example of a 
drug with a score of 3 is the antipsychotic haloperidol. The total ARS score of a therapeutic regimen is 





The ARS has several limitations, for example it does not take drug dosage into consideration (which could 
further increase the likelihood of anticholinergic adverse effects for some drugs) and it does not include topical, 
ophthalmic, otologic, or inhaled medications (which could contribute, albeit little, to systemic anticholinergic 
activity if there was enough absorption of the drug through the mucosa). Also, it assigns similar scores to drugs 
that may have different degrees of anticholinergic activity (for example, a drug in category "3" can have higher 
anticholinergic potential than another one in the same category). The ARS sums the scores from each drug 
without consideration as to whether drugs may interact with each other. Lastly, there is variation between the 
ARS and other tools developed to identify anticholinergic adverse effects (Duran, Azermai, & Vander Stichele, 
2013).  
 
The ARS scale was validated in populations of older adults in primary care and hospital settings, both in the 
United States and abroad (Lowry et al., 2011; Pasina et al., 2013; Rudolph et al., 2008). Higher scores in the 
ARS scale were shown to be associated with an increased risk of central (dizziness, confusion, falls, and others) 
and peripheral (dry mouth, dry eyes, constipation, and others) anticholinergic adverse effects. Higher scores 
were also associated with lower cognition (as measured by the Short Blessed Test) and higher disability levels 
(as measured by the Barthel Index), even after adjustment for relevant factors such as age, education level, and 
neurologic conditions such as stroke or transient ischemic attacks (Lowry et al., 2011; Pasina et al., 2013). In 
one study, higher scores in the ARS scale were also associated with increases in mortality among patients 
experiencing hyponatremia, a frequent clinical complication in hospitalized settings (Lowry et al., 2011).  
 
There are no defined cutoffs for the ARS scale. Total ARS scores as low as 1 or 2 points are statistically 
significantly associated with increased risk of anticholinergic adverse effects as compared to ARS scores equal 
to zero (Rudolph et al., 2008). Higher scores have been shown to be associated to greater risks of anticholinergic 
adverse effects in a dose-response relationship (Pasina et al., 2013). The distribution of ARS scores in the 
investigated populations tends to be right-skewed, with most scores in the lowest categories, including zero 
(Rudolph et al., 2008). 
 
When compared to other scales developed to identify anticholinergic potential it has been suggested that the 
ARS scale may be more specific but less sensitive (Pasina et al., 2013). In other words, the scale does not 




demonstrated to correlate more efficiently than other scales with higher levels of clinically significant cognitive 
and physical impairment (Duran et al., 2013).  
 
This scale has been validated for use in secondary data and for populations of older adults living in the 
community (Rudolph et al., 2008), like our sample. The ARS scale reflects a conservative estimate of the 
number of persons at risk of anticholinergic adverse effects. Because this scale is more specific than sensitive, it 
is likely that there will be persons at risk for anticholinergic adverse effects in our sample that will remain 
unidentified. However, when a person receives a non-zero ARS score, the likelihood that they are truly at risk of 
clinically relevant adverse effects is greater.     
 
While tools to evaluate other types of adverse effects have been developed, they may be restricted to specific 
classes of drugs (Lingjaerde, Ahlfors, Bech, Dencker, & Elgen, 1987; Simpson & Angus, 1970), may require 
extensive information on the person's underlying health conditions and therapeutic characteristics to be 
implemented (Naranjo et al., 1981), or they may only be applicable once symptoms and signs of adverse effects 
are present (Morimoto, Gandhi, Seger, Hsieh, & Bates, 2004). Anticholinergic adverse effects may arise from a 
wide variety of drugs used to treat diverse conditions and organ systems, and the ARS accordingly covers a 
broad range of drug classes. 
 
3.1.8 Inappropriate Prescribing – Tool: Beers Criteria  
 
We used the American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use 
in Older Adults (Beers Criteria) to assess the possibility of inappropriate prescribing among our sample (AGS, 
2012). The Beers Criteria is an explicit (criterion-based) tool to identify high-risk drugs that have an 
"unfavorable balance of risks and benefits" for the aging population (American Geriatrics Society Beers Criteria 
Update Expert, 2012).This is a very important tool to screen persons with polypharmacy because it helps 
identify which specific drugs may pose greater risk.  
 
The Beers Criteria consist in a list of drugs that should be avoided in persons over age 65. The criteria are 




medical literature. The Beers Criteria divides drugs in two drug lists: drugs to be avoided in all older adults, and 
drugs to be avoided only if specific diseases or syndromes are present.  
 
There are several advantages to employing a tool such as the Beers Criteria to screen individuals for increased 
risk of age-associated adverse effects in our sample. First, this list is very comprehensive. The Beers Criteria 
include from antibiotics to drugs used to treat common chronic diseases.  Therefore, it is applicable to the 
general population of older adults in our study, who live in the community and who can be expected to have a 
wide variety of conditions. Second, the Beers Criteria describe drugs that should be avoided in all older adults 
regardless of underlying health conditions. This is also an advantage because we use secondary data and not all 
of the diagnoses of the participants may be known. Third, the Beers Criteria has been validated against hard 
clinical outcomes in many different populations, and it has been demonstrated to be valid and reliable to identify 
situations of greater drug risk that are associated with worse clinical outcomes (Kaufmann, Tremp, Hersberger, 
& Lampert, 2014; Koyama, Steinman, Ensrud, Hillier, & Yaffe, 2014). Lastly, the Beers Criteria are widely 
utilized in studies of older adults, facilitating comparison between the results of our study and results from other 
populations.  
 
There are limitations to this tool; mainly, it does not take into consideration drug dosage, other treatments in use, 
and individual differences between patients, such as preferences and comorbidities. These aspects can be 
addressed by implicit (clinical judgment-based) tools applied on a case-by-case basis (Kaufmann et al., 2014). 
The Beers Criteria heavily focus the definition of inappropriateness on the potential for drug adverse effects. 
Other aspects of appropriateness, such as the potential for non-adherence, the cost-effectiveness profile of the 
drug, and the possibility of under-treatment, are left unaddressed. Also, the Beers Criteria do not recommend 
alternative, safer options to the drugs that they recommend should be avoided. Nevertheless, since their first 
development in 1991, the Beers Criteria have been widely used by clinicians and researchers, including for the 
analysis of secondary data.  
 
In the present study we used the last update of the Beers Criteria, developed by the American Geriatrics Society 
in 2012, to identify potentially inappropriate prescribing in our sample. Due to data limitations we used only the 
component of the Beers Criteria applicable to all older adults irrespective of underlying diagnoses. Out of the 




information (reserpine, aspirin, digoxin and spironolactone). We examined the sliding-scale insulin criteria 
using fast-acting human insulin (ATC code A10AB01) as a proxy.  
 
3.1.9 Drug-Drug Interactions – Tool: Hines’ Review of Potentially Harmful Drug-Drug Interactions in 
the Elderly 
 
In order to examine the presence of DDIs in our sample, we used a list of potentially harmful DDIs compiled by 
Hines and Murphy from a reviewed of evidence from the medical literature focusing specifically on the 
population aged 65 and over (Hines & Murphy, 2011). The final list comprehends over 20 drug classes in 
pairwise combinations. All listed DDIs are severe and clinically relevant, as they are associated with 
significantly increased risk of hospitalization or mortality among the elderly.  
 
We opted for applying the Hine's list to identify DDIs in our sample because of its direct relationship with 
clinically relevant outcomes. Although the list itself has not been validated as a tool, each of the interactions that 
it contains has being explicitly validated against hard clinical outcomes such as hospitalization or mortality. 
Because our main goal was to identify high-risk types of polypharmacy we wanted to minimize the possibility 
of false-positives that could arise from using a computerized DDI screening tool. The results from a previous 
study investigating the possibility of DDIs in the first wave of the SABE survey corroborate our rationale 
(Secoli, Figueras, Lebrao, de Lima, & Santos, 2010). This study, which used a commercial computerized system 
(Micromedex ®) to identify DDIs, found a very high number of individuals exposed to a potential DDI (over 
50% of individuals who took two or more drugs). However, the vast majority (80%) of the DDIs identified were 
of mild to moderate severity. The most frequently identified DDI combinations in that study were captured in 










The overall aim of this study is to quantify the occurrence of drug adverse effect potential among the older adult 
population in Sao Paulo, characterizing the type and level of risk, and its association with polypharmacy. 
 
Specifically, we aim to:  1) measure the overall prevalence of polypharmacy among older adults in Sao Paulo; 2) 
quantify the occurrence of drug risk among those with polypharmacy, assessing the types and levels of risk; 3) 
identify time trends in the occurrence of polypharmacy and in its association with drug risk among this 






Overview of the SABE Study 
 
We use data from a household survey of older individuals age 60 years and older living in the community in the 
city of Sao Paulo, Brazil – the SABE study (Saúde, Bem-Estar e Envelhecimento – Health, Wellbeing and 
Aging). This survey was modeled on the United States Health and Retirement Study. The survey was carried out 
by the University of Sao Paulo in partnership with the Pan-American Organization in 2000, and replicated by 
the team of investigators from University of Sao Paulo in 2006 and 2010.  
 
The SABE study aimed to assess overall patterns of health and wellbeing among the Sao Paulo older adult 
population. The survey employed a multi-stage sampling process based on the Sao Paulo census frame. 
Individuals aged 75 and older were oversampled. When weighted by the inverse probability of selection the 
SABE sample is representative of the non-institutionalized population of 60 year-olds and over living in Sao 
Paulo in each of the survey years. The study's sampling process and data collection protocols were described in 






3.3.2 Variables  
 
The SABE study collected extensive personal and clinical information, mostly through self-report. When 
individuals were unable to adequately inform, interviews were conducted with a proxy.  A summary of the main 
variables collected in the SABE study is presented in Chapter 2.   
 
Demographic characteristics collected included age, gender, marital status (binary coded as married or in a civil 
union versus single, widowed or divorced), race (binary coded as white versus other), and religion (binary coded 
as catholic versus other). Socio-economic characteristics included years of schooling (number of school years 
completed; repeated grades were not considered), number of people who lived in the household, having living 
children (yes, no), having a caregiver (yes, no), and per capita income. Income was measured in Brazilian Reais. 
Participants were asked to inform their total income per month from all different sources (wages, investments, 
pensions, rent, remittances, etc.). Per capita monthly income was calculated by dividing the total reported 
income by the number of people that depended on the income as informed by the participants. 
 
Health care utilization characteristics included health insurance coverage status (having or not having private 
health insurance), number of physician visits in the last 12 months, and whether the participant underwent a 
preventative exam (mammogram for women and prostate exam for men) in the last 24 months.  
 
Health status characteristics included presence and type of chronic conditions, presence and type of symptoms, 
level of disability, and self-reported health status. 
Information on chronic disease was obtained by asking participants if they were ever diagnosed by a doctor or 
nurse with one or more of the following conditions: hypertension, diabetes, heart disease, lung disease, stroke, 
neuropsychiatric disorders, cancer, osteoporosis, and arthritis. Positive responses were aggregated to obtain the 
number of chronic diseases reported by each participant. 
 
Information on symptoms was obtained by asking participants whether they experienced any of the following 




tiredness or fatigue, nausea or vomiting, fecal or urinary incontinence. Positive responses were aggregated to 
obtain the number of symptoms reported by each participant. 
 
Information on disability was obtained by asking participants whether they had difficulties performing one or 
more activities of daily living: walking across a room, getting dressed, bathing, feeding, transferring to/from 
bed, using the toilet, preparing meals, dealing with money, transportation, grocery shopping, using the phone, 
light household chores, and heavy household chores. Positive responses were aggregated to obtain the level of 
disability reported by each participant. 
 
Self-reported health status was obtained by asking participants how they assessed their current health. 
Participants could choose from the following options: excellent, very good, good, regular, bad, or very bad 
health. The information provided by the participants was aggregated to create a binary variable “good” 
(excellent, very good, or good) versus “bad” (regular, bad or very bad) health status.   
 
Health behavior characteristics included smoking, alcohol, and self-medication habits. Smoking was classified 
as currently smoking versus not currently smoking. Alcohol use was classified as current alcohol use versus no 
current alcohol use. Self-medication information was obtained by asking who had issued the prescription for 
each of the drugs that a participant was using. If any of the drugs been started by the participant on their own 
will or on recommendation from family members/ friends, without a prescription issued by a health provider, 
the information was recorded as self-medication. If all drugs were prescribed by a health professional, or if the 
person did not take any drugs, the information was recorded as no self-medication. 
 
3.3.3 Drug Utilization 
 
Although medicines were not the primary focus of the SABE survey, comprehensive information on drug 
utilization was collected from both participants' self-report and from investigators' direct observation of pill 
bottles, blister packs, and medicine boxes. Information on drug dosage or number of intakes a day was not 
collected. All types of pharmaceutical products were recorded.  That included prescription and over-the-counter 
drugs, compounded drugs, and herbal and homeopathic products.  
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The SABE study recorded prescription and over-the-counter drugs using the World Health Organization's 
Anatomical Therapeutic Chemical (WHO-ATC) classification. The goal of the WHO-ATC classification is to 
operationalize drug utilization research, providing a "standard language" for "exchanging and comparing data on 
drug use at international, national or local levels" (WHO Collaborating Centre for Drug Statistics Methodology). 
The WHO-ATC classification indexes active ingredients of allopathic drugs using alphanumeric codes. In this 
classification the drugs are first divided according to the organ or system in which they act (level 1), and then 
they are progressively subdivided according to therapeutic subgroup (level 2), pharmacological subgroup (level 
3), and chemical subgroup (level 4). The final level (level 5) identifies the specific drug (WHO, 2017). The 
WHO-ATC classification does not include products such as herbal and homeopathic preparations.
 
As an example, we present the WHO-ATC code for the commonly used painkiller acetaminophen, also called 
paracetamol and commercially available as Tylenol®. The main WHO-ATC code for paracetamol is N02BE01. 
The code reveals the following information (Box 3.1):  
Box 3.1 WHO-ATC code for paracetamol 
 
Source: WHO-ATC index, https://www.whocc.no/atc_ddd_index/?code=N02BE01 
There are 14 therapeutic groups represented as first-level categories in the WHO-ATC classification (Box 3.2): 
N Nervous System 
N02 Analgesics 




Box 3.2 WHO-ATC therapeutic groups 
Source: WHO-ATC index, https://www.whocc.no/atc_ddd_index/ 
Each of the allopathic drugs in use by a SABE participant was recorded not by the drug's name, but by the drug's 
alphanumeric WHO-ATC code. General labels specifying their category recorded herbal, homeopathic, and 
compounded products. The labels did not contain information on the product's active ingredients, preventing us 
from using herbal, homeopathic, and compounded products in our analysis.  
Using the survey information we created an indicator variable to identify polypharmacy (individuals using five 
or more prescription or over-the-counter drugs) and an indicator variable to identify excessive polypharmacy 
(individuals taking ten or more prescription or over-the-counter drugs).  
We also counted the number of different WHO-ATC level-1 categories that were represented in each 
participant’s drug regimen. A larger number of WHO-ATC categories reflected persons taking drugs to treat 
multiple organs or systems. If a person was taking five drugs to treat asthma, for example, their number of 
medicines in use would be five, they would classify as polypharmacy, but they would have only one WHO-ATC 
category. 
A participant recorded drug expenditures as the total amount reportedly spent on pharmaceuticals, in Brazilian 
Reais, in the last month.   
Code  Contents 
A  Alimentary tract and metabolism 
B  Blood and blood forming organs 
C  Cardiovascular system 
D  Dermatologicals 
G  Genito-urinary system and sex hormones 
H  Systemic hormonal preparations, excluding sex hormones and insulins 
J Anti-infectives for systemic use
L  Antineoplastic and immunomodulating agents 
M  Musculo-skeletal system 
N  Nervous system 
P  Anti-parasitic products, insecticides and repellents 
R  Respiratory system 
S  Sensory organs 





3.3.4 Implementation of the Drug Risk Assessment Tools 
 
The prescription and over-the-counter drugs used by the SABE study participants had been recorded using 
WHO-ATC codes. In order to operationalize the analysis of participants' drug regimens, we encoded the drugs 
listed in our selected tools using the same WHO-ATC classification.  
 
Each of the tools that we selected contained a list of drugs that were associated with a particular type of risk. We 
converted the drug names provided in each of the tools into the drugs' corresponding WHO-ATC codes. We 
defined two guidelines when encoding the drug names. First, all the tools focused on drugs of oral use. 
Therefore, in the case that the WHO-ATC classification provided more than one code for the same drug 
according to the mode of utilization (oral versus topic), we applied only the code that corresponded to the drug's 
oral preparation.  
 
Second, the WHO-ATC classification provides different codes for the same drug according to whether the drug 
is part of a single or combined preparation. For example, the acetaminophen in Tylenol is coded as N02BE01 
because it is the only active ingredient in the pill. The acetaminophen in Excedrin, however, is coded as 
N02BE51 because the pill is a combination of acetaminophen and caffeine. We were interested in capturing all 
the possible commercial preparations of each drug; therefore, we applied all single- and combined-preparation 
codes for each drug provided in the WHO-ATC classification, as long as they corresponded to oral use. 
 
We systematically evaluated the drug regimens from each of the SABE participants using our selected drug risk 
tools. We used Stata Statistical Software9 to automate the application of the tools to the SABE dataset. The 
software compared the WHO-ATC drug codes in each participant's record to the WHO-ATC drug codes listed 
in each of the tools.  
 
For the Beers Criteria, the software produced a binary result for each drug that the participant was taking. If 
there was no match, i.e., if the drug was not part of the Beers Criteria, the result was zero. If there was a match, 
i.e., if the participant's drug was part of the Beers Criteria, the result was one.  
 
                                                      




The results from the Beers Criteria were used to create two variables: one variable indicated the presence of any 
inappropriateness. This variable was equal to one if any of the participant's drugs matched the Beers Criteria. 
The other variable indicated the total level of inappropriateness identified in the participant's drug regimen. This 
variable was equal to the total number of drugs in a participant's regimen that matched the Beers Criteria.  
 
For the ARS scale, the software produced a categorical result attributing a score to each of the drugs.  Again, if 
there was no match between the participant's drug and the ARS scale, the result was zero. When there was a 
match between the participant's drug and the ARS scale, the result corresponded to the drugs' score in the ARS. 
For drugs identified in the ARS as having no anticholinergic potential the result was zero; for drugs with 
moderate anticholinergic potential the result was one; for drugs with strong anticholinergic potential the result 
was two; and for drugs with very strong anticholinergic potential the result was three.  
 
The results from the ARS scale were used to create two variables: one variable indicated the presence of any 
anticholinergic drug risk. This variable was equal to one if any of the participant's drugs had a score equal to or 
greater than one in the ARS scale. The other variable indicated the total anticholinergic risk represented in the 
participant's drug regimen. This variable was equal to the sum of ARS scores for all the drugs that a participant 
was taking.  
 
For the Hines DDI list, the software analyzed not drugs, but drug combinations. The software first identified 
whether each drug in a participant's regimen was part of the Hines list. If yes, the software then analyzed all the 
other drugs in the regimen to check if they presented a DDI combination with the first drug. The software 
produced two variables for each participant. The first variable indicated the presence of any DDI combinations 





In the first part of the analysis we examined the combined pool of all participants in the SABE study. This 
analysis reflects average patterns across the three survey waves. We did not employ inverse-probability weights 





The pooled analysis examined overall sample characteristics as well as general patterns of drug utilization and 
drug risk. Specifically, we examined the main characteristics of SABE participants, the overall frequency and 
level of drug use; the distribution of drug risk criteria across the overall sample and across different levels of 
drug utilization; the relationship between the multiple risk measurements; and the relationship between drug risk 
levels and clinical characteristics. 
 
In the second part of the analysis, we examined the sample from each of the survey waves separately. We 
applied the survey’s inverse-selection probability weights to reconstruct the Sao Paulo population of older adults 
in each of the survey years. This analysis reflects year-specific estimates of patterns of drug utilization and drug 
risk among the Sao Paulo older adult population.  
 
The cross-sectional analysis examined differences over time in drug utilization and drug risk. We examined 
drug utilization trends by therapeutic drug class; trends in prevalence and levels of chronic diseases; and trends 
in utilization of drugs according to the ARS scale and the Beers Criteria.  
 
We utilized cross-tabulations and graphs to explore the associations between polypharmacy and inappropriate 
polypharmacy. We used Chi-squared tests (in the case of dichotomous or categorical variables) and t-tests (in 
the case of continuous variables) to compare characteristics across persons with and without polypharmacy or 
drug inappropriateness. We used Stata Statistical Software to perform most of the analysis, and Microsoft 
Excel10 to produce some of the graphs. 
  
                                                      







3.4.1 Part I – Pooled Analysis 
 
Sample Characteristics - Overview 
 
The final sample of the SABE study constituted of a total of 4,889 participants distributed as follows: 2,143 
participants in 2000, 1,413 participants in 2006 and 1,333 participants in 2010. Out of the total 4,889 
participations in the SABE study 2,796 (57%) individuals participated in only one wave; 1,408 (29%) 
participated in two waves; and 685 (14%) participated in the three survey waves11. 
 
The main characteristics of the SABE study participants - demographic, socio-economic, health status, health 
care utilization and health behavior - are displayed in Table 3.1. 
 
 In summary, participants in the pooled SABE sample tended to be women on their mid-70’s, who were white, 
catholic, and married, tended to have low- to medium socioeconomic status, to be in poor health, to have about 
two comorbid chronic conditions and to have disability about two activities of daily living. Participants 
frequently utilized health services but most often were not covered by private health insurance. Unhealthy 
behaviors such as smoking, drinking, and self-medicating were infrequent. We describe and discuss each of the 
characteristics in more detail below.   
 
                                                      
11 There may be correlations across participants in each of the survey waves, as some individuals participated multiple times. We do not 
believe this was a major limitation, because most individuals participated in one single wave and those who participated in more than one 
were distributed across the three years. 
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Table 3.1!Characteristics of the SABE study participants (pooled sample) 
!
Notes: N: number of participants with information. ADL: Activities of daily living. 
The SABE study participants were on average 73 ± 9 years old. The minimum age was 60 years and the 
maximum age was 104 years. Most of the participants (61%) were female, married (51%), white (67%) and 
catholic (67%). 
Participants completed on average 4.1 years of education. The minimum was no formal education (zero years) 




amount represented almost 2 times the minimum wage.12 The median income was R$ 340.00, which was about 
the minimum wage. Income varied from no income (if an individual had no personal income and depended 
exclusively on others) to a maximum of R$ 25,000.00 per month. The relatively high average income observed 
in the sample was driven by a very right-skewed distribution that likely reflects the very stark income inequality 
in the city of Sao Paulo.  Most participants (96%) had at least one child who was alive. On average participants 
had 3.5 living children. Twenty-seven percent of participants had a caregiver.  
 
Less than half of participants (45%, n=2161) reported feeling in good, very good, or excellent health. Most 
participants (55%, n=2660) felt in regular, bad, or very bad health. The information on chronic diseases, 
symptoms and disability levels is in line with this finding. Less than a fifth of participants (17%, n=806) did not 
have a chronic disease; 83% had at least one chronic disease. Each individual had, on average, about 2 chronic 
diseases. The maximum number of chronic diseases was eight, which is very high given that information was 
collected on only nine chronic conditions. The most common number of chronic conditions was two per person 
(26% of participants, n=1285, and only about 6% of participants than five or more chronic diseases.  
 
The level of clinical symptoms and the level of disability reflect the severity of disease. These characteristics are 
important to differentiate between individuals with chronic conditions that are stable and under control from 
individuals who have a greater burden from the chronic conditions. The number of symptoms captures the 
degree to which a participant feels clinically unwell. The level of disability captures the degree to which the 
participant is impaired in their capacity to perform activities of daily living.  
 
Participants reported an average of 1.5 symptoms. The minimum number of symptoms per person was zero (no 
symptoms) and the maximum was eight. Most individuals (34%, n=1683) had no symptoms. About 7% of 
participants had five or more symptoms. Three participants (0.06%) reported experiencing all of the eight 
symptoms investigated.  
 
                                                      
12 The minimum wage mid-period between 2000 and 2010 was R$ 300. The minimum wave in Brazil was R$ 180.00 in 2000 and reached 





Participants reported disability in performing an average of 1.9 activities of daily living. The majority of 
participants (51%, n=2501) did not have any disability. Fourteen percent (n=692) of participants reported 
disability in performing one activity of daily living; 18% (n=892) had disability in two, three or four activities; 
and about 16% (n=804) had disability in five or more activities of daily living. Of note, 99 participants (2%) 
reported disability in all 12 activities of daily living investigated in the survey. 
 
Less than half of participants had private health insurance (43%, n=2084). The majority of participants (57%, 
n=2802) depended exclusively on the public health system to obtain their care. Yet, participants reported an 
average of six medical visits in the last year, and the majority of participants reported having undergone a 
preventative exam in the last two years.  
 
Twelve percent of participants reported currently smoking (n=589); 28% reported currently using alcohol 
(n=1373) and 28% reported self-medicating (n=1837). 
 
Drug Utilization in the Pooled Sample  
 
The majority of SABE participants took at least one prescription or over-the-counter drug. In summary, 
participants tended to use multiple drugs belonging to diverse therapeutic groups. Polypharmacy was relatively 
common but excessive polypharmacy was rare. Use of herbal and homeopathic products was relatively frequent, 
but participants tended to use very low numbers of these products as compared to prescription or over-the-
counter drugs.  Out of pocket drug expenditures were in general low. We describe the main drug utilization 
characteristics of the SABE study participants in greater detail below (Table 3.2). 
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Table 3.2 Overview of drug utilization metrics among SABE participants 
!
Note: WHO-ATC: World Health Organization's Anatomical Therapeutic Chemical classification; Drug Expenditure: self-reported out-of-
pocket payments with drugs on the last month, in Brazilian Reais.  
Most participants (86%, n=4196) were taking at least one prescription or over-the-counter drug at the time of the 
survey. Fourteen percent (n=693) were not taking any prescription or over-the-counter drug. Participants used 
on average 3.25 prescription or over-the-counter drugs, corresponding on average to 2.15 therapeutic groups of 
the WHO-ATC classification.
About 27% of participants were with polypharmacy (n=3562); about 2.5% (n=121) were on excessive 
polypharmacy. The maximum number of prescription or over-the-counter drugs reported by a participant was 17 
drugs. About 30% of participants (n=1501) took at least one herbal or homeopathic product. On average, 
participants took less than one herbal or homeopathic product. When all types of pharmaceutical products were 
considered, the maximum number of pharmaceutical products reported by a participant was 19. 
Information on drug expenditures was missing for 12% of participants (n=572).  Those with information 
reported spending an average of R$ 64.87 per month on pharmaceuticals. The median monthly expenditure with 
pharmaceuticals was R$ 25.00. Participants reported spending up to R$ 2,000.00 per month on pharmaceuticals.  
About 20% of individuals with spending information (870 out of 4317 participants) reported not having spent 
money on pharmaceuticals in the last month. Of those who were taking drugs 19.5% also reported not having 
spent any money on pharmaceuticals in the last month (829 out of 4244 individuals).  
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Figure 3.1 displays the overall pattern of drug utilization among the participants. The overall distribution of drug 
utilization in the pooled SABE sample was as follows: from the total 4,889 participants, 693 (14%) were not 
taking any drugs and 4,196 (86%) were taking at least one prescription or over-the-counter drug.   
A total of 2,869 participants (59% of the sample, 68% of those taking drugs) were using drugs but not 
polypharmacy (1-4 drugs). A total of 1,327 individuals (27% of the sample, 32% of those taking any drugs) 
were with polypharmacy (5 or more drugs). Of those, 121 individuals (2% of the total sample) were taking 
excessive polypharmacy (10 or more drugs). 
Figure 3.1 Pattern of drug utilization among pooled SABE participants!
 
Note: Only prescription and over-the-counter drugs are included in the analysis. 
Inappropriate polypharmacy - Patterns of drug risk in the pooled sample 
Overall, 2012 (41%) of the individuals in our sample had at least one criterion for increased drug risk. The 
possibility of drug risk was higher among participants with polypharmacy (66%) and on those with excessive 




The Beers Criteria was most common form of drug risk identified in our sample. Anticholinergic effects 
measured by the ARS scale and DDIs measured by the Hines’ List were the second and third most frequent 
forms of drug risk. Of the overall sample, 38% of participants had at least one drug that was part of the Beers 
Criteria, 13% had at least one drug that had anticholinergic properties, and 2% had a clinically relevant drug 
interaction (Table 3.3). The average Beers score across the pooled sample was 0.49. The Beers score reflects the 
total number of drugs from a person’s pharmaceutical regimen that are identified as potentially inappropriate by 
the Beers Criteria. This indicates that the average person tended to be taking half a Beers-criteria drug. Of the 
1,835 participants who had a positive Beers criterion, 74% (n=1,364) had only one drug that was potentially 
inappropriate; 21% (n=382) had two drugs, 4% (n=73) had three drugs and 1% (n=16) had four drugs that were 
potentially inappropriate. 
 
 The average ARS score across the pooled sample was 0.32. Differently from the Beers, the ARS score is not a 
simple count. Rather, the ARS score reflects the total anticholinergic potential of a person’s pharmaceutical 
regimen. Each separate drug contributes points to the total score according to its anticholinergic potential: a drug 
can have from 0 points - no anticholinergic potential - up to 3 points – very strong anticholinergic potential. A 
person’s total ARS score is the sum of all points corresponding to the drugs in their pharmaceutical regimen.  
 
Out of 619 individuals who had a positive ARS score, 48% (n=298) had a total ARS score of 3. These 
individuals could be taking one single drug with very strong anticholinergic potential (3 points), or they could 
be taking combinations of drugs with moderate (1 point) or strong (2 points) anticholinergic potential. The next 
most common ARS score was 1 (n=165, 27%), indicating individuals who were taking only one drug with 
moderate anticholinergic potential (1 point). ARS scores higher than 3 were rare (less than 10% of those with 
positive ARS score). However, ARS scores were as high as 12. This score could reflect drug combinations of, 
for example, four drugs with very strong anticholinergic potential (3 points each), or six drugs with strong 
anticholinergic potential (2 points each), etc.  
 
Drug interactions were very rare in our sample. Only about 2% of the participants (n=88) had a drug interaction 
captured by the Hines list. Most of them had only one DDI; three people had two DDIs and one had three DDIs. 





Table 3.3 Patters of drug risk in the pooled sample and according to the number of drugs  
 
Notes: ARS: anticholinergic risk scale; DDI: drug-drug interaction. p-values correspond to the comparison across the three drug utilization 
groups (1-4 drugs, 5-9 drugs, and 10 or more drugs) and were calculated by F-tests in linear regressions of each risk variable on the three 




Relationship between number of drugs and presence and type of drug risk  
 
All measures of drug risk tended to increase at greater numbers of drugs in a pharmaceutical regimen (Table 3). 
Any drug risk was present in 39% of persons taking 1-4 drugs, 66% of those taking 5-9 drugs, and 84% of those 
taking 10 or more drugs (Figure 3.2).  
 
In univariate analyses, persons with polypharmacy had about three times greater odds of any drug risk as 
compared to persons taking drugs but not polypharmacy (odds ratio: 2.97; 95% confidence interval: 2.62 – 
3.38). Persons on excessive polypharmacy had over eight times greater odds of any drug risk as compared to 
those taking 1-4 drugs (odds ratio: 8.41, 95% CI: 5.12 – 13.80). Each additional drug on a therapeutic regimen 
increased the odds of drug risk by about 50% on average (odds ratio: 1.52, 95% CI: 1.48 – 1.57).  
 
The main form of drug risk identified in all utilization groups was captured by the Beers Criteria: 36% of those 
taking 1-4 drugs, 58% of those taking 5-9 drugs, and 81% of those taking 10 or more drugs had at least one 
potentially inappropriate drug identified by the Beers Criteria. Beers scores also tended to increase as the 
number of drugs in a pharmaceutical regimen increased – the average Beers score in the 10+ drugs group was 
over three times higher than the average score of those taking 1-4 drugs. Each additional drug increased the odds 
of having positive Beers Criteria by about 40% on average (odds ratio: 1.43, 95% CI: 1.39 – 1.47). 
 
Variable All	sample 1-4	drugs 5-9	drugs 10+	drugs
Mean	(sd) N=4889 N=2869 N=1206 N=121
Any	risk	criteria 	0.41	(0.49) 	0.39	(0.49) 	0.66	(0.48) 	0.84	(0.37) <0.0001
1	Criteria 	0.31	(0.46) 	0.32	(0.47) 	0.46	(0.50) 	0.33	(0.47) <0.0001
2	Criteria 	0.10	(0.30) 	0.07	(0.26) 	0.19	(0.39) 	0.49	(0.50) <0.0001
3	Criteria 	0.00	(0.05) 	0.00	(0.00) 	0.01	(0.09) 	0.02	(0.16) <0.0001
Any	BEERS	Criteria 	0.38	(0.48) 	0.36	(0.48) 	0.58	(0.49) 	0.81	(0.39) <0.0001
BEERS	score 	0.49	(0.73) 	0.42	(0.61) 	0.85	(0.91) 	1.41	(0.96) <0.0001
Any	ARS	drug 	0.13	(0.33) 	0.10	(0.30) 	0.23	(0.42) 	0.48	(0.50) <0.0001
ARS	score 	0.32	(0.94) 	0.24	(0.77) 	0.58	(1.24) 	1.38	(2.03) <0.0001
Any	DDI 	0.02	(0.13) 	0.00	(0.05) 	0.05	(0.22) 	0.09	(0.29) <0.0001
p-value
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A similar pattern was observed in the distribution of anticholinergic risk as measured by the ARS scale. Any 
anticholinergic risk was over two times more frequent among persons taking 5-9 drugs (23%) and over four 
times as frequent among those taking 10 or more drugs (48%) than among persons taking 1-4 drugs per day 
(10%). 
The distribution of DDI was markedly associated with increased number of drugs in a therapeutic regimen- of 
the 81 persons with a DDI, about 76% (n=62) were taking 5-9 drugs and 14% (n=11) were taking 10 or more 
drugs. It is important to mention, however, that about 10% of DDIs occurred among persons taking 1-4 drugs. 
Also, the highest number of DDIs – 3 DDIs – was identified in a participant taking four drugs (Glibenclamide, 
Nifedipine, Erythromycin and Buspirone). Figure 3.2 displays the overall pattern of drug risk identified in the 
pooled SABE sample. Only participants who took at least one drug are displayed.  





Relationship between the different drug risk metrics   
 
As shown in Figure 3.2, 67% of persons with polypharmacy had at least one drug risk criterion, as opposed to 
39% of those without polypharmacy. In general (unadjusted analyses), polypharmacy was associated with a 
70% greater probability of having at least one drug risk criterion in our sample.   
  
Figure 3.2 also shows that there was an overlap between some of the criteria – people scoring on two or more 
criteria. Among those without polypharmacy, a total of 1329 different risk criteria were identified, but only 1118 
participants had a positive criterion. In this group, 211 individuals had some overlap between the metrics. 
Among those with polypharmacy, the overlap was even higher. A total of 1206 different criteria were identified, 
but only 894 persons had a positive drug risk criteria. In this group, 312 individuals had some overlap between 
the metrics.  
 
We explore the degree of overlap between the metrics by creating a Venn diagram of the three drug risk metrics 
(Figure 3.3). We observe that the main overlap occurs between the Beers Criteria and the ARS scale. The degree 
of overlap is very significant: 77.5% (480 out of 619) of those who had any anticholinergic risk according to the 
ARS score were also positive for a potentially inappropriate medication according to the Beers Criteria.  
 
However, the 480 individuals with overlapping Beers and ARS criteria represented only 26% of the 1,835 total 
individuals who had a positive Beers criterion. These findings indicate that the Beers Criteria is able to detect a 
significant portion of pharmaceutical regimens’ anticholinergic risk. Using a tool such as the ARS scale allowed 
us to identify about 8% more cases of drug risk than we would had found using the Beers Criteria alone. 
 
The overlap between Beers Criteria and the Hines list of DDIs was also noteworthy. Out of the 81 total DDI 
cases identified by the Hines list, 41 (51%) were also captured by the Beers Criteria. Even though the total 
number of DDI cases was very small (about 2% of the total sample), the use of the Hines list allowed us to 




There was minimal overlap between the results from the ARS and the Hines tools. Most of the overlap between 
these tools (13 out of 15 cases) was also picked up by the Beers Criteria.   
Figure 3.3 Overlap between the different drug risk assessment tools!
Note: percentages reflect the proportion of people taking at least one drug who fulfill each criterion. All persons taking at least one drug 
(n=4,196) are accounted for in the figure. ARS: anticholinergic risk scale; DDI: drug-drug interaction. 
Relationship between number of drugs and level of drug risk  
Most of the overlap between the tools occurred in persons who were using greater number of drugs (Figure 3.4). 
Among persons taking 1-4 drugs, 61% (n=1751) did not have any drug risk criteria; 32% (n=907) had one 
criterion; 7% (n=211) had two; and no persons had all three drug-risk criteria. 
Among persons taking 5-9 drugs, 34% (n=414) did not have any drug risk criteria; 46% (n=555) had one 
criterion; 19% (n=227) had two; and 1% (n=10) had all three drug-risk criteria.  
Among persons taking 10+ drugs, 16% (n=19) did not have any drug risk criteria; 33% (n=40) had one criterion; 
49% (n=59) had two; and 2% (n=3) had all three drug-risk criteria.  
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Figure 3.4 Level of risk according to the number of drugs 
!
Relationship between level of drug risk and individual characteristics 
It is important to understand whether having greater number of drug risk criteria reflects a simple 
methodological issue of overlap between the tools, or whether greater number of drug risk criteria truly 
represent greater levels of risk.  
Table 3.4 compares selected demographic, health status, health care utilization, and health behavior 
characteristics across different levels of drug risk as identified by the Beers Criteria, ARS scale and Hines list of 
clinically relevant DDIs.  
Persons with greater levels of drug risk tended to be older, more frequently female, have poorer health and 
greater number of medical visits than persons with lower levels of drug risk. There was no difference in terms of 





Taken together, these findings indicate that greater levels of drug risk as measured by the different tools do 
correlate with differences in health status. It is not possible to identify the extent to which (if at all) drug risk 
may be contributing to the observed differences in health status. Further research should be conducted to 
elucidate these associations.  
 
Table 3.4 Relationship between drug risk levels and clinical characteristics 
 
Note: ADL: Activities of daily living. 
  
 
3.4.2 Part 2 – Cross Sectional Analysis – Differences over Time  
 
Across the three waves of the SABE study – 2000, 2006 and 2010 – there was a great increase in drug 
utilization. While a high number of participants (82%) was taking medicines in 2000, an even higher number 
(90%) was taking medicines in 2010. Theaverage number of drugs per person was about 2.7 drugs in 2000 and 
increased to about 4 drugs in 2010. The maximum number of drugs per person also increased, from 14 in 2000 
Variable No	risk 1	Criteria 2-3	Criteria p-value
Mean	(sd) N=2,877 N=1,502 N=510
Demographic
Age 	73.07	(9.24) 	73.54	(8.62) 	74.70	(8.93) 0.0006
Female	gender 	0.57	(0.49) 	0.65	(0.48) 	0.73	(0.44) <0.0001
Health	Status
Good	self-reported	health 	0.53	(0.50) 	0.34	(0.47) 	0.33	(0.47) <0.0001
Any	chronic	diseases 	0.77	(0.42) 	0.92	(0.26) 	0.92	(0.27) <0.0001
Nr.	chronic	diseases 	1.62	(1.35) 	2.40	(1.42) 	2.70	(1.56) <0.0001
Nr.	of	symptoms 	1.29	(1.50) 	1.77	(1.70) 	2.18	(1.84) <0.0001
Nr.	ADLs	with	disability	 	1.50	(2.63) 	2.30	(3.14) 	3.23	(3.58) <0.0001
Health	Care	Utilization
Health	insurance 	0.42	(0.49) 	0.41	(0.49) 	0.49	(0.50) 0.0082
Medical	visits	last	12	months 	4.97	(8.59) 	6.82	(9.46) 	9.29	(17.43) <0.0001
Preventative	exam	last	24	mo. 	0.48	(0.50) 	0.49	(0.50) 	0.51	(0.50) NS
Health	Behaviors
Currently	smoking 	0.14	(0.34) 	0.10	(0.30) 	0.10	(0.29) 0.0008
Current	alcohol	use 	0.32	(0.47) 	0.24	(0.43) 	0.20	(0.40) <0.0001




to 17 in 2010.  The frequency of polypharmacy more than doubled, from 18% to 40%, and the frequency of 
excessive polypharmacy quintupled from 1% to 5% over the 10-year period (Table 3.5).  
 
The occurrence of drug risk, however, exhibited a different trend. In 2000, 43% of individuals had any form of 
drug risk ; in 2010, 39% of individuals had some form of drug risk. Most of this change was driven by a decline 
in the frequency of risk detected by the Beers Criteria. In 2000, 40% of participants had one or more Beers 
Criteria; in 2010, 35% of participants had one or more Beers Criteria.  The average Beers score also declined, 
from an average of 0.54 criteria per person in 2000 to 0.44 criteria per person in 2010.  
 
In fact, drug risk measured by the ARS scale and by the Hines list of clinically significant DDIs exhibited 
growth, not decline, over the 10-year period. Any anticholinergic risk went from 11% of the sample to 13% of 
the sample; the average ARS score increased from 0.27 to 0.36; and the presence of DDIs according to the 
Hines list went from 1% to 3% of the sample in this period.  
 
As we discussed earlier, however, the relative contribution of the ARS and the Hines tools to the overall drug 
risk detection was very small. The largest component of risk detection in this sample was captured by the Beers 
Criteria, and so the decrease in the frequency of Beers-detected risk had a greater impact on the overall trend 
than the increases in the frequency of ARS- and Hines-detected risk.    
 
Figure 3.5 displays a comparison between the increases in drug utilization  and the increases in drug risk over 
time. Drug risk is presented as the proportion of cases with any risk criteria. While any utilization increased by 
about 1% a year, any risk decreased by about 0.4% a year. While polypharmacy increased by about 2% a year, 
the percentage of individuals with drug risk among those with polypharmacy grew at a slower rate, of about 1% 
a year.   
 
While 77% of persons with polypharmacy (n=294 out of 382) had at least one risk criteria in 2000, 68% (n=279 
out of 410) had at least one risk criteria in 2006 and 60% (n=321 out of 525) had at least one risk criteria in 





These findings suggest that, although drug utilization grew significantly among older adults in Sao Paulo in the 
10-year period, the type of drugs that individuals are taking is changing. Most specifically, older adults are less 
likely to be exposed to drugs deemed of "potential inappropriate use" by the Beers Criteria. This may not 
necessarily reflects changes in prescription practices. In Brazil, many drugs may be purchased without a medical 
prescription. Hence, there may be other drivers, such as cultural preferences, availability of drugs in the market, 
drug prices, and others, that may be contributing to the shift on the types of drugs being used by the Sao Paulo 
older adult population.  
 
In addition, the reduction is not occurring across all dimensions of drug risk. The two other tools that we utliized 
identify relatively small, but important increases in the occurrence of anticholinergic risk and drug interactions 
over time. These sources of risk, although less frequent than the inappropriateness captured by the Beers Criteria, 
are also clinically relevant and should not be ignored.  
 
Table 3.5 Trends in drug utilization and drug risk across the SABE survey waves 
 
Note: polypharmacy: five or more prescription or over-the counter drugs; excessive polypharmacy: ten or more prescription or over-the 
counter drugs; ARS: anticholinergic risk scale; DDI: drug-drug interaction. p-values and were calculated by F-tests in linear regressions of 
each variable on indicators for the three years. 
Variable( Year(2000( Year(2006( Year(2010(
p/value(Mean((sd)( N=2143( N=1413( N=1333(
Drug(Utilization( ! ! ! !
Any!drugs! !0.82!(0.38)! !0.88!(0.33)! !0.90!(0.30)! <0.0001!
Avg.!nr.!drugs! 2.67!(2.19)! 3.34!(2.55)! 4.09!(2.97)! <0.0001!
Nr.!drugs,!range! 0!!=!!14!! 0!!=!!15!! 0!!=!!17!! !
Polypharmacy! !0.18!(0.38)! !0.29!(0.45)! !0.40!(0.49)! <0.0001!
Excessive!polyph.! !0.01!(0.09)! !0.03!(0.16)! !0.05!(0.22)! <0.0001!
Drug(Risk( ! ! ! !
Any!risk!criteria! !0.43!(0.50)! !0.41!(0.49)! !0.39!(0.49)! 0.0319!
1!Criteria! !0.34!(0.47)! !0.30!(0.46)! !0.27!(0.44)! 0.0001!
2!Criteria! !0.09!(0.29)! !0.10!(0.31)! !0.11!(0.32)! 0.0007!
3!Criteria! !0.00!(0.02)! !0.00!(0.07)! !0.00!(0.07)! 0.0312!
Any!BEERS!
Criteria!
!0.40!(0.49)! !0.36!(0.48)! !0.35!(0.48)! 0.0035!
BEERS!score! !0.54!(0.76)! !0.47!(0.72)! !0.44!(0.69)! 0.0005!
Any!ARS!drug! !0.11!(0.32)! !0.14!(0.35)! !0.13!(0.34)! 0.0429!
ARS!score! !0.27!(0.83)! !0.35!(1.03)! !0.36!(1.01)! 0.0061!






Figure 3.5 Year trends in drug utilization and risk  
 
Note: The table presents a comparison between the proportion of individuals in the SABE study that had any drug utilization and the 
proportion of persons with any drug use who also had any drug risk criteria (left); and a comparison between the proportion of individuals in 
the SABE study that had polypharmacy and the proportion of persons with polypharmacy who also had any drug risk criteria (right). 
 
Drug Utilization Trends by Therapeutic Class 
 
In order to contribute to elucidating the trends in drug risk that we described in the previous section, we explore 
the drugs most commonly utilized among our sample in each of the survey waves. First, we examine the 
different therapeutic drug classes according to the WHO-ATC classification (Table 3.6).  We also explore trends 
in the underlying health conditions that might require such drugs. We describe chronic disease trends in the next 
section. 
 
The drug classes that exhibited the most significant increases were drugs related to the cardiovascular system 
(WHO-ATC category C), which increased from 0.94 to 1.61 drugs per person in the 10-year period.  The second 
largest increase occurred among drugs related to the alimentary tract and metabolism (WHO-ATC category A), 
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the nervous system (WHO-ATC category N), which increased from 0.45 to 0.61 drugs per person in the 10-year 
period. 
 
The use of systemic hormonal preparations, excluding sex hormones and insulin (WHO-ATC category H) 
increased from 0.04 to 0.16 drugs per person; and drugs related to the sensory organs (drugs for ophthalmic and 
otologic use, WHO-ATC category S) increased from 0.05 to 0.10 drugs per person in the period.  
 
No drug class had decreases in utilization over time. Drugs related to the blood and blood forming organs, 
dermatologic drugs, genito-urinary system and sex hormones, anti-infective, antineoplastic and 
immunomodulating agents, drugs related to the musculo-skeletal system, anti-parasitic products, drugs related to 




Table 3.6 Drug utilization trends by WHO-ATC therapeutic class  
 
Note: contents represent average number of drugs per person among the pooled SABE sample (left) and in each of the study waves. p-values 
calculated by F-tests in linear regressions of each variable on indicators for the three years. "Sensory" drugs are those for ophthalmic and 
otologic use.  
 
 
Figure 3.6 displays the trajectories of each WHO-ATC therapeutic class across the study periods, so that the 
relative patterns of change across classes can be visualized. Although drugs related to the cardiovascular system, 
Nr.	Drugs	WHO	Category Pooled Year	2000 Year	2006 Year	2010 p-value
Mean	(sd) N=4889 N=2143 N=1413 N=1333
	A	 Aliment-Metabol 	0.63	(0.93) 	0.49	(0.80) 	0.61	(0.90) 	0.88	(1.08) <0.0001
	B	 Blood 	0.21	(0.44) 	0.19	(0.42) 	0.28	(0.49) 	0.18	(0.42) <0.0001
	C	 Cardiovascular 	1.24	(1.32) 	0.94	(1.12) 	1.35	(1.31) 	1.61	(1.49) <0.0001
	D	 Dermatologic 	0.04	(0.23) 	0.04	(0.23) 	0.04	(0.24) 	0.03	(0.21) NS
	G	 Genito-Urinary 	0.04	(0.21) 	0.04	(0.22) 	0.03	(0.18) 	0.05	(0.23) NS
	H	 Hormones 	0.09	(0.30) 	0.04	(0.21) 	0.09	(0.29) 	0.16	(0.39) <0.0001
	J	 Antiinfectives 	0.04	(0.21) 	0.04	(0.21) 	0.04	(0.21) 	0.04	(0.22) NS
	L	 Antineoplastics 	0.01	(0.10) 	0.01	(0.09) 	0.01	(0.08) 	0.01	(0.12) NS
	M	 Musculo-Skeletal 	0.24	(0.51) 	0.24	(0.51) 	0.22	(0.48) 	0.26	(0.53) NS
	N	 Nervous	System 	0.49	(0.78) 	0.45	(0.73) 	0.43	(0.77) 	0.61	(0.87) <0.0001
	P	 Antiparasitic 	0.01	(0.08) 	0.01	(0.08) 	0.01	(0.08) 	0.00	(0.07) NS
	R	 Respiratory 	0.13	(0.46) 	0.13	(0.44) 	0.13	(0.48) 	0.14	(0.48) NS
	S	 Sensory 	0.07	(0.36) 	0.05	(0.28) 	0.08	(0.40) 	0.10	(0.42) 0.0001
	V	 Various 	0.01	(0.09) 	0.01	(0.10) 	0.01	(0.12) 	0.00	(0.05) 0.0348
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the alimentary tract, and the nervous system exhibited utilization increases over time, the magnitude of the 
change and the levels of utilization were far more marked among drugs related to the cardiovascular system. 
This pattern may reflect the epidemiologic changes in our sample that we describe below. 
Figure 3.6 Drug utilization trends by WHO-ATC therapeutic class  
Epidemiologic Trends – Prevalence and Type of Chronic Diseases 
We examined the trends in the chronic disease diagnoses among our sample (Table 3.7) in order to explore 
whether any corresponding disease patterns could be identified. Overall, the prevalence and number of chronic 
diseases increased significantly during the time period.  
About 79% of participants had a chronic disease in 2000, and 87% had a chronic disease in 2010 (of note, the 
same percentage of individuals reported a chronic disease in 2006). The average number of chronic diseases per 
participant increased from 1.69 to 2.19 during the period.  
None of the chronic diseases examined by the SABE study exhibited a significant decrease in prevalence over 




from 17% to 25%; neuropsychiatric conditions increased from 14% to 23%; joint diseases increased from 29% 
to 34%; and osteoporosis increased from 15% to 21%.  
 
There was also a reported increase in cancer, from 4% to 8% of the sample. Health disease, lung disease, and 
stroke had stable rates across the three time periods.  
 
 
Table 3.7 Chronic disease trends in the SABE study 
 
Note: contents represent average chronic disease rates among the pooled SABE sample (left) and in each of the study waves. NCDs: chronic 
non-communicable diseases. p-values calculated by F-tests in linear regressions of each variable on indicators for the three years.   
 
 
The chronic disease trends largely correspond to the trends in utilization described for the multiple drug classes. 
The most frequently prescribed drug classes (cardiovascular, metabolic, and neuropsychiatric drugs) matched 
the most commonly reported chronic diseases (hypertension, diabetes, and neuropsychiatric conditions).  
 
The increase in the reporting of cancer was not accompanied by increased report of anticancer drugs. This may 
be due to the nature of the survey question, which asked participants if they had ever been diagnosed with each 
of the chronic conditions. Therefore, the rates described here may not necessarily reflect active disease. The 
reporting of cancer may reflect historical as well as current cases.  
 
Of note, the increase in reporting of joint disease and osteoporosis did not seem to be accompanied by increases 
in the use of musculo-skeletal drugs.  
Variable Pooled Year	2000 Year	2006 Year	2010 p-value
Mean	(sd) N=4889 N=2143 N=1413 N=1333
Any	NCDs	 	0.84	(0.37) 	0.79	(0.40) 	0.87	(0.34) 	0.87	(0.34) <0.0001
Nr.	NCDs. 	1.97	(1.46) 	1.69	(1.31) 	2.19	(1.53) 	2.19	(1.53) <0.0001
Chronic	Diseases
Hypertension 	0.61	(0.49) 	0.54	(0.50) 	0.64	(0.48) 	0.68	(0.47) <0.0001
Diabetes 	0.20	(0.40) 	0.17	(0.37) 	0.21	(0.41) 	0.25	(0.43) <0.0001
Heart	Disease 	0.23	(0.42) 	0.20	(0.40) 	0.25	(0.43) 	0.24	(0.43) 0.0005
Lung	Disease 	0.10	(0.31) 	0.10	(0.30) 	0.12	(0.32) 	0.09	(0.29) NS
Stroke 	0.08	(0.28) 	0.08	(0.27) 	0.09	(0.29) 	0.08	(0.28) NS
Cancer 	0.05	(0.23) 	0.04	(0.19) 	0.06	(0.23) 	0.08	(0.27) <0.0001
Neuropsychiatric 	0.20	(0.40) 	0.14	(0.35) 	0.24	(0.43) 	0.23	(0.42) <0.0001
Joint	Disease 	0.32	(0.47) 	0.29	(0.45) 	0.36	(0.48) 	0.34	(0.47) <0.0001
Osteoporosis 	0.20	(0.40) 	0.15	(0.36) 	0.25	(0.43) 	0.21	(0.41) <0.0001
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There was agreement in the mostly stable trends of respiratory diagnoses and drug utilization. Other conditions 
such as those affecting sensory organs and hormones were not inquired in the survey. 
Drug risk trends according to the risk assessment tools 
As previously described, a decrease in the frequency of Beers-detected drug risk was observed across the survey 
waves. Below we plot the trajectory of the eight most frequently utilized drugs across all the survey waves 
(Figure 3.7). Diclofenac, nifedipine, methyldopa, chlorpropamide, and orphenadrine, which were among the 
most frequently utilized drugs in 2000, exhibited dramatic declines in utilization across the three survey waves. 
A less marked, but significant increase in utilization occurred for amitriptyline, doxazosin, and ibuprofen in this 
period. 



































Table 3.8 displays the 15 most commonly utilized drugs that are identified as potentially inappropriate for the 
older adult population according to the Beers Criteria. This table identifies additional patterns such as reductions 
in estrogen, dexclorpheniramine, and a stable use of carisoprodol 
Table 3.8 Utilization trends of potentially inappropriate drugs     
 
Note: colors represent drugs that were among the 10 most frequently utilized in the corresponding year (light brown= 2000, dark 
brown=2006, orange=2010); and the 15 most frequently utilized in the pooled sample (blue). 
We also examine the utilization patterns for drugs with anticholinergic effects (Figure 3.8). Among the most 
commonly utilized drugs with anticholinergic potential, most drugs exhibited decreasing or stable utilization 
trends over time.  
Ranitidine, cimetidine, metoclopramide and dexclorpheniramine exhibited marked decreases in utilization. 
Diphenidramine, loperamide, haloperidol, imipramine, and levodopa also exhibited decreased utilization. 
Carisoprodol was relatively stable, although with fluctuations, over time.  
The only ARS drug that exhibited a utilization increase over time was amitriptyline. It is possible that other, less 
frequently used drugs, drove the increase in ARS risk verified in the SABE sample over time. 
Three of the most frequently used ARS drugs were also captured by the Beers Criteria: amitriptyline, 
carisoprodol and dexclorpheniramine. This exemplifies some of the overlap that we identified earlier.  
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Figure 3.8 Drug utilization trends according to the ARS scale  
3.5 DISCUSSION 
This study contributed to the understanding of the association between drug utilization and drug risk among 
older adults in Sao Paulo, Brazil.  
We found that drug risk is frequent, and is strongly associated with taking higher number of drugs per day. Drug 
risk was a special concern among persons with polypharmacy. About two-thirds of people with polypharmacy 
were exposed to some form of drug risk, and the risk increased with higher numbers of drugs in a 
pharmaceutical regimen. The composition of drug treatments followed the patterns of the underlying health 
conditions reported by the participants. We did not find a specific group of drugs or drug combinations 




































These findings suggest that the association between polypharmacy and drug risk should receive greater attention 
from public health decision-makers in Sao Paulo, and that public health interventions aimed at reducing drug 
risk should target all older adults with polypharmacy.  
 
Improving the level and the quality of monitoring of persons with polypharmacy might help promote early 
detection and better management of drug risk. Developing therapeutic guidelines that recommend periodic 
review of pharmaceutical regimens for all older adults with polypharmacy could help raise providers’ awareness 
and help change prescribing behaviors. Drug reviews would provide an opportunity to improve health care 
integration across multiple prescribers and increase prescribers’ accountability. Other strategies to raise 
providers’ awareness of the association between polypharmacy and drug risk – “Dear Doctor” letters, for 
example - could be implemented by the regulatory agency, the Ministry of Health, or professional associations, 
and could help change prescribing and improve monitoring.  
 
It is important to raise awareness about the association between polypharmacy and drug risk for the public as 
well. Public awareness campaigns could be carried out either on the general media or in more targeted outlets 
such as pharmacies. Raising awareness could motivate older adults with polypharmacy to discontinue self-
prescribed drugs and to request better monitoring from their providers. Lastly, raising awareness might help 
patients contribute to health care integration by providing more complete drug information when they seek 
multiple providers.  
 
We found that higher levels of drug risk were associated with worse health – higher comorbidities, higher 
disability, more clinical symptoms, and worse self-reported health status – in our sample. Our study could not 
address whether there were any causal links between drug risk and poor health status. It is possible that drug risk 
might have contributed to participants’ worse health status. It is also possible that both drug risk and worse 
health might have been driven by a common cause such as underlying chronic diseases. The medical literature 
indicates that both mechanisms are possible, and so further studies to elucidate the relationship between drug 
risk and poorer health among Brazilian older adults are needed. It is important that these studies control for the 





Drug risk was present in a significant proportion of individuals who took few (four or less) drugs a day. Because 
of the association with worse health, drug risk should remain a matter of concern even among people without 
polypharmacy. 
 
Our study found that, even though the frequency of drug utilization and the frequency of polypharmacy 
increased sharply in the 10-year interval, the overall drug risk levels exhibited a decline. Drug risk decreased 
both among the overall sample and among persons with polypharmacy in this period.  
 
Similar findings were described in the context of French older adults (Bongue et al., 2009). These investigators 
concluded that changes in prescription practices were the main underlying driver. In Brazil, however, not all 
drugs require a medical prescription.  Many of the drugs used to treat chronic conditions are in fact over-the-
counter. Therefore, drug choices may be subject to a greater variety of influences in Brazil, and this should be 
taken into consideration by future investigations. 
 
The decrease in drug risk identified in our sample was largely driven by a reduction in drug inappropriateness as 
measured by the Beers Criteria. Anticholinergic risk detected by the ARS scale and DDIs detected by the Hines 
list actually increased in the study period. It is important to understand what drove these differences. The 
trajectories of specific drugs or drug classes may provide useful insights to understand drivers of utilization and 
prescription patterns. We found that some particular drugs – diclofenac, nifedipine, methyldopa, and others - 
drove most of the decline in drug risk. Future investigations may gain more insights if they focus on such drugs 
to understand which factors motivated their reduction. 
 
The Beers Criteria captured most of the persons with drug risk identified by the ARS scale the Hines list of 
DDIs in our sample. Still, we recommend against using the Beers Criteria as the single tool to identify drug risk 
in similar population-level studies. Individuals with multiple risk criteria tended to have worse health than those 
with only the Beers Criteria in our study. Examining multiple dimensions of drug risk helps identify individuals 
who may be at greater risk of poorer health outcomes. Assessing a single metric of drug risk may mislead public 
health decision-making and may prevent some particularly serious forms of drug risk, such as drug interactions 





Our study had several limitations. First, the data that we utilized was collected by a household survey whose 
main goal was to investigate health dimensions not related to drug utilization. Nevertheless, the study collected 
comprehensive information on drug use, both via self-report and via direct observation of pill boxes. The use of 
WHO-ATC codes to record the drugs greatly contributed to data quality. Given the particularities of the 
Brazilian context, a survey may be the best source of information on drug use.  
 
Private insurance does not cover outpatient drugs in Brazil; hence, administrative claims data are not available. 
Drugs are purchased out-of-pocket, so pharmacy claims data are also not available. Many individuals obtain 
drugs from the public system. However, only drugs from a selected formulary are provided by the public health 
system. Any data from public drug provision would not capture the totality of drugs utilized by the population. 
Electronic health records are proprietary of certain health providers or insurers; they may not capture drugs that 
were self-prescribed or that were prescribed by out-of-network providers. Even if they were available, none of 
these sources would likely be representative of the total population of older adults in Sao Paulo, which was 
another strength of our data.  
 
Our study did not have information on drug dosage and posology. This prevented us from addressing issues of 
drug toxicity. However, drug toxicity is not a frequent source of drug risk (Edwards & Aronson, 2000). Most of 
the drug risk assessment tools available in the medical literature do not take drug dosage into consideration. It 
would be very important to develop tools that could comprehensively assess drug risks taking into consideration 
not only the drug dosage and posology, but also a more comprehensive picture of a person's clinical 
characteristics such as underlying health conditions and metabolic capacity. Such comprehensive tools would be 
a valuable contribution to clinical practice and to efforts towards to personalized medicine. 
 
We utilized only the part of the Beers Criteria that applied to the general older adult population. We did not 
examine disease-specific drug risks.  While this approach allows for the evaluation of drug risk patterns among 
the general older adult population, it assumes that the risks from the examined drugs are independent from the 
underlying health conditions that a person may have.  
 
A limitation of this approach is that this assumption may not hold in all situations. An individual with an 




different burden from a given ARS drug than another person without underlying health conditions. However, 
having looked at the interaction between drugs and diseases would have addressed a different research question 
than the one that we set up to explore. The level of granularity required for the investigation of drug and disease 
associations would have been better addressed by studies that focus on a particular condition, for example, 
diabetes, or on a particular drug class.  
 
More comprehensive investigations would also have required specialized software systems, for example for a 
comprehensive analysis of drug interactions. Our use of a list-based tool to identify drug interactions has likely 
limited our ability to detect DDIs in our study population, and so our findings may have underestimated the true 
occurrence of DDIs among Sao Paulo older adults. However, most cases of DDIs among that population are of 
mild or moderate clinical significance (Secoli, 2010), and those were not the primary goal of our study. We were 
primarily interested in identifying cases of severe clinical risk. The Hines list identifies a set of DDIs that are 
associated with hard clinical outcomes such as death and hospitalization. Therefore, it was likely an appropriate 
tool for our goal.  
 
Our methods are in line with several recent investigations of drug utilization in other settings, which have 
mostly employed the Beers Criteria (Baldoni, 2012; Koyama, 2013; Kaufman, 2014). By introducing additional 
tools to capture additional dimensions of drug risk we empirically demonstrated the importance of a 
comprehensive drug risk assessment in population studies. Better tools that combine these and other dimensions 




4. CHAPTER IV: INDIVIDUAL AND COMMUNITY FACTORS 




ABSTRACT   
 
Background: Polypharmacy exposes individuals to increased risk of drug-related problems and negative 
clinical outcomes.  Older adults are especially vulnerable. Not all polypharmacy may be explained by clinical 
need. It is possible that characteristics at the community level may influence polypharmacy independently of 
individual characteristics. Understanding the main factors associated with polypharmacy is important in order to 
devise potential policy targets. 
 
Aims: This study investigated the occurrence of polypharmacy among older adults in Sao Paulo, Brazil's largest 
city and main economic center. We aimed to identify time trends and geographic variation in polypharmacy and 
inappropriate polypharmacy, as well as individual and community-level characteristics associated with their use. 
 
Method: We implemented multi-level latent variable and mixed-effects models combining data from a 
household survey of non-institutionalized older adults living in Sao Paulo – the SABE study – with community 
data from official public sources. The SABE study surveyed a representative sample of the Sao Paulo non-
institutionalized population 60 years and older in 2000, 2006 and 2010. We defined "communities" as the 31 
administrative areas in which Sao Paulo is divided and where the participants lived. We defined polypharmacy 
as the use of five or more drugs per day, and inappropriate polypharmacy as polypharmacy combined with at 
least one drug risk criterion. 
 
Results: The prevalence of polypharmacy and inappropriate polypharmacy among older adults doubled over the 
10-year period. A very small portion (about 2%) of the variation in polypharmacy was associated with living in 
a given community. Individual-level factors were the most associated with polypharmacy – worse health, higher 




polypharmacy, but living in areas with higher insurance coverage was associated with higher odds of 
polypharmacy even after controlling for individual-level factors. Higher socio-economic status at the 
community level and higher older adult mortality were also independently associated with increased odds of 
polypharmacy. The investigation of inappropriate polypharmacy had similar findings. 
 
Conclusion: Polypharmacy and inappropriate polypharmacy are increasing in Sao Paulo older adults. It is likely 
that they are mainly driven by individual characteristics. However, our findings indicate an independent role of 










4.1.1 Policy Problem: Exposure to Polypharmacy and Inappropriate Polypharmacy  
 
Polypharmacy, the excessive use of prescription drugs, is a growing worldwide phenomenon, especially among 
older adults. There is no consensus among clinical communities regarding how many drugs are too many. In 
general, a threshold of five or more drugs is used because it has been shown to correlate with an increased risk 
of adverse effects and mortality.  
 
Polypharmacy exposes individuals to increased risk of drug adverse effects as well as negative clinical outcomes 
such as falls, frailty, cognitive impairment and mortality.  Older adults are especially vulnerable, as they tend to 
be prescribed more drugs, and they to have less metabolic reserve with which to process pharmaceuticals. 
Problems with care coordination may result in drugs being prescribed without appropriate monitoring, 
compounding risks without adding benefits. Depending on the insurance benefits, polypharmacy may use up 
financial resources, which can be especially burdensome for older adults, who generally have fixed incomes.  
 
Polypharmacy may result from the need to treat increasingly frequent and multi-factorial chronic conditions. 
Other characteristics such as a person's higher income and educational levels, and higher tendency to seek 
physician care, have been shown to affect polypharmacy even when controlling for chronic conditions. In 
addition, characteristics of the areas where individuals live and seek care may exert influence in the propensity 
for polypharmacy independently of personal characteristics. 
 
Because public resources are often spent to provide older adults' drug treatments, polypharmacy is also a matter 
of appropriate management and rational use of public resources. These questions are especially relevant in the 
context of low-and middle-income countries like Brazil, where the demands of rapidly growing aging 
populations pose significant burden on public health systems, but where scarce resources are divided between 





In this study, we examine the phenomenon of polypharmacy among older adults living in Sao Paulo, Brazil. We 
explore temporal trends in polypharmacy over a period of 10 years, and we investigate the association between 
polypharmacy and multiple factors at the individual and at the community level. In addition, we investigate the 
occurrence of inappropriate polypharmacy among this population. We define inappropriate polypharmacy as the 
cases where, in addition to being with polypharmacy, individuals also have some form of objectively measured 
drug risk.  
 
Our main objective is to provide evidence to support public health decision-making to mitigate the growing 





Latin American countries in general, and Brazil in particular, have experienced fast population aging rates (A. 
Palloni et al., 2002). The prevalence of chronic diseases is growing significantly in LMICs, and some diseases 
such as diabetes have higher prevalence in Brazil than in other countries of the region (A. Palloni & McEniry, 
2007).  
 
Chronic conditions often require combined pharmaceutical approaches for their appropriate management. Their 
pathophysiologic mechanisms tend to be multi-factorial, and these conditions tend to occur in patterns of 
multiple comorbidities. Pharmaceuticals are needed not only as treatments, but also as prevention – either 
primary or secondary – of these conditions.  
 
It is clear there are patient circumstances that will determine the need for certain drugs. Studies have also 
shown, however that other factors aside of need may influence can influence the number of drugs prescribed. 
The main examples are the availability and type of insurance, and the prescribing preferences and practices of 
health care providers (Cutler et al., 2013). 
 
A cultural model where patients expect and doctors deliver “a pill for every ill” has been described among many 




prescribers to medicalize symptoms that are not inherently pathological but that are part of the life cycle. This 
phenomenon has been called the "pharmaceuticalization" of health (J. G. Biehl, 2007; Davis, 2015; Williams, 
Martin, & Gabe, 2011), and it has been described to affect conditions across the life spectrum – from attention 
deficit disorders in childhood, to pre-menstrual syndrome in early adulthood, and to menopause in later life, for 
example. In older ages, it is possible that "pharmaceuticalization" of health may contribute to polypharmacy 
through the prescription of unnecessary drugs to address symptoms that are not pathological, but are part of the 
aging process.  
 
In the Brazilian context other factors may contribute to greater exposure to polypharmacy independently of 
need. The context of Brazil has two main singularities: first, access to "prescription" drugs does not always 
require a prescription. With the exception of controlled substances such as mental health treatments, opioids, 
and antimicrobial drugs, most drugs to treat chronic diseases can be purchased over the counter without a 
written medical prescription in Brazil. This is in accordance with national regulations and is a widespread 
practice. Because a prescription is not necessarily required in order to maintain treatments, access to care may 
affect polypharmacy primarily via greater drug initiation. Persons with greater access to care may have their 
conditions diagnosed earlier and more often than persons without access to care, so that they know which 
treatments they need. About two-thirds of medical visits in Brazil result in a prescription (Boing, Bertoldi, & 
Peres, 2011). However, persons with lower access to care may lack opportunities for appropriate monitoring and 
follow-up, which may in turn result in fewer opportunities to discontinue unnecessary drug treatments.  
 
In Brazil, the availability of private pharmacies may play a significant role in enabling the continuation of 
polypharmacy. Because obtaining current medical prescriptions is not a requirement for continued drug 
utilization, the role of private pharmacies with polypharmacy is likely to be independent from health services 
utilization.   
 
Second, the type of service (public or private) matters. As a result of longstanding national regulations private 
insurance plans do not cover outpatient drugs in Brazil.13 Drugs for outpatient use are mostly purchased in the 
                                                      
13 Regulations changed in 2015 to accommodate for the provision of oral cancer treatments. This recent change is limited to one drug class 
and has been incorporated to varying extents by the insurance companies. Also, it occurred after our data was collected, so we do not expect 




private market by out-of-pocket payments. The government provides drugs free of cost to individuals who 
cannot afford to purchase drugs in the private market. However, public provision of drugs is limited to a 
national formulary.14 Drugs provided in the public system are dispensed only in public pharmacies and typically 
require medical prescriptions that must be current and must be issued by a public health service (Secretaria de 
Políticas de Saúde, 2000).  
 
Because of the different requirements and administrative procedures, it is likely that the relationship between 
health care access and drug provision is different between the private and the public sectors in Brazil. It is also 
possible that providers working in the public and in the private systems may have different prescribing 
preferences and practices. For example, public providers may be more limited in their prescriptions if they 
restrict their options to those that are part of national formularies (Boing, Bertoldi, Boing, Bastos, & Peres, 
2013). Private providers may be more aggressive in prescribing drugs and may be more likely to 
"pharmaceuticalize" normal aging processes (Williams et al., 2011).  
 
In addition, the Brazilian economy has significantly developed in recent years and the pharmaceutical market 
has greatly expanded; several governmental policies to increase access to medicines have been implemented; 
and average incomes have increased, allowing families to purchase more medicines in the private market 
(Branco, 2010). These factors may have contributed to polypharmacy, and not only by helping individuals 
access the treatments they need. When drugs become more accessible, there is less incentive to discontinue 
ongoing treatments once they become unnecessary.  
 
Fragmentation of care and lack of care coordination may also contribute to polypharmacy by not providing 
adequate monitoring of ongoing treatments. Multi-drug regimens, especially polypharmacy, pose great 
challenges in terms of detecting and managing drug risks. In the Brazilian setting it has been demonstrated that 
patients may remain on contra-indicated drugs for long periods of time even after an adverse effect has been 
detected (Barbosa et al., 2006). 
 
                                                      
14 The provision of medicines is shared between federal, states and local governments. Some states and municipalities can complement the 




Even drugs that have been prescribed for an appropriate indication, at the appropriate doses and for the 
appropriate duration may cause harm. Prescribing polypharmacy without appropriate clinical monitoring may 
make it difficult to identify an adverse effect when it occurs. If an adverse effect goes undetected, new drugs 
may be prescribed to treat it without discontinuing the offending drug. This "prescribing cascade" is often 
associated with polypharmacy and may have serious clinical consequences.   
 
In order to mitigate the risks associated with polypharmacy, it is important to first understand which factors are 
associated with its use. Most of the literature on the determinants of polypharmacy indicates that persons of 
older ages (Franchi et al., 2013; Hovstadius, Hovstadius, et al., 2010; Jiménez Herrera & Fernández Rojas, 
2008; Linjakumpu et al., 2002; Nobili et al., 2011), of the female gender (Cashion et al., 2015; Perry & Turner, 
2001), with higher number of chronic diseases (Chan et al., 2009; Jiménez Herrera & Fernández Rojas, 2008; 
Jyrkka et al., 2009a; Kim et al., 2014), and with greater disability (Chan et al., 2009) tend to have more 
polypharmacy. In addition, persons with multiple providers, supplemental health insurance, and greater levels of 
physician visits are more likely to have polypharmacy (Kim et al., 2014). Understanding the determinants 
associated with polypharmacy important in order to devise potential targets for policies aimed at mitigating its 
use.  
 
Geographic variation studies have demonstrated that health care utilization varies dramatically across regions, 
and not fully explained by the needs of the underlying populations (Cutler et al., 2013; Fisher et al., 2003a, 
2003b; J. Wennberg & Gittelsohn, 1973; Zuckerman et al., 2010). Some factors that occur at the geographic-
area level may also influence polypharmacy in addition to the individual characteristics described above. It has 
been demonstrated that living in urban and metropolitan areas (Jiménez Herrera & Fernández Rojas, 2008) and 
areas with higher income (Perry & Turner, 2001) were associated with increased likelihood of polypharmacy 
even after controlling for individual characteristics. Geographic variation in polypharmacy has also been 
described in Brazil, in association with higher area-level income (Coelho Filho et al., 2004).  
 
In this study we investigate the occurrence and the determinants of polypharmacy in the context of Sao Paulo, 





Sao Paulo is a city of country-size proportions, both in terms of population and economic production. Its 
population of over 11 million inhabitants is larger than countries such as Belgium and Bolivia. Sao Paulo would 
represent the world's 77th largest population if it were a country (Factbook, 2010). There is great heterogeneity 
across the multiple geographic areas of Sao Paulo. The richest, and arguably also the poorest people in Brazil 
live there. Because of its gigantic proportions the administration of Sao Paulo is divided between 31 sub-
prefectures, which are in charge of most public works at the local level, including the delivery of health care 
through the public health system.  
 
There is evidence that the population of older adults in Sao Paulo is exposed to polypharmacy and has a high 
drug risk potential (Secoli et al., 2010). The Sao Paulo population is progressively aging, and so the occurrence 
of polypharmacy is expected to increase. In addition to investigating general cases of polypharmacy, we will 
also investigate cases of inappropriate polypharmacy, which we define as individuals who are taking five or 
more drugs a day and who also have at least one criterion for increased drug risk. We reason that our findings 
may be valuable for public health decision-makers in Sao Paulo who face the progressively larger needs from a 




This study aims to, first, describe temporal trends and geographic variation in polypharmacy and inappropriate 
polypharmacy among the older adult population from Sao Paulo, Brazil.  
 
We aim to identify individual factors associated with higher likelihood of polypharmacy, and to identify 
community factors associated with higher likelihood of polypharmacy when controlling for individual 
characteristics. We aim to use the same framework to investigate associations with inappropriate polypharmacy. 
 
In the current article we address the individual and community-level characteristics associated with 
polypharmacy and inappropriate polypharmacy. We address the association between polypharmacy and multiple 










The SABE Survey - Survey on Health, Well-Being and Aging 
 
We use information from a household survey of non-institutionalized older adults living in Sao Paulo – the 
SABE Study (Survey on Health, Well-Being and Aging, or Saúde, Bem-Estar e Envelhecimento in the original 
in Portuguese). This survey sampled individuals 60 years and older in large metropolitan cities of Latin America 
in 2000. The study centers at the time were: Brazil (Sao Paulo), Argentina (Buenos Aires), Chile (Santiago), 
Uruguay (Montevideo), Mexico (Mexico City), Cuba (Havana) and Barbados (Bridgetown). In Brazil, the local 
team of investigators replicated the sample using the same questionnaire and methodology in 2006 and 2010.  
 
The sampling process of the SABE survey in Brazil was conducted in two stages. In the first stage, census 
sectors (primary sampling units) were selected from the master sampling frame of the Brazilian 1996 Census. 
The census sectors were stratified according to the proportion of the heads of households who were illiterate, 
and were selected within each stratum with probability proportional to their size (number of households). In the 
second stage, households were selected within each census sector. In this stage all households had equal 
probability of selection. All persons over 60 years of age living in the household were selected to participate. In 
addition, individuals above 75 years of age were oversampled. These individuals were part of an additional 
sample, selected with equal probability for all subjects. The SABE study sample is representative of the non-
institutionalized population aged 60 years and older from the metropolitan area of Sao Paulo when weighted 
according to the selection probability (Lebrao & Duarte, 2003; Alberto Palloni & Peláez, 2000). A detailed 
description of the survey, its participants, and main variables collected, is provided in Chapter 2. 
 
The SABE sample comprehended a total of 2,143 participants in the first wave (2000), 1,413 participants in the 





Box 4.1 The Sao Paulo SABE Study – Overview 
 
Source: adapted from Lebrão, 2003, and the SABE dataset. 
 
The SABE study collected extensive information on participants' demographic, socio-economic, and clinic 
characteristics. The survey recorded all drugs in use by the participants, including prescription and over-the-
counter drugs, herbal and homeopathic products, and compounded substances. Participants self-reported drugs 
in use and investigators double-checked medicine cabinets, prescriptions and pill boxes. Drug information was 
recorded using alphanumeric codes developed by the World Health Organization's Anatomical Therapeutic 
Chemical classification (WHO-ATC) (WHO Collaborating Centre for Drug Statistics Methodology). There was 
no information on drug dosage or treatment duration.  
 
We used the information on drug use to generate two variables: polypharmacy, which we defined as the use of 
five or more drugs per day, and inappropriate polypharmacy, which we described as the use of five or more 
drugs per day together with a drug risk criterion. We implemented three tools to assess drug risk in the SABE 
sample: the Beers Criteria, to capture potentially inappropriate prescribing (American Geriatrics Society Beers 
Criteria Update Expert, 2012), the ARS scale, to capture anticholinergic adverse effects (Rudolph et al., 2008), 
and the Hines list to capture clinically relevant drug-drug interactions (DDIs) (Hines & Murphy, 2011). A 
detailed description of each tool, as well as the methodology that we used for their implementation, is provided 
in Chapter 3.  
 
We took advantage of the extensive clinical, demographic and health utilization characteristics collected in the 
SABE study to investigate multiple factors associated with polypharmacy at the individual level. We also 
aggregated some of the characteristics at the area level, in order to examine the possibility of contextual effects. 
The main variables utilized in this study, together with their description and the number of subjects with 
information, are provided in Table 4.1 below. The maximum number of subjects with information corresponds 
to the total of interviews across the three waves of the SABE study (N=4889). 
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Table 4.1 Individual characteristics collected by the SABE study 
Variable Type N Definition 
Drug Utilization    
Medicines count 4889 Number of prescriptions and over-the-count drugs in use. 
Medicines were coded using the WHO-ATC 
classification 
Polypharmacy binary 4889 Five or more prescription or over-the-counter drugs per 
day. Reference: zero to 4 drugs. 
Inappropriate 
Polypharmacy 
binary 4889 Five or more prescription or over-the-counter drugs per 
day, with at least one positive drug risk criterion15. 
Reference: any number of drugs with no risk criterion. 
Excessive 
Polypharmacy 
binary 4889 Ten or more prescription or over-the-counter drugs per 
day. Reference: zero to 4 drugs. 
Socio-Demographic    
Age count 4889 In years 
Gender binary 4889 Reference: males 
Marital status binary 4870 Married or in a civil union; reference: single, widowed 
or divorced 
Income continuous 4258 In Brazilian Reais (R$). Income from multiple sources 
(pensions, investments, wages, and others) was recorded. 
Per capita income was calculated by dividing the total 
reported income by the number of people that depended 
on the income as informed by the participants. 
Health Insurance binary  4886 Having private health insurance; reference: not having 
Health Status       
Chronic Diseases count  4889 Self-reported information on ever having been diagnosed 
by a doctor or nurse with one or more of the following 
conditions: hypertension, diabetes, heart disease, lung 
disease, stroke, cancer, psychiatric conditions, joint 
diseases, or osteoporosis. 
Level of symptoms count  4887 Self-reported information on having experienced 
persistent chest pain, swelling of feet or ankles, dyspnea, 
dizziness or vertigo, tiredness or fatigue, nausea or 
vomiting, fecal or urinary incontinence in the last 12 
months.  
Level of disability count  4888 Self-reported information on having difficulty 
performing one or more activities of daily living: 
walking across a room, getting dressed, bathing, feeding, 
transferring to/from bed, using the toilet, preparing 
meals, dealing with money, transportation, grocery 
shopping, using the phone, light household chores, and 
heavy household chores.  
Health Utilization    
Medical visits  count 4484 Self-reported information of the number of medical visits 
in the last 12 months.  
                                                      
15 Drug Risk Criteria: Beers Criteria, Anticholinergic Risk Scale, and Hines list of Drug-Drug-Interactions (see detailed definitions in 




Preventative exam  binary 4609 Self-reported information on having undergone a 
preventative exam in the last 24 months. Mammogram 
for women or prostate exam for men. Reference group: 
no preventative exam.  
Behaviors      
Smoking  binary 4887 Reference: not currently smoking 
Alcohol  binary 4884 Reference: no current use of alcohol 
Source: SABE Study. 
 
Demographic characteristics collected included age, gender, marital status (binary coded as married or in a civil 
union versus single, widowed or divorced), race (binary coded as white versus other), and religion (binary coded 
as catholic versus other). Socio-economic characteristics included years of schooling (number of school years 
completed; repeated grades were not considered), number of people who lived in the household, having children 
who were still alive (yes, no), having a caregiver (yes, no), and per capita income. Income was measured in 
Brazilian Reais. Participants were asked to inform their total income per month from all different sources 
(wages, investments, pensions, rent, remittances, etc.). Per capita monthly income was calculated by dividing 
the total reported income by the number of people that depended on the income as informed by the participants. 
 
Health care utilization characteristics included health insurance coverage status (having or not having private 
health insurance), number of physician visits in the last 12 months, and whether the participant underwent a 
preventative exam (mammogram for women and prostate exam for men) in the last 24 months. Health status 
characteristics included presence and type of chronic conditions, presence and type of symptoms, level of 
disability, and self-reported health status. Information on chronic disease was obtained by asking participants if 
they were ever diagnosed by a doctor or nurse with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, neuropsychiatric disorders, cancer, osteoporosis, and arthritis. 
Positive responses were aggregated to obtain the number of chronic diseases reported by each participant. 
 
Information on symptoms was obtained by asking participants whether they experienced any of the following 
symptoms in the last 12 months: persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, 
tiredness or fatigue, nausea or vomiting, fecal or urinary incontinence. Positive responses were aggregated to 
obtain the number of symptoms reported by each participant. 
 
Information on disability was obtained by asking participants whether they had difficulties performing one or 




bed, using the toilet, preparing meals, dealing with money, transportation, grocery shopping, using the phone, 
light household chores, and heavy household chores. Positive responses were aggregated to obtain the level of 
disability reported by each participant. 
 
Self-reported health status was obtained by asking participants how they assessed their current health. 
Participants could choose from the following options: excellent, very good, good, regular, bad, or very bad 
health. The information provided by the participants was aggregated to create a binary variable “good” 
(excellent, very good, or good) versus “bad” (regular, bad or very bad) health status.   
 
Health behavior characteristics included smoking, alcohol, and self-medication habits. Smoking was classified 
as currently smoking versus not currently smoking. Alcohol use was classified as current alcohol use versus no 
current alcohol use. Self-medication information was obtained by asking who had issued the prescription for 
each of the drugs that a participant was using. If any of the drugs been started by the participant on their own 
will, or on recommendation from family members/ friends, without a prescription issued by a health provider, 
the information was recorded as self-medication. If all drugs were prescribed by a health professional, or if the 
person did not take any drugs, the information was recorded as no self-medication. 
 
Missing values were not a major problem in the SABE study. The characteristic with the most missing values 
was income, with 13% (n=631) missing values. The number of medical visits in the last 12 months was the 
second most frequently missing variable, with about 8% (n=406) of missingness. Having a preventative exam 
was the third with about 6% of missing values (n=280). All other variables had less than 5% missing values.  
 
In our analysis, we excluded individuals with missing information for any variable, except for the three 
variables with most missing values that we described above (income, medical visits in the last 12 months, and 
preventative care in the last 24 months). The total number of individuals excluded from the analysis was 17 
(0.8%) in 2000, 63 (4.5%) in 2006, and 24 (1.8%) in 2010.We dealt with missing values differently for each of 
these three variables.  
 
For individuals with missing income information (n=631; 13%) we imputed the average per capita income for 




represented missing income. No association between polypharmacy and missing income was found across the 
multiple analyses.  
 
There were 348 individuals with missing values for medical visits in the last 12 months in 2000 (representing 
16% of the 2000 sample). These individuals were identified by an indicator variable for missingness and were 
included in the analyses for the year 2000. Missingness was associated with 64% lower odds of polypharmacy 
(p<0.05) in that year. We discuss this finding in chapter 4. Individuals with missing values for medical visits in 
the last 12 months in 2006 (N=54, 3.8% of the 2006 sample) and 2010 (N=4, 0.3% of the 2000 sample) were not 
included in the regressions. 
 
There were 263 individuals (representing 19.7% of the 2010 sample) with missing values for preventative care 
in the last 24 months in 2010. These individuals were identified by an indicator variable for missingness and 
were included in the analyses for the year 2010. There was no association between missing information on 
preventative care in the last 24 months and the odds of polypharmacy in 2010. Individuals with missing values 




Geographic- Level Data 
 
We took advantage of the distribution of SABE survey participants across the multiple areas of Sao Paulo 
(Figure 4.1) to implement a multi-level analysis investigating for community-level factors while controlling for 
the individual-level characteristics that we described above.   
 
Most of the 31 geographic areas were represented in the SABE sample: 27 of the 31 sub-prefectures were 
represented in 2000; 30 sub-prefectures were represented in 2006; and 30 sub-prefectures were represented in 
2010. The three sub-prefectures that were not represented in 2000 but were represented in 2006 and 2010 were: 
Ermelino Mattarazzo, Guaianases and Sao Mateus.  The sub-prefecture that was not represented in any of the 
survey waves was Cidade Tiradentes. Because our study depended on characteristics measured at the individual 
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level, areas that had no participants could not be included in our analyses. The three areas that were not 
available in 2000 contributed information to the 2006 and 2010 analyses.  
Figure 4.1 Distribution of survey participants across the geographic areas of Sao Paulo 
Source: Lebrão, 2003. 
Community Characteristics Calculated from the SABE Study Data 
We calculated community-level characteristics using aggregated information from SABE study participants 
(Table 4.2). The participant-derived community characteristics were obtained for each sub-prefecture. Each 
characteristic was calculated as a weighted average of the participants living in that area. Importantly, each 
characteristic reflects the average of the characteristic only among older adults age 60 and over, and not the 





Table 4.2 Community-Level characteristics derived from the SABE Study data 
Variable Definition 
Drug Utilization   
Polypharmacy % of individuals who were with polypharmacy 
Socio-Demographic 
Age Average age of the population in years 
Gender % of population who are females  
Marital status % of population who were married or in a civil union 
Income Average income in Brazilian Reais (R$) 
Health Insurance % of population with private health insurance 
Health Status    
Chronic Diseases 
Average number of chronic conditions per capita (conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint 
diseases, or osteoporosis) 
Level of symptoms 
Average number of clinical symptoms per capita (symptoms: persistent chest pain, 
swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness or fatigue, 
nausea or vomiting, fecal or urinary incontinence in the last 12 months) 
Level of disability 
Average level of disability per capita (activities: walking across a room, getting 
dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing 
meals, dealing with money, transportation, grocery shopping, using the phone, 
light household chores, and heavy household chores) 
Health Utilization 
Medical visits Average number of medical visits in the last 12 moths per capita 
Preventative exam % of the population who underwent a preventative exam in the last 24 months 
(women: mammogram; men: prostate exam). 
Behaviors   
Smoking % of population currently smoking 
Alcohol % of population currently using alcohol 
Note: Aggregated data from individuals 60 years old and over. Source: SABE database.  
 
 
Community Characteristics Obtained from Official Government Sources 
 
In order to compare the results from our sample-generated community variables, we utilized community 
variables obtained from official government sources. Specifically, we utilized the following variables: 
 
• Percentage of seniors: proportion of residents age 60 years old and over. Data for 2000 and 2010 was 
obtained from the Brazilian Demographic Census; values for 2006 were calculated from Census data, 





• Rural area indicator: data for 2000 and 2010 was obtained from the Brazilian Demographic Census. 
We assigned a value of 1 if a sub-prefecture had 50% of more area with any rural characteristics. We 
assigned values for 2006 by interpolating information from the 2000 and 2010 Census, as follows: if a 
sub-prefecture had the same profile (rural-rural or urban-urban) in both years, we maintained the same 
value for 2006. Only three sub-prefectures had differing values between 2000 and 2010. All three sub-
prefectures had rural characteristics in 2000 and did not have in 2010. In these three cases we assumed 
that there were no rural characteristics in 2006. 
 
• All-cause mortality among individuals age 60 years old and over: data for all three years was collected 
from information from the Ministry of Health's Vital Statistics Registry, accessed via the Infocidade 
online database (http://infocidade.prefeitura.sp.gov.br/) in May, 2015. 
 
• Hospital admissions, individuals age 60 years old and over: information obtained from the Sao Paulo 






We draw from the conceptual framework of Societal and Individual Determinants of Medical Care Utilization 
developed by Andersen & Newman (R. Andersen & Newman, 1973) (Figure 4.2). In our study the main 
outcome of interest – "health service utilization" – is the use of polypharmacy; also, we study the occurrence of 
inappropriate polypharmacy. 
 
Andersen and Newman's framework envisioned health services utilization as the result of a "sequence of 
conditions". At the individual level, the framework divided these conditions as: predisposing conditions ("the 
predisposition of the individual to use services"), enabling conditions (the individual's "ability to secure 
services"), and illness level (the diagnoses, level of symptoms and disability perceived by the individual or 
ascertained by the health provider).  
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At a broader level the framework identified determinants of health services use at the societal and health 
system's levels. The model assumes, however, that societal and health systems determinants affected service 
utilization only via modifications on individual-level determinants. The possibility that societal and health 
systems factors might directly affect health services utilization is not included in the model.  
There are many alternative versions of the model, adapted to accommodate different levels of detail as well as 
different interconnections between the spheres of determinants. Of interest, one of the model's versions included 
a set of community determinants also affecting health services utilization (R. M. Andersen, 1995). 
Figure 4.2 Conceptual framework – societal and individual determinants of medical care utilization  
Source: Andersen & Newman (1973) 
In this study, we begin with the conceptual model developed by Andersen, but adapt its graphic display to show 
the community determinants (Figure 4.2). We adapt it to identify this study's objectives, as we describe below 
(Figure 4.3): 
We are interested in, first, estimating the effect of individual determinants with polypharmacy (straight arrow). 
Second, we are interested in estimating the effect of community determinants with polypharmacy. We assume 
that community determinants have both direct effects with polypharmacy (straight arrow) as well as indirect 
effects that act through modifications on individual conditions (dashed arrow). Lastly, we are interested in 
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estimating the direct effect of health system determinants with polypharmacy. In the present study, we assume 
that the effect of health services system determinants is captured by health services utilization. We will examine 
the effect of each of the health systems characteristics in the next chapter (Chapter 5).  
We assume that societal determinants (technology and norms) are constant across areas. Technology represents 
drugs - the drugs available in the private market, the drugs included in government formularies – as well as their 
prices. Norms represent legislation and regulation establishing the rules for drug prescription, distribution and 
commercialization. Because our sample comes from one single city, it is highly unlikely that technology and 
norms would vary significantly across the different areas. For the most part drug regulation and legislation are 
established at the national level in Brazil. Only certain governmental formularies might be defined by states and 
cities; still, the formularies would be the same across all sub-prefectures. Still, it would be possible that stock-
outs of government formulary drugs might affect some areas more than others. This might occur because of 
difficulties in transportation, logistics, or because of differences in administrative capacity in each of the areas. 
We cannot examine this possibility, however. We assume that the effect of area-level income may capture this 
effect if it is true. 
Figure 4.3 Adapted conceptual framework used in this paper 
 






Using figure 4.3 as the paradigm, we implement a series of analytical models in order to, first, estimate the 
relationships between individual-level determinants and polypharmacy; second, estimate the relationships 
between community-level determinants and polypharmacy; third, estimate the relationships between 




We model the log odds of polypharmacy using a logistic model [1] and a multi-level generalized latent mixed 
model [2], as follows:  
 
Log [Pr(Yij=1)/ Pr(Yij=0)] = β0 + β1Individualij + β2Communityi      [1] 




• Log [Pr(Yij=1)/ Pr(Yij=0)] is the log odds of polypharmacy for subject j living in area i; 
• β0 represents the average baseline propensity for polypharmacy in the logistic model [1]; 
• β0i, which can be decomposed as β0i = β0 + b0i, is a random intercept that represents the baseline 
propensity for polypharmacy in each geographic area in the multi-level model [2]; 
• Individualij is the vector of predisposing, enabling, and illness level characteristics of subject j living in 
area i; 
• Communityi is a vector enabling and illness level characteristics of area i;  
• β1, β2 and β3 represent log odds ratios for a change in the response variable associated with a 1-unit 











The following assumptions are common to both analytical models: 
 
A) Underlying latent variable response: 
 Y*ij >0    à  Yij =1   
 Y*ij <=0   à   Yij=0 
The models assume that there is a latent (unobserved) continuous response that represents the probability of the 
observed outcome (polypharmacy or no polypharmacy) for each subject j living in area i. A positive outcome 
(polypharmacy) will be observed when the individual's underlying latent variable Y*ij is greater than zero and a 
negative outcome (no polypharmacy) will be observed when the individual's underlying latent variable Y*ij is 
equal to or lower than zero. 
 
B) Error term:  
E[εij|Individualij , Communityi] = 0  
εij ~logistic(0, π2/3) 
εij  is an unobserved error term that represents the degree of heterogeneity in the propensity of polypharmacy 
(represented by the latent variable Y*ij) across all individuals. The models assume that the unobserved error 
term εij has a logistic cumulative density function given all the covariates, with average of zero and variance 
equal to π2/3. 
 
C) The models assume that each covariate (represented by the vectors Individual and Community) has the same, 
fixed effect for every individual. However, the logistic models assume that the effect is the same for every 
individual regardless of the area where they live, but the multi-level model assumes that the fixed effect is 









The following are additional assumptions specific to the multi-level model [2]: 
 
D) Random intercept:  
E[b0i] = 0  
 b0i ~ N(0, τ2)  
The multi-level model [2] assumes that the baseline propensity for a positive outcome (polypharmacy) varies 
across areas. The baseline propensity of each individual area is captured by its random intercept b0i. Differences 
in the area-specific baseline propensity for polypharmacy are a result of differences in both measured and 
unmeasured characteristics of each area. The multi-level model assumes that the random intercepts b0i have a 
normal distribution independent from the area-level covariates, with mean of zero and variance denoted by τ2.  
 
E) Correlation between individuals living in the same geographic area: 
Corr(Yij, Yik)= ρ 
The multi-level model assumes that the propensity for polypharmacy for individuals j and k living in the same 
geographic area is correlated. The model assumes that responses are independent once the baseline propensity 
for polypharmacy of an area (captured by the area-specific random intercept b0i) is accounted for.  
 
F) Total variance of the response variable: 
 Var(Y*ij)= Var(εij) + Var(b0i) 
Different from the logistic model, the multi-level model assumes that the total variance in the propensity for 
polypharmacy (represented by the latent variable Y*ij) across all individuals equals the variance of the error 
term plus the variance of the random intercept.  
 
G) Conditional vs. marginal effects: while the coefficients from the logistic model [1] represent average effects 
at the population level, the coefficients from the multi-level model [2] represent effects within a given 
geographic area. In the multi-level model there is a different baseline propensity for polypharmacy in each 
geographic area. This baseline propensity must be taken into consideration when interpreting the fixed effects 
from the various covariates in the multi-level model. In the multi-level model a coefficient represents the 
expected change in the log odds of polypharmacy associated with a one-unit change in a given covariate 







We ran a series of descriptive statistics in order to describe the levels of individual and geographic 
characteristics at all survey waves. The individual characteristics were explored using inverse probability 
weighting in order to reconstruct the non-institutionalized population of 60 year-olds and over in Sao Paulo. The 
geographic characteristics were explored using one data point per each geographic area. The descriptive analysis 
of the geographic characteristics was performed without the use of weights.  
 
For the analysis of the associations between the multiple individual and geographic characteristics and the 
outcome of interest (polypharmacy) we implemented the logistic and multi-level approaches described above. 
We implemented the logistics models that do not account for geographic clustering because these are frequently 
used in the literature. We compared the logistic model results to multi-level models accounting for geographic 
clustering, in order to understand the extent to which ignoring the geographic clustering may impact findings in 
this context.  
 
We implemented three different versions of each model: Individual Models (Model 1) using only individual-
level covariates, Geographic Models using only area-level covariates, and Full Models (Model 2) using both 
individual and area-level covariates.  
 
We ran the analytical models separately for each year that the survey was available (2000, 2006 and 2010). 
Following the sample design, we applied inverse-probability weights to all models in order to reconstruct the 
population of non-institutionalized individuals 60 year-old and over living in Sao Paulo in each year.  In 
addition to individual weights, the multi-level model also required the specification of area-level weights. 
Because the area-level weights had been factored in the calculation of individual weights at the time of survey 
design, we assumed that all areas had equal weights and we set all area-level weights equal to 1. In order to 
account for unequal variances we utilized robust standard errors clustered at the primary sampling units (census 






In addition, we ran a series of model checks and sensitivity analyses in order to assess the fit of our chosen 
models and the robustness of our findings. 
 
4.4 RESULTS 
4.4.1 Part 1 - Descriptive Analysis 
 
Sample Characteristics – Overview 
 
The final sample of the SABE survey constituted of 2,143 individuals living in 27 areas in 2000; 1,413 
individuals living in 30 areas in 2006; and 1,333 individuals living in 30 areas in 2010 (Table 4.3).  
 
Individuals did not necessarily participate in all three waves. Of the total 4,889 observations across the three 
survey waves, 2,796 (57%) were individuals who participated in only one wave; 1,408 (29%) participated in two 
survey waves; and 685 (14%) participated in three survey waves. Because the majority of participants had 
contributed information to a single survey wave, and because those that contributed with two waves of data 
were distributed across the survey waves (i.e, were not all concentrated in the same two waves), we utilized 
information from all participants who had available data in each year.  
 
In 2000, an average of 107.7 participants were included per sub-prefecture (ranging from 13 to 182 per sub-
prefecture). There was a tendency of decreasing sample size per area, so that in 2006 the average number of 
participants per area was 63.8 (ranging from 5 to 111) and in 2010 the average number of participants per area 
was 63.8 (ranging from 4 to 105). 
 
 




Nr.$of$Areas 27 30 30
Nr.$participants 2,143 1,413 1,133
Participants.per.Area
Avg$(sd) 107.7$(48.5) 63.8$(26.2) 56.8$(21.7)





Polypharmacy and Drug Utilization  
 
Use of medicines among the population 60 years and older increased significantly between 2000 and 2010. The 
number of people taking drugs increased as well as the number of medications per person. The prevalence of 
polypharmacy increased significantly in the 10-year period. Table 4 summarizes the drug utilization metrics in 
each of the survey years.  
 
The prevalence of taking at least one drug among the population of 60 year-olds and over was estimated to be 
84.3% in 2000 (95% CI: 82.5% - 86.2%). In 2010, this prevalence was 90.6% (95% CI: 88.9% - 92.4 The 
maximum number of drugs per day that any individual in the sample took was 14 in 2000, 15 in 2006, and 17 in 
2010. 
 
The estimated prevalence of polypharmacy (five or more drugs) was 16.1% in 2000 (95% CI: 14.4% - 17.9%). 
The prevalence of polypharmacy more than doubled in 2010, up to a total of 37.6% (95% CI: 34.8 – 40.4%). 
Women had higher prevalence of polypharmacy both at baseline and after 10 years (2000 prevalence= 19.9%, 
95% CI: 17.5% - 22.3%. 2010 prevalence= 42.7%, 95% CI: 39.1% - 46.3%). Men had lower prevalence of 
polypharmacy at baseline (2000 prevalence=10.7%, 95% CI: 8.3% - 13.1%) and also after 10 years (2010 
prevalence= 30% 95% CI: 25.5% 34.6%). The rate of increase in polypharmacy was higher in men than women 
- almost three-fold increase compared to a doubling.  
 
The prevalence of inappropriate polypharmacy (five or more drugs where at least one is identified as 
inappropriate by the Beers Criteria, the anticholinergic risk scale or the Hines list of clinically relevant drug-
drug interactions) was 12.6% in 2000 (95% CI: 11.0% - 14.1%). It almost doubled in the 10-year interval, to 
22.5%     (95% CI: 20.1% - 24.9%). However, the proportion of the population with inappropriate polypharmacy 
declined. In 2000, an estimated 78% of individuals with polypharmacy had inappropriate polypharmacy; in 
2010, this proportion was 60%. 
 
The prevalence of excessive polypharmacy (ten or more drugs) was estimated in 0.7% in 2000 (95% CI: 3.4% - 




polypharmacy far outweighed the rate of increase of all other drug utilization metrics, including any medication 
use, number of drugs per person, polypharmacy, and inappropriate polypharmacy (Table 4.4). 
 
Table 4.4 Polypharmacy and drug utilization across the survey waves 
 
Notes: *Weighted averages and standard deviations calculated using inverse selection probability weights specific for each survey wave. 
Variables have no missingness except noted otherwise. 
** St.diff: standardized difference between 2010 and 2000. Calculated as the difference in weighted means (mean 2010 - mean 2000) 
divided by a pooled standard deviation (square root of the sum of variance 2010 plus variance 2000). 
(a) Polypharmacy: use of five or more drugs a day. 
(b) Inappropriate polypharmacy: use of five or more drugs where at least one is identified as inappropriate by the Beers Criteria, the 
anticholinergic risk scale or the Hines list of clinically relevant drug-drug interactions. 
(c) Excessive polypharmacy: use of ten or more drugs a day. 
 
 
Geographic Variation in Polypharmacy 
 
There was significant variation in the rates of polypharmacy and inappropriate polypharmacy across the 
multiple geographic areas of the city of Sao Paulo at each given year. Across time, areas tended to have greater 
prevalence of polypharmacy on average. Also, the variability in rates of polypharmacy across areas tended to 
increase. Figure 4.4 displays the evolution in the rates of polypharmacy across the multiple Sao Paulo sub-
prefectures from 2000 to 2010.  
 
Year 2000 2006 2010 )st.diff**
Weighted)mean(sd)* N=2143 N=1413 N=1333 2010<2000
%"Taking"at"least"1"medicine "84.3"(36.3) "86.9"(33.7) "90.6"(29.1) 0.1
Avg."nr."of"medicines 2.51"(2.15) "3.12"(2.42) "3.94"(2.94) 0.39
%"Polypharmacy"(a) "16.1"(36.8) "26.0"(43.9) "37.6"(48.5) 0.4
%"Inappropriate"polypharmacy"(b) "12.6"(33.1) "17.1"(37.7) "22.5"(41.8) 0.2




Figure 4.4 Prevalence of polypharmacy among older adults across the Sao Paulo geographic areas, 2000-2010 
 
Source: SABE dataset. 
 
In 2000, the estimated average prevalence of polypharmacy among individuals 60 years old and older across the 
geographic areas was 15.1% (95% CI: 11.5%-18.7%). The lowest prevalence of polypharmacy in any given area 
was 1.3% and the highest was 25.1%.  In 2010, the estimated average prevalence of polypharmacy was 36.9% 
(95% CI: 33.5%-40.3%). The lowest prevalence of polypharmacy in a geographic area was 6.6% and the highest 
was 56.6%.   
 
The average prevalence of polypharmacy across the geographic areas grew 2.5 times from 2000 to 2010. Table 
4.5 summarizes the trends in the rates of polypharmacy and inappropriate polypharmacy at the geographic area 





Table 4.5 Average Rates of Polypharmacy and Inappropriate Polypharmacy among 60 year-olds and Older across the 
Geographic Areas of Sao Paulo  
 
 
Notes: Means and standard deviations were calculated using one data point per area. Rates reflect estimated prevalence among individuals 
60 years and older in each geographic area. Polypharmacy: use of five or more drugs a day. Inappropriate polypharmacy: use of five or more 
drugs per day, plus at least one positive measure of drug risk. 
 
The distribution of polypharmacy rates across the geographic areas tended to be left-skewed in all years, 
representing the fact that, while most areas tended to have rates of polypharmacy closer to the average, there 
were some areas with lower rates (Figure 4.4). The spread of the distribution increased over time, reflecting 
higher variability in the prevalence of polypharmacy across geographic areas over time.  
 
Figure 4.5 Trends in the Distribution of Polypharmacy Prevalence per Geographic Area over Time (Kernel Density 
Estimates) 
 





Mean(sd) )15.1%)()5.4) )25.3%)(11.3) )36.9%)(10.0)
Range ))1.3–25.1% ))0.0–45.4% ))6.6–56.6%
Mean(sd) )11.9%)()4.9) )16.1%)()8.0) )22.1%)()8.5)
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Figure 4.6 displays means and standard deviations in the prevalence of polypharmacy per geographic area per 
year, and displays the median prevalence of polypharmacy across all areas for each year (dotted lines). The 
increase in average rates of polypharmacy and in the variation around overall common values can be visualized 
over time. 
Figure 4.6 Average and Standard Deviations for the Prevalence of Polypharmacy in each of the Sao Paulo Sub-Prefectures, 
by Year  
Note: Average ± standard deviations in the prevalence of polypharmacy among 60 year-olds and over presented for each of the Sao Paulo 
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Most sub-prefectures tended to experience increases in the prevalence of polypharmacy over time. However, 
trends were not uniform across areas. Figure 4.7 displays fitted lines identifying average trends per area over the 
10-year interval. 
 
Figure 4.7 Trends in Polypharmacy Rates per Area over the 10-Year Interval 
 
 
Note: Fitted lines demonstrate the average linear trajectory of the weighted rates of polypharmacy at the area level over time. Standard 
errors and confidence intervals not shown. One line per geographic area. Dotted line represents the overall average. 
 
To understand the differences in the rates of change across areas we plotted the 10-year differences against the 
baseline prevalence of polypharmacy for each of the areas (Figure 4.8). The highest differences seemed to have 
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Figure 4.8 10-Year Differences in the Prevalence of Polypharmacy according to the Baseline Values 
 
Note: One data point per geographic area. Source: SABE database. 
 
Geographic Variation in Inappropriate Polypharmacy 
 
The overall trends in the prevalence of inappropriate polypharmacy tended to follow those of polypharmacy 
across the geographic areas. There was a tendency of increase in average rates of inappropriate polypharmacy 
over time across most areas, and a tendency of increasing variation around common values. However, 
prevalence of inappropriate polypharmacy was lower than prevalence of polypharmacy (Figure 4.9).  
 
In 2000 the estimated average prevalence of inappropriate polypharmacy among 60 year-olds and over across 
the geographic areas was 11.9% (95% CI: 9.1% - 14.7%). By 2010 the prevalence had almost doubled to 22.1% 
(95%CI: 19.4%-24.8%). There was a very high correlation between rates of polypharmacy and rates of 
inappropriate polypharmacy at baseline across the areas (r=0.89); this correlation was still positive but lower in 
magnitude in 2010 (r=0.55). The positive correlations between rates of polypharmacy and inappropriate 
polypharmacy indicate that, in general, areas with higher rates of polypharmacy tend to have higher rates of 
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Figure 4.9 Trends in Prevalence of Polypharmacy and Inappropriate Polypharmacy across the Geographic Areas  
 
 
Note: estimated prevalence among non-institutionalized individuals 60 years and older. Source: SABE database. 
 
 
Individual Characteristics across the Survey Waves 
 
SABE participants tended to be composed of older and sicker individuals, who sought more care (including 
preventative care), and had higher incomes and health insurance coverage over time. Table 4.6 summarizes the 
main individual characteristics in each of the survey waves. We present inverse-probability weighted averages, 
which reflect the characteristics of the Sao Paulo older adult population in each year. 
 
The average age of individuals increased from 69.4 in 2000 to 70.4 years in 2010. The maximum age increased 
from 100 years in 2000 to 104 years in 2010. On average around 60% of the population was composed of 
women and 57% of individuals were married; these proportions did not significantly change over time. The 
prevalence of chronic diseases increased from 79% in 2000 to 86% in 2010, accompanied of an increase in the 
number of chronic diseases per person, from an average of 1.64 in 2000 to 2.13 in 2010. Individuals tended to 
report slightly higher number of symptoms (average of 1.47 symptoms per person in 2000 and 1.56 in 2010) and 




























Note: one observation per area. Source: SABE database




Individuals tended to have higher incomes and higher rates of private health insurance over time. The average 
per capita income almost tripled from R$ 370.80 in 2000 to R$ 905.01 in 2010. The maximum per capita 
income increased four fold from R$ 7,000.00 in 2000 to R$ 25,000.00 in 2010. These numbers are not adjusted 
for inflation. In 2000, 41% older adults had private health insurance, increasing moderately to 45% in 2010. 
 
Individuals were more likely to seek care over the ten year period: an average of 77% of individuals reported 
seeking care at least once in the last 12 months in 2000, increasing to 87% in 2010. Those who sought care 
tended to have a similar distribution of number of visits in all years, with the majority reporting between 1-6 
visits in the last 12 months (43% in 2000 and 72% in 2010) and a very low number of individuals reporting 
more than 24 visits in the last 12 months (1% in 2000 and 2% in 2010). The levels of preventative care, 
represented by mammograms in women or prostate exam for men in the last 24 months, increased from 40% in 
2000 to 61% in 2010. Levels of smoking were low and tended to decrease over time (16% in 2000 and 12% in 






Table 4.6 Individual Characteristics across the Survey Waves 
 
Notes:   
*Weighted averages and standard deviations calculated using inverse probability weights specific for each survey wave. Variables have no 
missingness except noted otherwise. 
** St.diff: standardized difference between 2010 and 2000. Calculated as the difference in weighted means (mean 2010 - mean 2000) 
divided by a pooled standard deviation (square root of the sum of variance 2010 plus variance 2000). 
(a) Married or in a civil union. Reference: single, widowed or divorced. Number of missing values: 1 (2000), 2 (2006) and 16 (2010). 
(b) In Brazilian Reais. Number of missing values: 339 (2000), 171 (2006), 121 (2010). 
(c) Number of missing values: 2 (2000), 1 (2006). 
(d) Self-reported information on ever having been diagnosed by a doctor or nurse with one or more of the following: hypertension, diabetes, 
heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
(e) Having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness or fatigue, nausea or 
vomiting, fecal or urinary incontinence in the last 12 months. Mild: 1-2 symptoms. Moderate: 3-5 symptoms. Severe: 6+ Symptoms. 
Number of missing values: 2 (2010). 
(f) ADL: activities of daily living. Having difficulty performing one or more of the following activities: walking across a room, getting 
dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, transportation, grocery shopping, 
using the phone, light household chores, and heavy household chores. Mild: 1-4 ADLs. Moderate-Severe: 5+ ADLs. Maximum exhibited in 
the sample: 12 ADLs. Number of missing values: 1 (2000). 
(g) Low utilization: up to 6 medical visits per year. High utilization: more than 6 medical visits per year (over 75th percentile). Number of 
missing values: 348 (2000), 54 (2006), 4 (2010). 
(h) Mammogram for women or prostate exam for men. Number of missing values: 14 (2000), 3 (2006), 263 (2010). 
Year 2000 2006 2010 )st.diff
Weighted)mean(sd)*) N=2143 N=1413 N=1333 2010<2000**
Socio<Demographic
Avg.%age %%69.4%(7.42) %%69.6%(7.51) %%70.4%(8.27) 0.09
%%of%subjects%aged%60=69 %%0.59%(0.49) %%0.59%(0.49) %%0.54%(0.50) =0.1
%%of%subjects%aged%70=79 %%0.30%(0.46) %%0.30%(0.46) %%0.31%(0.46) 0.01
%%of%subjects%aged%80=89 %%0.10%(0.29) %%0.10%(0.29) %%0.13%(0.34) 0.11
%%of%subjects%aged%90+ %%0.01%(0.12) %%0.02%(0.13) %%0.02%(0.15) 0.06
Female%gender %%0.59%(0.49) %%0.59%(0.49) %%0.60%(0.49) 0.02
Married%(a) %%0.57%(0.50) %%0.57%(0.49) %%0.54%(0.50) =0.03
Per%Capita%Income%%(b) %%370.80%(560.3) %%675.26%(1210.2) %%905.01%(1611.2) 0.31
Private%health%Insurance%(c) %%0.41%(0.49) %%0.44%(0.50) %%0.45%(0.50) 0.05
Health)Status
%%with%chronic%diseases%(d) %0.79%(0.41) %0.86%(0.35) %0.86%(0.35) 0.14
Nr.%Chronic%Diseases%(d) %%1.64%(1.28) %%2.09%(1.51) %%2.13%(1.51) 0.25
Avg.%nr.%symptoms%(e) 1.47%(1.63) %1.33%(1.57) %1.56%(1.67) 0.04
%%no%symptoms% %%0.37%(0.48) %%0.39%(0.49) %%0.35%(0.48) =0.03
%%mild %%0.39%(0.49) %%0.42%(0.49) %%0.40%(0.49) 0.02
%%moderate %%0.21%(0.41) %%0.16%(0.37) %%0.21%(0.41) 0.00
%%severe %%0.03%(0.16) %%0.03%(0.17) %%0.03%(0.17) 0.03
Avg.%level%of%disability%(f) %1.23%(2.38) %1.61%(2.71) %1.55%(2.61) 0.09
%%no%disability %%0.65%(0.48) %%0.56%(0.50) %%0.55%(0.50) =0.13
%%mild %%0.26%(0.44) %%0.30%(0.46) %%0.32%(0.47) 0.10
%%moderate=severe% %%0.10%(0.29) %%0.14%(0.34) %%0.13%(0.33) 0.07
Health)Care)Utilization
%%sought%any%care%in%last%12mo%(g) %0.77%(0.42) %0.89%(0.31) %0.87%(0.34) 0.18
%%Low%utilization%(g) %%0.62%(0.48)) %%0.71%(0.46) %%0.85%(0.36) 0.26
%%High%utilization%(g) %%0.21%(0.41) %%0.29%(0.46) %%0.15%(0.36) =0.16
%%preventative%exam%last%24mo%(h) %%0.40%(0.49) %%0.56%(0.50) %%0.61%(0.49) 0.50
Behaviors
Current%smoking%(i) %%0.16%(0.37) %%0.14%(0.35) %%0.12%(0.32) =0.08




(i) Reference: not currently smoking. Number of missing values: 1 (2000), 1 (2010). 
(j) Reference: no current use of alcohol. Number of missing values: 4 (2006), 1 (2010). 
 
 
Geographic Characteristics across the Survey Waves 
 
The populations across the multiple geographic areas tended to be older and sicker, have higher incomes, higher 
health insurance coverage, and higher health care utilization over time. Table 4.7 summarizes the geographic 
area characteristics in each of the survey years. These characteristics were calculated from the survey data and 
they apply exclusively to the population of 60 year-olds and over in each area. 
 
The average age of the population 60 years and over in each area increased from 69.33 years in 2000 to 70.55 
years in 2010. The prevalence of chronic diseases in each area increased from 80% in 2000 to 86% in 2010, and 
the average number of chronic diseases in the population increased from an average of 1.65 per person in 2000 
to 2.01 in 2010.  
 
Average per capita incomes at the geographic area level increased almost three fold, from R$ 341.97 in 2000 to 
R$ 920.72 in 2010. In this period, the average rates of private insurance coverage among 60 year-olds and over 
increased from 37% to 44%, and health care utilization increased significantly by all metrics (more preventative 
exams, higher frequency of receiving any medical visits in the last 12 months, and higher percentage of high 
utilizers – having utilization above the median for the year). The characteristics calculated from the survey data 
were in line with information for each area collected from official sources such as the Brazilian census, the 






Table 4.7 Geographic characteristics across the survey waves 
 
Notes:  
* Means and standard deviations were calculated using one data point per area.  
** Standardized differences between the 2010 and 2000 calculated as the difference in weighted means (mean 2010 - mean 2000) divided by 
a pooled standard deviation (square root of the sum of variance 2010 plus variance 2000). Standardized differences between 2010 and 2006 
were presented when data for 2000 was not available.  
*** Average age, number of chronic diseases, per capita income, health insurance, and preventative services utilization were calculated 
from the SABE survey data. All other variables were obtained from official public sources in Sao Paulo, Brazil. With exception of the 
percentage of seniors, all other variables refer to non-institutionalized individuals 60 years and older living in Sao Paulo.  
**** Health care utilization rates are presented among individuals 60 years and older. All health resources are presented as number of 
resources per 100,000 population.  
(a) NCDs: non-communicable diseases. Self-reported information on ever having been diagnosed by a doctor or nurse with one or more of 
the following conditions: hypertension, diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or 
osteoporosis.  
(b) In Brazilian Reais.  
(c) Mammogram (women) or prostate exam (men) in the last 24 months among individuals 60 years and older.  








We first investigate the links between polypharmacy and individual-level characteristics ignoring information 
about the area where individuals reside. We utilize logistic regression models to investigate these associations. 
We apply inverse probability weights to reconstruct the population of 60 year-olds and over living in the city of 
São Paulo at each year. We cluster the standard errors at the census tract level (primary sampling units) in order 
to account for unequal variances. Table 4.8 displays the results of weighted logistic regression models for the 
odds of polypharmacy using individual characteristics exclusively (Individual Models).  
Year 2000 2006 2010 st.diff
Mean(sd)* N=277areas N=307areas N=307areas 201092000**
Socio9Demographic***
Avg.%age%(years) %69.33%(1.83) %69.34%(3.77) %70.55%(3.73) 0.29
Avg.%prevalence%of%NCDs%(%)%(a) %0.80%(0.06) %0.87%(0.08) %0.86%(0.05) 0.79
Avg.%Nr.%of%NCDs%per%person%(a) %1.65%(0.18) %1.95%(0.27) %2.01%(0.28) 1.09
Avg.%per%capita%income%(b) %341.97%(206.6) %654.60%(465.5) %920.72%(621.6) 0.88
%%Private%health%insurance %0.37%(0.20) %0.42%(0.20) %0.44%(0.21) 0.22
Health7Care7Utilization***
%%Preventative%exams%(c) %0.38%(0.11) %0.56%(0.10) %0.74%(0.08) 2.78
%%Any%care%in%last%12%mo.%(d) %0.77%(0.08) %0.90%(0.11) %0.86%(0.10) 0.71





These models estimate that the baseline odds of polypharmacy for a 60-year-old individual who is male, not 
married, does not have health insurance and does not have an income, does not have any chronic diseases, any 
symptoms or disability, has not sought care in the last 12 months, did not undergo a preventative prostate exam 
in the last 24 months, and does not smoke or use alcohol, as 0.004 in 2000, 0.011 in 2006 and 0.013 in 2010. 
These values of odds allow us to calculate corresponding probabilities of polypharmacy of 0.4% in 2000, 1% in 
2006 and 1.3% in 2010.  
 
At the individual level, the most important factors associated with polypharmacy were those reflective of health 
status. The number of chronic diseases was the characteristic with the highest association with polypharmacy at 
all survey waves. The association between chronic diseases and polypharmacy was found to vary between 
women and men. With the exception of 2006, this difference was statistically significant, at the p<0.05 (2000) 
and p<0.01 (2010) levels. 
 
For each additional 10 years of age, the odds of polypharmacy were increased by 32% in 2000, and 48% in 
2010, all other things being equal. Both associations were statistically significant at the 0.01 level.  Women had 
three times higher odds of polypharmacy than men in 2000 (p<0.01) and 2.14 times higher odds of 
polypharmacy than men in 2010 (p<0.01). When controlling for all other individual characteristics, marital 
status was not significantly associated with polypharmacy, although in 2006 there was a marginally significant 
relationship, indicating 40% higher odds of polypharmacy among married individuals as compared to not 
married.  
 
For men, each additional chronic disease was associated with 2.2 times greater odds of polypharmacy in 2000 
and 2006, and 3 times greater odds of polypharmacy in 2010 (all significant at the p<0.01 level), holding other 
characteristics constant. While women tended to have significantly higher odds of polypharmacy than men at 
baseline, the increase in the odds of polypharmacy associated with each additional chronic disease was slightly 
lower (28% in 2000 and 34% lower in 2010) among women than it was estimated among men.  
 
To illustrate, while each additional chronic disease was associated with 2.2 times higher odds of polypharmacy 




polypharmacy among women. In 2010, while each additional chronic disease was associated with three times 
higher odds of polypharmacy among men, each additional chronic disease was associated with two times higher 
odds of polypharmacy among women. There were no other differential effects between women and men that 
could be detected in our sample. 
 
There was a dose-response relationship between higher levels of physical symptoms with higher odds of 
polypharmacy, when controlling for the same levels of chronic diseases, health care utilization, and all other 
individual characteristics. Level of clinical symptoms is utilized in this study as a metric of disease severity, as it 
helps differentiate between individual with controlled from those with non-controlled conditions. We assume 
that persons with a chronic disease that is under control will have fewer symptoms than a person with an 
actively symptomatic chronic condition. 
 
The dose-response pattern was present in all years but was most striking in 2000, where a person with one or 
two symptoms had 2.3 times higher odds of polypharmacy, a person with three to five symptoms had 2.8 times 
higher odds of polypharmacy, and a person with six or more symptoms had seven times higher odds of 
polypharmacy when compared to individuals with no symptoms (and keeping all other characteristics constant).   
 
In 2000, all these associations were statistically significant at the p<0.01 level. In 2006 and 2010 the dose-
response pattern was still observed but the increases in magnitude associated with higher levels of symptoms 
were less striking than 2000. Also, only the highest level of symptoms was statistically significantly associated 
with polypharmacy in 2006 (and only at the p<0.10 level) and in 2010 (at the p<0.01 level). In 2010 the second-
lowest level of symptoms was also associated with polypharmacy, at the p<0.10 level – holding all other factors 
constant, and when compared to individuals with no symptoms.  
 
Higher levels of disability (as measured by the difficulty in executing activities of daily living) did not present a 
clear dose-response relationship with polypharmacy. Disability was included in our study as a metric of long-
term, cumulative effect from chronic diseases. The relationships were not as marked and not statistically 
significant, except for 2006 when having disability in five or more activities was associated with 2.4 times 





Higher income was associated with higher likelihood of polypharmacy in 2000 and 2010. In 2000, each 
additional R$100 in a person's income was associated with 3.5% greater odds of polypharmacy (p<0.05), 
keeping all other characteristics constant. In 2010 this association, still significant at the p<0.05 level, was of a 
1% greater odds of polypharmacy. Having health insurance was positively associated with polypharmacy, but 
only for the two first waves (2000 and 2006) and only at the p<0.10 level. The odds of polypharmacy associated 
with having private health insurance were 42% higher as compared to people without private health insurance in 
2000, and 38% higher in 2006, keeping all other factors constant. 
 
There was also a marked, dose-response relationship, between higher health care utilization and polypharmacy. 
Persons with similar levels of other characteristics who sought more care in the last 12 months had higher odds 
of polypharmacy. The odds of polypharmacy increased at higher levels of care in all years, although they 
reached statistical significance only in 2000 and 2010. A person who had one to six medical visits in the last 
year had 1.5 times higher odds of polypharmacy than a person with no medical visits in 2000, and 2.5 higher 
odds of polypharmacy in 2010.  
 
Persons with very high health care utilization (over 24 medical visits in the last year) were estimated to have 
five times higher odds of polypharmacy in 2000 and over seven times higher odds of polypharmacy in 2010, as 
compared to similar persons with no medical visits in the last year. All relationships were statistically significant 
at least at the p<0.05 level in 2000 and 2010. Again, the relationships were present but less marked in terms of 
magnitude and statistical significance in 2006. 
 
Having undergone a preventative exam (mammogram for women, prostate exam for men) is another measure of 
health care utilization. Contrary to the findings on medical visits, having a preventative exam was statistically 
significantly associated with polypharmacy only in 2006 – in that year, having a preventative exam was 
associated with 1.7 times higher odds of polypharmacy as compared to not having a preventative exam (all other 
things being equal). This association was statistically significant at the p<0.01 level. The association between 
preventative exams and polypharmacy was positive in 2000 and 2010 (1.1 times higher odds of polypharmacy in 





Lastly, behaviors such as smoking and alcohol use were not significantly associated with polypharmacy 
according to the weighted logistic models. 
 
 
Table 4.8. Logistic Models Exploring the Association between Polypharmacy and Individual-Level Characteristics 
 
Notes:  
Logistic regression models weighted by year-specific inverse probability weights. Robust variance estimators. Coefficients are odds ratios, 
displayed as estimates (standard errors). 
 * p<0.10; **p<0.05; ***p<0.01 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) reference: males 
(c) reference: single, widowed or divorced. 
(d) Income measured in Brazilian Reais and presented at $100 intervals.  Individuals with missing income information (n=631; 13%) were 
imputed the average per capita income for the corresponding gender and year, and were identified by an indicator variable for missing 
income. No association between missing income and polypharmacy was found.  
(e) Reference: no private health insurance 
(f) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
Year 2000 2006 2010
Total-N=2143- Total-N=1413 Total-N=1333
Socio5Demographic
Age$(a) $1.325$(0.087)*** $1.164$(0.104) $1.481$(0.094)***
Female$gender$(b) $1.493$(0.209)* $1.067$(0.195) $0.866$(0.173)
Married$(c) $1.183$(0.157) $1.424$(0.177)** $0.981$(0.160)
Per$capita$income$(d) $1.035$(0.015)** $1.010$(0.006) $1.009$(0.004)**
Health$insurance$(e) $1.430$(0.182)** $1.370$(0.177)* $1.012$(0.165)
Health-Status-
Nr.$Chronic$Diseases$(f) $1.764$(0.072)*** $1.952$(0.061)*** $2.276$(0.062)***
Nr.$of$Symptoms:$1M2$(g) $2.327$(0.263)*** $1.113$(0.217) $1.046$(0.162)
$$$3M5$symptoms $2.710$(0.316)*** $1.506$(0.292) $1.449$(0.211)*
$$$6+$symptoms $6.957$(0.440)*** $2.195$(0.466)* $2.490$(0.434)**
ADLs$w/Disability:$1M4$(h) $1.290$(0.175) $1.189$(0.221) $1.028$(0.163)
5+$ADLs$w$disability $1.148$(0.255) $2.323$(0.249)*** $0.982$(0.270)
Health-Utilization
Medical$visits/year:$1M6$(i) $1.490$(0.206)* $1.236$(0.327) $2.530$(0.310)***
6M24$visits $2.376$(0.224)*** $2.047$(0.362)** $2.642$(0.377)**
24+$visits $5.254$(0.505)*** $2.403$(0.543) $7.198$(0.543)***
Preventative$exam$(j) $1.139$(0.144) $1.716$(0.200)*** $1.137$(0.190)
Behaviors
Current$smoking$(k) $0.683$(0.245) $0.703$(0.337) $0.792$(0.230)
Current$alcohol$use$(l) $1.017$(0.214) $0.818$(0.188) $0.797$(0.173)
Constant $0.007$(0.380)*** $0.015$(0.422)*** $0.023$(0.425)***
Regression-Statistics-(m)
N 2126 1350 1309
DF_model 19 18 19
LL M281150.97 M422112.72 M641654.84




(g) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness 
or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. Reference: no symptoms. 
(h) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. Reference: no disability. 
(i) Self-reported information of the number of medical visits in the last 12 months. Reference group: no medical visits. There were 348 
individuals with missing values for this variable in 2000 (16%). These individuals were identified by an indicator variable for missingness. 
Missingness was associated with 64% lower odds of polypharmacy (p<0.05) in that year. Individuals with missing values in 2006 (N=54, 
3.8%) and 2010 (N=4, 0.3%) were not included in the regressions. 
(j) Mammogram for women or prostate exam for men. There were 263 individuals (19.7%) with missing values for prevention in 2010. 
These individuals were identified by an indicator variable for missingness. There was no association between missingness and the odds of 
polypharmacy in 2010. Individuals with missing values in 2000 (N=14, 0.65%) and 2006 (N=3, 0.21%) were not included in the regressions. 
(k) Reference: not currently smoking 
(l) Reference: no current use of alcohol 
(m) Regression statistics displayed: number of individuals in the regression; number of degrees of freedom in the regression (parameters -1); 
log-likelihood of the model; pseudo-R squared. 
 
Gender Differences  
 
There is extensive literature demonstrating differences between men and women in the occurrence of 
polypharmacy. In order to explore whether these differences were associated with other individual 
characteristics in our sample, we examined the relationships between polypharmacy and individual 
characteristics separately for men and women.  We did this by first analyzing each gender separately (Table 
4.9). We also explored interaction terms between each variable and gender. In the case that there are other 
variables whose relationships with polypharmacy change across genders, this finding may help clarify why the 
gender differences occur. Table 4.9 displays the gender-specific associations.  
 
Women composed the majority of the sample in all years (59% in 2000, 61% in 2006, and 65% in 2010). The 
baseline probability of polypharmacy tended to be slightly higher among women. Some variables demonstrated 
differential associations with polypharmacy across genders: the association between polypharmacy and chronic 
diseases tended to be lower among women, as was the association with income. Age, health insurance, and care 
utilization tended to have higher associations with polypharmacy among men. Taken together, the set of 
individual characteristics tended to explain a higher proportion of the variation in polypharmacy among men 





For a 60-year-old individual who was not married, had no income, no health insurance, no chronic diseases, no 
symptoms or disabilities, did not have medical visits in the last 12 months, did not undergo preventative exams 
in the last 24 months and did not smoke or drink, the probability of polypharmacy was 1.3% for women vs. 
0.20% for men in 2000, 2.5% or women vs. 0.50% for men in 2006, and 2.8% for women vs. 0.90% for men in 
2010.  
 
According to the individual models, chronic diseases were the characteristic most strongly associated with 
polypharmacy. When men and women were analyzed together, each additional chronic disease was associated 
with 76% higher odds of polypharmacy in 2000, 95% higher odds in 2006 and 176% higher odds in 2010 (all 
other things being equal) (Table 2A). When women and men were analyzed separately a gender-specific 
association between chronic diseases and polypharmacy was identified. Although higher numbers of chronic 
conditions were associated with higher odds of polypharmacy in both genders, this association was lower for 
women in all years. All other variables did not have significant interaction terms with gender. 
 
In 2000, each additional chronic disease was associated with 132% higher odds of polypharmacy among men. 
Among women, however, each additional chronic disease was associated with 60% higher odds of 
polypharmacy, all other things being equal. In 2006, the difference between men and women decreased slightly: 
men had an average of 122% higher odds of polypharmacy for each additional chronic disease and women had 
80%. In 2010 the difference increased significantly. Each additional chronic disease was associated with 210% 
higher odds of polypharmacy among men but 101% higher odds among women, all other things being equal. All 
associations were statistically significant at the p<0.001 level. 
 
Gender differences in the effect of chronic diseases with polypharmacy were also captured by an interaction 
term between chronic diseases and female gender in the overall logistic individual models, which was smaller 
than zero (indicating lower magnitude among women as compared to men) and statistically significant in the 
three survey years. 
 
Age and medical care worked differently. In 2000, each additional year of age was associated with on average 
4% higher odds of polypharmacy among women (statistically significant at the p<0.01 level), and 2% higher 




average 5% higher odds of polypharmacy among women (statistically significant at the p<0.01 level), and 4% 
higher odds among men (statistically significant at the p<0.05 level), all other things being equal.  
 
Medical care, as measured by the number of medical visits in the last 12 months, was associated with higher 
odds of polypharmacy among women. The association was verified in 2000 and 2010, but not in 2006. The 
greater the care utilization, the greater the difference in effects comparing women to men. At lower levels of 
care (1-6 medical visits per year), there tended to be a minimal difference between genders (less than 1%), 
where men even tended to have higher magnitude of effects than women. At higher levels of care (6-24 visits 
and above 24 visits a year) the association with polypharmacy was much greater among women. It is possible 
that this reflects the small sample size of the group of men, but it should be further investigated. When measured 
by having undergone a preventative exam in the last 12 months women tended to have smaller odds of 
polypharmacy than men. However, with the exception of 2006 the associations were not statistically significant 
at the significance level p<0.05.  
 
The associations of both age and medical care utilization were positive when investigated through interaction 
terms added to the overall logistic individual models. However, the interaction terms were not statistically 
significant. We hypothesize that differences in the sample sizes between women and men, and especially 
between genders for each category of age and medical care utilization (both of which have a predominance of 
women in their highest levels) might help explain why the interaction terms lacked statistical significance.  
 
Health insurance tended to have larger (more positive) associations with the odds of polypharmacy among 
women, but income levels tended to have lower (less positive) associations among women. These findings are 
surprising because income and private health insurance are highly correlated and can be interpreted to represent 
higher purchasing power, and therefore would be expected to behave similarly. Their different associations with 
gender raises questions related to the relative importance of greater purchasing power (as identified by higher 
income levels) versus greater access to care (as identified by higher health insurance coverage) across genders, 




Table 4.9 Gender-Specific Analyses of the Links between Polypharmacy and Individual Characteristics  
 
Notes:   
Logistic regression models weighted by year-specific inverse probability weights. Robust variance estimators. Coefficients are odds ratios, 
displayed as estimates (standard errors).  * p<0.10; **p<0.05; ***p<0.01 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) reference: males 
(c) reference: single, widowed or divorced. 
(d) Income measured in Brazilian Reais and presented at $100 intervals.  Individuals with missing income information (n=631; 13%) were 
imputed the average per capita income for the corresponding gender and year, and were identified by an indicator variable for missing 
income. No association between missing income and polypharmacy was found.  
(e) Reference: no private health insurance 
(f) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
(g) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness 
or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. Reference: no symptoms. 
(h) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. Reference: no disability. 
(i) Self-reported information of the number of medical visits in the last 12 months. Reference group: no medical visits. There were 348 
individuals with missing values for this variable in 2000 (16%). These individuals were identified by an indicator variable for missingness. 
Missingness was associated with 64% lower odds of polypharmacy (p<0.05) in that year. Individuals with missing values in 2006 (N=54, 
3.8%) and 2010 (N=4, 0.3%) were not included in the regressions. 
(j) Mammogram for women or prostate exam for men. There were 263 individuals (19.7%) with missing values for prevention in 2010. 
These individuals were identified by an indicator variable for missingness. There was no association between missingness and the odds of 
polypharmacy in 2010. Individuals with missing values in 2000 (N=14, 0.65%) and 2006 (N=3, 0.21%) were not included in the regressions. 
(k) Reference: not currently smoking 
(l) Reference: no current use of alcohol 
Women& Men Women& Men Women& Men
Socio+Demographic
Age$(a) $1.361$(0.114)*** $1.189$(0.155) $1.143$(0.150) $1.160$(0.172) $1.506$(0.109)*** $1.404$(0.157)**
Married$(c) $1.069$(0.192) $2.344$(0.379)** $1.241$(0.239) $2.238$(0.396)** $0.924$(0.197) $1.149$(0.344)
Per$capita$income$(d) $1.030$(0.015)* $1.057$(0.024)** $1.005$(0.007) $1.020$(0.008)** $1.010$(0.005)** $1.008$(0.010)
Health$insurance$(e) $1.618$(0.209)** $0.906$(0.331) $1.466$(0.221)* $1.257$(0.325) $0.919$(0.189) $1.276$(0.286)
Health&Status&
Nr.$Chronic$Diseases$(f) $1.630$(0.077)*** $2.325$(0.151)*** $1.841$(0.071)*** $2.223$(0.132)*** $2.011$(0.074)*** $3.103$(0.129)***
Nr.$of$Symptoms:$1K2$(g) $2.046$(0.289)** $3.202$(0.456)** $0.914$(0.269) $1.543$(0.335) $0.957$(0.222) $1.231$(0.329)
$$$3K5$symptoms $2.386$(0.325)*** $4.144$(0.557)** $1.355$(0.348) $1.587$(0.465) $1.283$(0.258) $1.933$(0.399)*
$$$6+$symptoms $5.479$(0.470)*** $17.441$(0.920)***$1.403$(0.578) $5.374$(0.746)** $1.667$(0.443) $1.000$(0.000)
ADLs$w/Disability:$1K4$(h) $1.394$(0.214) $0.903$(0.361) $1.213$(0.262) $1.207$(0.371) $1.130$(0.186) $0.808$(0.320)
5+$ADLs$w$disability $1.177$(0.284) $1.268$(0.588) $2.649$(0.292)*** $2.061$(0.473) $1.212$(0.312) $0.507$(0.460)
Health&Utilization
Medical$visits/year:$1K6$(i) $1.703$(0.255)** $1.177$(0.371) $0.974$(0.443) $1.807$(0.531) $2.773$(0.381)*** $2.276$(0.496)*
6K24$visits $2.614$(0.234)*** $2.384$(0.438)** $1.958$(0.495) $1.918$(0.566) $2.808$(0.446)** $2.764$(0.731)
24+$visits $8.159$(0.579)*** $2.429$(0.981) $2.910$(0.693) $1.451$(1.034) $16.397$(0.608)***$2.420$(0.792)
Preventative$exam$(j) $0.999$(0.185) $1.728$(0.304)* $1.721$(0.218)** $1.767$(0.340)* $0.966$(0.205) $1.693$(0.363)
Behaviors
Current$smoking$(k) $0.673$(0.317) $0.788$(0.439) $0.461$(0.413)* $1.216$(0.484) $0.703$(0.286) $0.941$(0.533)
Current$alcohol$use$(l) $0.968$(0.254) $1.190$(0.343) $0.848$(0.239) $0.778$(0.335) $0.911$(0.231) $0.614$(0.277)*
Constant $0.013$(0.377)*** $0.002$(0.837)*** $0.026$(0.525)*** $0.005$(0.707)*** $0.029$(0.449)*** $0.009$(0.804)***
Regression&Statistics&(m)
N 1253 873 830 520 841 460





(m) Regression statistics displayed: number of individuals in the regression; number of degrees of freedom in the regression (parameters -1); 
log-likelihood of the model; pseudo-R squared.   
 
 
Comparison between Logistic and Multi-Level Latent and Mixed Effects Models  
 
Multi-level regression models take into consideration the correlations that may exist between individuals living 
in the same geographic area. Individuals living in the same area may share exposures and circumstances that 
may influence their likelihood of polypharmacy in addition to what is determined by their personal exposures 
and characteristics. This aggregation is not taken into consideration by regular logistic regression models. When 
the correlation between individuals living in the same area is not accounted for in the analytical models, the 
assumption of independence between observations may be violated, and the estimates may be biased.   
 
The nature of our investigation, where we seek to ultimately parse out the association of geographic and 
individual characteristics to the odds of polypharmacy, requires that we consider the aggregation at the 
geographic level even when we investigate individual-level characteristics. Table 4.10 displays the results of 
multi-level latent and mixed effects regression models in comparison to logistic regression models.  
 
The main effect introduced by the multi-level models is the estimation of a random intercept at the area level. In 
the multi-level model the baseline propensity for polypharmacy for individuals living in each of the areas is 
captured by the area-level random intercept. It is assumed that individuals are independent from each other once 
the correlation between them is accounted for.  
 
The results from the two different models were qualitatively similar. Higher age, female gender, higher income, 
access to health insurance, greater health care utilization and lower health status were each independently 
associated with higher odds of polypharmacy. The multi-level model also found a difference in the effect of 
chronic diseases according to gender, where each additional chronic disease tended to be associated with higher 
odds of polypharmacy for both genders, but among women the associations tended to be of lower magnitude 
than among men.  
 
There was no major quantitative difference in the estimation of the fixed effects of the individual level variables 




significance of the majority of the variables investigated. With few exceptions the multi-level estimates tended 
to have lower magnitude than the logistic estimates, suggesting that not accounting for the area-level correlation 
between individuals introduced a small but positive bias in the estimation of most effects.  
 
Table 4.10 Comparison between Logistic and Multi-Level Generalized Latent Mixed Regression Models Exploring the 




Logistic regression models weighted by year-specific inverse probability weights. Robust variance estimators. GLLAMM: Multi-level 
generalized latent mixed regression models weighted by year-specific inverse probability weights. Include random intercept at the area level. 
Robust variance estimators.  
Coefficients are odds ratios, displayed as estimates (standard errors). 
 * p<0.10; **p<0.05; ***p<0.01 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) reference: males 
(c) reference: single, widowed or divorced 
(d) Income measured in Brazilian Reais and presented at $100 intervals.  Individuals with missing income information (n=631; 13%) were 
imputed the average per capita income for the corresponding gender and year, and were identified by an indicator variable for missing 
income. A statistically significant association at the 0.05 level between missing income and polypharmacy was found in 2010, where 
individuals with missing income had 0.8% higher odds of polypharmacy. No relevant associations were found between missing income 
and polypharmacy in the other two years.  
(e) Reference: no private health insurance 
(f) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
Year
LOGISTIC GLLAMM LOGISTIC GLLAMM LOGISTIC GLLAMM
Socio1Demographic
Age$(a) $1.325$(0.087)*** $1.275$(0.086)*** $1.164$(0.104) $1.096$(0.095) $1.481$(0.094)*** $1.439$(0.103)***
Female$gender$(b) $1.493$(0.209)* $1.430$(0.165)** $1.067$(0.195) $0.992$(0.192) $0.866$(0.173) $0.833$(0.175)
Married$(c) $1.183$(0.157) $1.148$(0.161) $1.424$(0.177)** $1.333$(0.158)* $0.981$(0.160) $0.998$(0.139)
Per$capita$income$(d) $1.035$(0.015)** $1.032$(0.006)*** $1.010$(0.006) $1.007$(0.006) $1.009$(0.004)** $1.007$(0.004)*
Health$insurance$(h) $1.430$(0.182)** $1.364$(0.206) $1.370$(0.177)* $1.161$(0.155) $1.012$(0.165) $0.849$(0.164)
Health:Status:
Nr.$Chronic$Diseases$(e) $1.764$(0.072)*** $1.779$(0.067)*** $1.952$(0.061)*** $2.027$(0.073)*** $2.276$(0.062)*** $2.335$(0.055)***
Nr.$of$Symptoms:$1M2$(f) $2.327$(0.263)*** $2.304$(0.195)*** $1.113$(0.217) $1.192$(0.219) $1.046$(0.162) $1.109$(0.167)
$$$3M5$symptoms $2.710$(0.316)*** $2.775$(0.277)*** $1.506$(0.292) $1.576$(0.298) $1.449$(0.211)* $1.494$(0.192)**
$$$6+$symptoms $6.957$(0.440)*** $6.649$(0.401)*** $2.195$(0.466)* $2.189$(0.551) $2.490$(0.434)** $2.690$(0.393)**
ADLs$w/Disability:$1M4$(g) $1.290$(0.175) $1.300$(0.166) $1.189$(0.221) $1.294$(0.257) $1.028$(0.163) $1.099$(0.150)
5+$ADLs$w$disability $1.148$(0.255) $1.193$(0.256) $2.323$(0.249)*** $2.493$(0.268)*** $0.982$(0.270) $0.999$(0.248)
Health:Utilization
Medical$visits/year:$1M6$(i) $1.490$(0.206)* $1.520$(0.200)** $1.236$(0.327) $1.293$(0.281) $2.530$(0.310)*** $2.812$(0.307)***
6M24$visits $2.376$(0.224)*** $2.468$(0.283)*** $2.047$(0.362)** $2.253$(0.293)*** $2.642$(0.377)** $3.155$(0.357)***
24+$visits $5.254$(0.505)*** $5.368$(0.551)*** $2.403$(0.543) $3.167$(0.447)*** $7.198$(0.543)*** $7.939$(0.542)***
Preventative$exam$(j) $1.139$(0.144) $1.157$(0.148) $1.716$(0.200)*** $1.788$(0.173)*** $1.137$(0.190) $1.164$(0.194)
Behaviors
Current$smoking$(k) $0.683$(0.245) $0.673$(0.212)* $0.703$(0.337) $0.709$(0.351) $0.792$(0.230) $0.807$(0.248)
Current$alcohol$use$(l) $1.017$(0.214) $0.989$(0.196) $0.818$(0.188) $0.733$(0.165)* $0.797$(0.173) $0.752$(0.139)**
Constant $0.007$(0.380)*** $0.007$(0.386)*** $0.015$(0.422)*** $0.011$(0.292)*** $0.023$(0.425)*** $0.019$(0.411)***
Regression:Statistics:(m)
N 2126 2126 1350 1350 1309 1309
DF_model$/$Nr.$Parameters 19 21 18 20 19 21
LL M281150.97 M276188.21 M422112.72 M400121.2 M641654.84 M626061.56





(g) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, 
tiredness or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. Reference: no symptoms. 
(h) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. Reference: no disability. 
(i) Self-reported information of the number of medical visits in the last 12 months. Reference group: no medical visits. There were 348 
individuals with missing values for this variable in 2000 (16%). These individuals were identified by an indicator variable for missingness. 
Missingness was associated with 63% lower odds of polypharmacy (p<0.05) in that year. Individuals with missing values in 2006 (N=54, 
3.8%) and 2010 (N=4, 0.3%) were not included in the regressions. 
(j) Mammogram for women or prostate exam for men. There were 263 individuals (19.7%) with missing values for prevention in 2010. 
These individuals were identified by an indicator variable for missingness. There was no statistically significant association between 
missingness and the odds of polypharmacy in 2010. Individuals with missing values in 2000 (N=14, 0.65%) and 2006 (N=3, 0.21%) were 
not included in the regressions. 
(k) Reference: not currently smoking 
(l) Reference: no current use of alcohol 
(m) Regression statistics displayed: number of individuals in the regression; number of degrees of freedom (parameters - 1) for the logistic 
model, number of parameters for the GLLAMM model; log-likelihood of the model; pseudo-R squared for the logistic model and variance 
and standard error of the random intercept for the GLLAMM model. 
 
4.4.3 Part 3 – Geographic Variation in Polypharmacy and Association with Community-Level 
Characteristics 
 
We first explored the geographic patterns of polypharmacy by aggregating individuals into the 30 geographic 
sub-divisions of the city of Sao Paulo (sub-prefectures). We were interested in identifying the extent of 
clustering in the patterns of polypharmacy across the geographic areas. We implemented multi-level generalized 
latent mixed regression models where we estimated a random intercept at the area level and we assumed an 
exchangeable correlation pattern among subjects living in the same area. Similarly to the logistic models, we 
also utilized inverse-probability weights in order to reconstruct the population of Sao Paulo in each of the years. 
 
We implemented "null" models without covariates in order to capture the extent of variation across areas (Table 
4.11). We obtained the probability of polypharmacy from the baseline log odds from each model. We found an 
estimated average prevalence of polypharmacy at the sub-prefecture level of 16.5% in 2000, 25.5% in 2006 and 
38% in 2010. These values are similar to the estimates from the weighted logistic regressions (the differences 





From the multi-level models, we calculated the 95% confidence interval for the baseline prevalence of 
polypharmacy. We found that 95% of the sub-prefectures have baseline prevalence of polypharmacy estimated 
between 10.4%-25.3% in 2000, 12.3%-45.5% in 2006, and 26.9%-50.5% in 2010.  
 
Using the multi-level models we also calculated the intraclass correlation coefficient (ICC) for each of the years. 
The ICC estimates the correlation between observations within a same cluster. The ICC was very low in all 
years, indicating that there was a very small correlation in terms of the likelihood of polypharmacy between 
individuals of the same cluster. This indicates that most of the variation in the odds of polypharmacy is driven 
by characteristics pertaining to individuals, and not by different propensities at the area level. This very low 
correlation was consistent across the survey waves.  
 
Table 4.11 Aggregation and Geographic Variation in Polypharmacy 
 
Notes:  
Models are devoid of covariates and weighted by inverse probability weights at the individual level. Gllamm:  multi-level generalized latent 
mixed regression model; includes random intercept for area (sub-prefecture) and assumes exchangeable correlation across observations from 
the same area. ICC: Intra-class correlation coefficient. 95%CI: confidence interval comprehending 95% of values around the average. 
 
Links between Community-Level Characteristics and Area-Level Odds of Polypharmacy 
 
We explored the associations between polypharmacy and geographic-level characteristics through two main 
methodological approaches. First we used geographic characteristics to model average likelihood of 
polypharmacy at the geographic level. This is important in order to understand which characteristics at the area 
level may be related to polypharmacy. However, because both sides of the analysis (outcomes and exposures) 
are used in an aggregated form this approach can often give rise to an ecological fallacy. An ecological fallacy 
happens when inferences about individuals are made based on analysis of aggregated data. In this case, 
inferences may be incorrect because it is not possible to ascertain which individuals were exposed and which 
developed the outcome. We evaluated the association between geographic-level characteristics and 
polypharmacy measured at the individual level in separate models (Table 4.11). 
2000 !0.161!(0.146–0.178) !0.165!(0.157–0.173) 0.165!(0.104–0.253) 0.022
2006 0.260!(0.232–0.291) 0.255!(0.247–0.264) 0.255!(0.123–0.455) 0.059












Because the number of geographic areas was small (n=30) we utilized "count" versions of the variables "number 
of symptoms" and "number of ADLs with disabilities", and we utilized a binary version of the variable "health 
care utilization". We favored this approach out of concern about having an excessive number of parameters in 
our models, given the small number of geographic units that limit the degrees of freedom of the model. The 
results from the aggregated geographic models are displayed in Table 12. 
 
The models estimate the baseline odds of polypharmacy at the area level (constant terms), which we can 
transform into a probability. The baseline probability of polypharmacy was 0.04% in 2000, 1% in 2006 and 
5.3% in 2010 for an area where the senior population had average age of 60 years, where all the individuals 
were men and none was married, where the prevalence of smoking and alcohol were zero, the average per capita 
income was zero and no one had health insurance, where people had on average no chronic diseases, no 
symptoms and no disabilities, where average health care utilization was low or none, and where no persons had 
undergone preventative exams (Table 4.12).  
 
Results from multi-level generalized latent mixed-effects regression models of the Odds of Polypharmacy 
Measured at the Geographic Area-Level 
 
Table 4.12 Links between Polypharmacy and Geographic Characteristics 
 
Notes: 
Year 2000 2006 2010
Average'age'(a) 1.06 (0.89–1.24) 0.504 1.90 (1.53–2.35) <0.001 1.32 (1.19–1.47) <0.001
'%'women 35.5 (19.65–64.23) <0.001 0.252 (0.14–0.46) <0.001 0.51 (0.31–0.83) 0.007
'%'married'(b) 5.00 (2.90–8.63) <0.001 1.21 (0.71–2.05) 0.488 0.566 (0.401–0.80) 0.001
Avg.'per'capita'income'(c) 0.91 (0.87–0.93) <0.001 0.964 (0.95–0.99) <0.001 1.05 (1.04–1.06) <0.001
'%'health'insurance'(d) 1.01 (0.74–1.36) 0.948 3.69 (2.79–4.8) <0.001 0.546 (0.416–0.719) <0.001
Avg.'nr.'chronic'diseases'(e) 1.09 (0.89–1.32) 0.375 2.45 (1.82–3.29) <0.001 2.08 (1.78–2.42) <0.001
Avg.'nr.'symptoms'(f) 0.634 (0.56–0.71) <0.001 0.847 (0.75–0.96) 0.006 0.903 (0.794–1.03) 0.12
Avg.'nr.'ADLs'w/disability'(g) 2.36 (2.16–2.57) <0.001 1.03 (0.86–1.23) 0.759 1.05 (0.985–1.11) 0.148
%'modKhigh'care'users'(h) 12.3 (7.14–21.34) <0.001 2.00 (1.39–2.86) <0.001 0.751 (0.467–1.21) 0.237
%'preventative'care'(i) 5.93 (3.37–10.44) <0.001 0.945 (0.45–1.97) 0.88 2.86 (1.59–5.15) <0.001
%'smoking'(j) 0.049 (0.03–0.09) <0.001 4.17 (1.69–10.26) 0.002 1.46 (0.71–3.0) 0.305
%'alcohol'use'(k) 64.42 (31.8–130.4) <0.001 2.26 (1.64–3.10) <0.001 0.364 (0.267–0.497) <0.001







































Multi-level generalized latent mixed regression models include random intercept at the area level (subprefecture). Models are not weighted. 
Estimates are odds ratios, presented with 95% confidence intervals and significance levels (p-value) 
Outcome: average odds of polypharmacy at the area level 
Area-level variables calculated from the data from the SABE survey, and reflect year-specific averages for the population of 60-year olds 
and over in each of the geographic areas. 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) Reference: not currently married or in a civil union. 
(c) Income measured in Brazilian Reais and presented at $100 intervals.   
(d) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
(e) Reference: no private health insurance 
(f) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness 
or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. 
(g) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. 
(h) Self-reported information of the number of medical visits in the last 12 months. Moderate-high utilization: 7 or more medical visits. 
Reference: 0-6 medical visits. 
(i) Self-report of having undergone mammogram (women) or prostate exam (men) in the last 24 months. 
(j) Reference: not currently smoking 
(k) Reference: no current use of alcohol 
 
The models estimate associations between community-level characteristics and the average odds of 
polypharmacy at the community level. Each coefficient represents the expected change in the average odds of 
polypharmacy associated with a one-unit change in the average level of the covariate in an area with average 
rates of polypharmacy.  
 
All variables exhibited some degree of relevant association with average odds of polypharmacy at the area level. 
Average age, average number of chronic diseases, and average levels of disability were consistently associated 
with higher odds of polypharmacy in all years. Higher levels of symptoms were consistently associated with 
lower odds of polypharmacy at the community level in all years. Average income had an association that, 
although statistically significant in all years, was very close to 1. 
 
Other characteristics, especially those that represented percentages, had associations that changed in both 
magnitude and direction across the survey waves.  A one-unit change in covariates that are percentages (such as 
percentage of married individuals and percentage of women) represents a change of 100% in that covariate. 
Coefficients in our models therefore represent the expected change in the odds of polypharmacy comparing 





Some of these comparisons may not be applicable in real life. For example, it is virtually impossible that any of 
the Sao Paulo sub-prefectures, which according to our data had about 400 thousand inhabitants on average, 
would actually have the entirety of their senior population composed of women or men. These comparisons may 
also represent large extrapolations from our data, aggravated by the small number of geographic areas (total of 
30 units).  
 
Also, characteristics such as female gender, higher age and married status tend to be correlated. 
Multicollinearity across variables may further help explain the changes in magnitude and direction of 
associations. In order to explore that, we analyzed each of the area-level covariates in a univariate regression 
model (Table 4.13).  
 
Table 4.13 Independent effect of area-level characteristics on the area-level odds of polypharmacy – Each row represents a 
different regression model that includes only the listed covariate 
 
Notes: Same as Table 4.12. 
 
Next we analyzed the association between area-level characteristics and the odds of polypharmacy at the 
individual level (Table 4.14). The findings from the models analyzing outcomes at the individual level were 
similar to those analyzing the outcome at the area-level. However, there were more data points contributing to 
the estimation in this model, which improved the efficiency of some of the estimates but not all of them. 
 
Year 2000 2006 2010
Average'age'(a) 1.97 '('1.80–'2.14) <0.001 1.42 '('1.32–'1.53) <0.001 1.55 '('1.42–'1.69) <0.001
'%'women 45.3 '(33.21–61.79) <0.001 0.97 '('0.72–'1.29) 0.81 2.07 '('1.37–'3.13) 0.001
'%'married'(b) 0.24 '('0.20–'0.30) <0.001 0.22 '('0.17–'0.29) <0.001 0.18 '('0.13–'0.25) <0.001
Avg.'per'capita'income'(c) 1.05 '('1.05–'1.06) <0.001 1.02 '('1.01–'1.03) <0.001 1.03 '('1.03–'1.04) <0.001
'%'health'insurance'(d) 1.98 '('1.82–'2.16) <0.001 3.35 '('2.94–'3.82) <0.001 2.17 '('1.91–'2.47) <0.001
Avg.'nr.'chronic'diseases'(e) 3.98 '('3.56–'4.46) <0.001 3.82 '('3.25–'4.50) <0.001 1.6 '('1.44–'1.78) <0.001
Avg.'nr.'symptoms'(f) 1.08 '('1.03–'1.14) 0.002 1.21 '('1.12–'1.30) <0.001 1.34 '('1.25–'1.44) <0.001
Avg.'nr.'ADLs'w/disability'(g) 1.16 '('1.12–'1.20) <0.001 1.29 '('1.24–'1.34) <0.001 1.1 '('1.06–'1.15) <0.001
%'modKhigh'care'users'(h) 2.53 '('1.59–'4.01) <0.001 1.67 '('1.44–'1.94) <0.001 1.71 '('1.15–'2.54) 0.008
%'preventative'care'(i) 7.51 '('5.96–'9.46) <0.001 10.38 '('7.01–15.37) <0.001 0.57 '('0.42–'0.77) <0.001
%'smoking'(j) 0.02 '('0.01–'0.03) <0.001 0.01 '('0.01–'0.02) <0.001 0.12 '('0.07–'0.20) <0.001






















Table 4.14 Links between Polypharmacy and Geographic Characteristics: Results from multi-level generalized latent mixed-
effects regression models of the Odds of Polypharmacy Measured at the Individual Level 
 
Notes: 
Multi-level generalized latent mixed regression models include random intercept at the area level (subprefecture). Models are not weighted. 
Estimates are odds ratios, presented with 95% confidence intervals and significance levels (p-value) 
Outcome: average odds of polypharmacy at the area level 
Area-level variables calculated from the data from the SABE survey, and reflect year-specific averages for the population of 60-year olds 
and over in each of the geographic areas. 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) Reference: not currently married or in a civil union. 
(c) Income measured in Brazilian Reais and presented at $100 intervals.   
(d) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
(e) Reference: no private health insurance 
(f) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness 
or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. 
(g) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. 
(h) Self-reported information of the number of medical visits in the last 12 months. Moderate-high utilization: 7 or more medical visits. 
Reference: 0-6 medical visits. 
(i) Self-report of having undergone mammogram (women) or prostate exam (men) in the last 24 months. 
(j) Reference: not currently smoking 
(k) Reference: no current use of alcohol 
 
 
Year 2000 2006 2010
Average'age'(a) 1.39 '('1.08–'1.79) 0.012 0.73 '('0.65–'0.80) <0.001 1.42 '('1.31–'1.53) <0.001
'%'women 2.57 '('1.34–'4.93) 0.004 0.24 '('0.16–'0.35) <0.001 1.36 '('0.98–'1.88) 0.064
'%'married'(b) 2.79 '('1.43–'5.44) 0.003 24.31 '(14.42–40.98) <0.001 1.71 '('1.43–'2.04) <0.001
Avg.'per'capita'income'(c) 0.93 '('0.89–'0.97) 0.001 0.94 '('0.93–'0.95) <0.001 0.99 '('0.98–'0.99) 0.001
'%'health'insurance'(d) 1.15 '('0.77–'1.73) 0.492 2.73 '('2.36–'3.17) <0.001 3.49 '('2.71–'4.48) <0.001
Avg.'nr.'chronic'diseases'(e) 1.13 '('0.93–'1.38) 0.227 1.15 '('0.94–'1.41) 0.162 1.85 '('1.66–'2.08) <0.001
Avg.'nr.'symptoms'(f) 1.18 '('0.94–'1.47) 0.153 1.41 '('1.26–'1.57) <0.001 0.98 '('0.88–'1.09) 0.769
Avg.'nr.'ADLs'w/disability'(g) 0.9 '('0.83–'0.98) 0.011 1.41 '('1.30–'1.54) <0.001 0.78 '('0.73–'0.82) <0.001
%'modKhigh'care'users'(h) 10.74 '('4.42–26.11) <0.001 0.97 '('0.82–'1.15) 0.762 1.05 '('0.67–'1.65) 0.825
%'preventative'care'(i) 1.85 '('0.90–'3.77) 0.092 15.96 '('9.51–26.78) <0.001 0.74 '('0.45–'1.22) 0.241
%'smoking'(j) 0.57 '('0.28–'1.15) 0.116 0.01 '('0.01–'0.02) <0.001 1.33 '('0.78–'2.27) 0.296
%'alcohol'use'(k) 1.12 '('0.60–'2.07) 0.726 3.05 '('2.34–'3.99) <0.001 0.57 '('0.47–'0.69) <0.001






























4.4.4 Part 4 – Association between Polypharmacy and Community Characteristics Controlling for 
Individual Characteristics (Contextual and Compositional Effects) 
 
In order to investigate for the effects of community-level variables on the odds of polypharmacy we implement 
a series of models where we assess the relationship between polypharmacy and the different area-level factors, 
controlling for all individual-level characteristics examined in the previous section.  
 
It is important to note that the current section and the next one describe results from conditional models 
(generalized latent and mixed-effects models). The interpretation of the results of conditional models reflects the 
associations occurring at areas with the average outcome (average rates of polypharmacy).  The effects are not 
marginal, and they do not necessarily have the same size or sign at different points of the outcome distribution. 
This is different from what would be expected to have in a linear regression analysis and will be reiterated 
ahead. 
 
The analysis of the multiple area-level characteristics elicits a pattern suggesting that area-level characteristics 
may also represent predisposing, enabling, and illness levels factors, which can be associated with the likelihood 
of polypharmacy independently from the individual characteristics. 
 
Table 4.15 displays the main results from this analysis. Each of the area-level variables was included in a model 
containing all individual-level characteristics but no other community-level characteristic, to avoid 
multicollinearity. Because we anticipate the possibility of measurement errors, we also investigated variables 
collected from other sources external to the SABE survey. We sought to obtain greater validity of our findings 
by examining multiple correlates of a same concept. Also, we sought to examine the multiple area-level 
characteristics in order to define which would be more appropriate to include in a full model. We display all 
measures that we analyzed, classified according to their category in the conceptual framework. 
 
We find that characteristics that identified an older and predominantly female composition of the population– 
the predisposing factors – tended to be positively associated with polypharmacy. These variables indicate that 
two individuals who share all the same individual-level characteristics but that live in areas that have different 




composition. The person who lives in an area with greater percentage of seniors, greater average age, or greater 
proportion of women (which, among seniors, is a proxy for older age) will be expected to have greater 
likelihood of polypharmacy.  
 
Variables indicative of higher illness levels in the population exhibited a different pattern: higher mortality 
tended to be associated with higher rates of polypharmacy, whereas greater number of chronic diseases, higher 
disability and higher levels of symptoms tended to be associated with lower polypharmacy. It is possible that 
these metrics correspond to different concepts. For example, areas with higher mortality may have especially 
high diseases lethality from certain conditions. Perhaps the same conditions yield less risk of death in other 
geographic areas. – For example, stroke, can be very lethal if there is no adherence to pharmacologic treatments, 
or low supportive care and monitoring. In areas where providers anticipate that there is elevated risk of a bad 
outcome from a stroke, the prescribed may be motivated to treat the stroke and its underlying conditions more 
aggressively.  
 
It is also possible that our disease metrics - greater number of chronic diseases, higher disability and higher 
levels of symptoms – may reflect community-level levels of disease morbidity. Perhaps providers working in 
areas with greater disease morbidity and greater disability may anticipate that their patients will be frail and 
therefore be motivated to prescribe less aggressively.  
 
Measures of higher socio-economic status of a community tended to support a positive association with 
polypharmacy. Individuals with same personal characteristics who differ only from living in an urban or 
predominantly rural area can be expected to have different odds of polypharmacy. All other things being equal, 
a person living in a predominantly rural area is expected to have about 48% lower odds of polypharmacy in 
2000 and 42% lower odds in 2010 than a person living in an urban area, as long both areas have average levels 
of the outcome.  
 
Average area-level per capita income was positively associated with the odds of polypharmacy, as was higher 
prevalence of health insurance among seniors. These findings indicate that, from two individual with same 
personal characteristics living in areas that differ only by their prevalence of heath insurance, the individual 




about five times greater odds of polypharmacy (in 2010) than the individual living in an area where no seniors 
have health insurance. These findings suggest that the resources at the area level may play a significant role in 
determining an individual's likelihood of polypharmacy, in excess of an individual's personal resources. 
 
Areas with greater private health insurance coverage also tended to have greater levels of polypharmacy. In fact, 
the coefficients associated with high health insurance coverage represent the largest magnitudes across all 
community-level variables. We attempt to clarify this association by controlling for confounding between the 
diverse level-2 variables in a multi-variate model described below. 
 
Lastly, the findings related to health care utilization do not form a clear pattern. Hospital admissions indicate a 
positive relationship with polypharmacy, but utilizing high levels of medical care has conflicting results between 
2000 and 2006.  
The effect of seeking physician care was positively associated with polypharmacy at the individual level, 
indicating that a person who sought more care (all other things being equal) had greater odds of having 
polypharmacy than a person who sought less care.  
 
At the area level, however, higher rates of health care utilization suggested an association with lower odds of 
polypharmacy. This indicates that if two individuals with similar personal characteristics live in areas that differ 
in the rates of health care utilization (but have similar other area-level characteristics), the odds of polypharmacy 
would be expected to be lower for the individual who lives in an area with greater health care utilization.   
 
It is possible that these metrics indicate differences in polypharmacy according to the type of service reviewed. 
It is also possible that these characteristics are "proxies" for other characteristics of health care – greater 
availability, or greater quality of care, for example. These, however, are speculations. We perform an empirical 









Notes: Multi-level generalized latent mixed regression models including random intercept at the area level (subprefecture). Models are 
weighted by inverse probability of selection. Models include all characteristics at the individual level, plus one of the community-area 
variables. Estimates are odds ratios, presented with 95% confidence intervals and significance levels (p-value). Outcome: average odds of 
polypharmacy, measured at the individual level. 
Area-level variables derived from the SABE study: average age, percentage of female, average number of chronic diseases, average number 
of symptoms, average levels of disability, average per capita income, average rate of private insurance, average rate of high care utilizers, 
and average rate of preventative exams. These variables reflect averages for the population of 60-year olds and over in each of the 
geographic areas. Mortality among 60-year olds and over, and hospital admissions obtained from the Ministry of Health's Vital Statistics 
and Health Utilization databases. Percentage of seniors and rural area characteristics obtained from the Brazilian Census. 
 
 
Table 4.16 displays a comparison between the two full models that we implemented: Model 1 examines the 
association between polypharmacy and individual characteristics. Model 2 examines the association between 
polypharmacy and area-level characteristics, controlling for individual factors. Our choice of area-level 
covariates was based on the investigation presented in Table 15.  
 
The inclusion of area-level factors did not modify the associations that we had estimated with the individual-
level regression models. The coefficients from Model 1 vary minimally when the area-level covariates are 
included, in Model 2.  
2000 2006 2010
PREDISPOSING Avg.%Age 2.7 %2.13*** 1.21
%(0.36–20.35) %(1.65–2.74) %(0.87–1.68)
%%seniors %7.62*** %60.08*** %70.47***
%(2.02–28.81) %(12.19–296.10) %(10.30–482.22)
%%women 1.32 %2.10* %0.09***
%(0.64–2.73) %(0.91–4.88) %(0.04–0.21)
ILLNESS/LEVEL Avg.%Nr.%NCDs 1.12 1.07 %0.56***
%(0.90–1.41) %(0.81–1.41) %(0.46–0.69)
Avg.%Nr.%Disabilities 0.95 %1.12** 0.92
%(0.84–1.07) %(1.01–1.25) %(0.83–1.03)
Avg.%Nr.%Symptoms %0.71*** %0.73*** %0.80**
%(0.60–0.84) %(0.60–0.88) %(0.65–0.99)
Senior%Deaths/1,000 %1.07*** %1.03*** %0.95***
%(1.05–1.08) %(1.01–1.04) %(0.93–0.96)
ENABLING Rural%Characteristics %0.52*** 0.9 %0.58***
%(0.45–0.59) %(0.78–1.04) %(0.50–0.66)
Avg.%Income %1.06*** %1.06*** %1.03***
%(1.03–1.10) %(1.04–1.07) %(1.01–1.04)
%%Private%H.%Insurance %1.56* %8.23*** %4.16***
%(1.00–2.46) %(4.76–14.26) %(2.46–7.04)
%%High%Utilizers %3.19*** %0.54* %0.09***
%(1.67–6.09) %(0.27–1.10) %(0.06–0.14)
%%Preventative%exam 1.54 N/A 0.98
%(0.68–3.50) N/A %(0.34–2.85)






The models still support the relationships between the area-level factors that we described in Table 15 and 
polypharmacy. Especially, enabling factors at the community level were associated with higher likelihood of 
polypharmacy independently of the individual characteristics. Higher income and higher rates of health 
insurance were associated with increased odds of polypharmacy, and predominance of rural areas was 
associated with decreased odds of polypharmacy. Similarly, a positive association between mortality of 
individuals 60 years old and over and polypharmacy, remaining after controlling for all individual and area-level 
characteristics simultaneously, supported the possibility that illness level factors at the community level may 
modify individual's likelihood of polypharmacy.  
 
Table 4.16 Full models of the association of individual and area-level characteristics and polypharmacy 
 
Notes:  
Multi-level generalized latent mixed regression models including random intercept at the area level (subprefecture). Models are weighted by 
inverse probability of selection. 
Model 1 includes characteristics at the individual level, identified as: enabling, predisposing, and illness level. 
Model 2 includes all individual-level characteristics, plus community characteristics divided as: enabling, illness levels. 
Estimates are odds ratios, presented with 95% confidence intervals and significance levels (p-value) 
Outcome: odds of polypharmacy, measured at the individual level 
Model&1 Model&2 Model&1 Model&2 Model&1 Model&2&
Individual/Level
Predisposing
Age/%10yr %1.25%(0.08)*** %1.26%(0.08)*** %1.05%(0.10) %1.07%(0.09) %1.38%(0.10)*** %1.39%(0.10)***
Female %1.37%(0.16)* %1.40%(0.16)** %1.00%(0.18) %0.96%(0.18) %0.85%(0.18) %0.86%(0.18)
Married %1.13%(0.16) %1.13%(0.16) %1.35%(0.16)* %1.36%(0.17)* %0.97%(0.14) %0.97%(0.15)
Smoking %0.67%(0.22)* %0.66%(0.21)* %0.73%(0.34) %0.73%(0.34) %0.83%(0.26) %0.82%(0.26)
Alcohol%use %0.94%(0.21) %0.95%(0.21) %0.76%(0.15)* %0.75%(0.16)* %0.80%(0.15) %0.81%(0.15)
Enabling
P.C.%Income/$%100 %1.03%(0.01)*** %1.03%(0.01)*** %1.01%(0.01) %1.01%(0.01) %1.01%(0.00)* %1.01%(0.00)*
Private%h.%insurance %1.32%(0.20) %1.33%(0.22) %1.13%(0.16) %1.13%(0.17) %0.85%(0.16) %0.83%(0.19)
High%care%utlization %1.87%(0.18)*** %1.86%(0.18)*** %1.72%(0.19)*** %1.69%(0.23)** %2.04%(0.18)*** %2.03%(0.19)***
Preventative%exam %1.17%(0.16) %1.16%(0.16) %1.79%(0.16)*** %1.82%(0.17)*** %1.13%(0.20) %1.12%(0.20)
Illness&Level
Nr.%Chronic%Diseases %1.81%(0.07)*** %1.82%(0.06)*** %2.05%(0.08)*** %2.04%(0.08)*** %2.26%(0.05)*** %2.25%(0.05)***
Nr.%Symptoms %1.22%(0.04)*** %1.22%(0.05)*** %1.13%(0.06)** %1.14%(0.06)** %1.12%(0.05)** %1.11%(0.05)**
Nr.%ADLs%with%Disability %1.17%(0.13) %1.04%(0.03) %1.12%(0.03)*** %1.12%(0.03)*** %1.03%(0.03) %1.03%(0.03)
Area/Level
Enabling
Rural%area %0.79%(0.04)*** %0.50%(0.06)*** %0.80%(0.07)***
Avg.%PC.%Income%/$%100 %1.04%(0.02)* %0.99%(0.01) %1.00%(0.01)
%%health%insurance %0.93%(0.30) %14.51%(0.35)*** %3.51%(0.30)***
%%high%care%utilizers %1.40%(0.27) %1.04%(0.26) %0.21%(0.26)***
Illness&Level
Deaths%60+%/1,000%hab %1.03%(0.00)*** %1.05%(0.01)*** %0.97%(0.01)***
Model&Statistics
Constant%term %0.01%(0.31)*** %0.00%(0.36)*** %0.01%(0.26)*** %0.00%(0.43)*** %0.03%(0.25)*** %0.15%(0.42)***
N 2126 2126 1350 1350 1309 1309





Area-level variables: average per capita income, average rate of private insurance, average rate of high care utilizers calculated from the data 
from the SABE survey, and reflect year-specific averages for the population of 60-year olds and over in each of the geographic areas. 
Mortality among 60-year olds and over, and rural area characteristics obtained from the Ministry of Health's Vital Statistics database and the 
Brazilian Census, respectively. 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) Reference: not currently married or in a civil union. 
(c) Income measured in Brazilian Reais and presented at $100 intervals.   
(d) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
(e) Reference: no private health insurance 
(f) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness 
or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. 
(g) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. 
(h) Self-reported information of the number of medical visits in the last 12 months. Moderate-high utilization: more medical visits than the 
median across all areas in each year. Reference: fewer number of medical visits than the year median. 
(i) Self-report of having undergone mammogram (women) or prostate exam (men) in the last 24 months. 
(j) Reference: not currently smoking 
(k) Reference: no current use of alcohol  
 
 
4.4.5 Part 5 – Individual and Community-Level Factors Associated with Inappropriate Polypharmacy  
 
We investigated the association between individual and community-level factors inappropriate polypharmacy 
utilizing the same framework presented for polypharmacy.  Table 17 describes the results.  
 
The findings related to inappropriate polypharmacy were largely the same as described in relation to 
polypharmacy in the previous section. At the individual level, inappropriate polypharmacy was associated with 
greater health care utilization, including private insurance coverage. Higher health need as indicated by illness 
levels was also positively associated with inappropriate polypharmacy. The findings from individual-level 
characteristics were not significantly modified when community characteristics were brought to the model. The 
community-level associations were also qualitatively similar to those described with polypharmacy. However, 
there was a general tendency for lower coefficients in this analysis, suggesting that the magnitude of the 
associations between the multiple factors and inappropriate polypharmacy may be relatively smaller than with 
polypharmacy.  
 
In the previous section we hypothesized that the effect from higher mortality at the community level and 




Physician prescribing practices may also underlie the associations that we found between higher rates of private 
health insurance coverage and higher likelihood of inappropriate polypharmacy, both at the individual and at the 
community level. These associations will be explored in more detailed in the next chapter. 
 
Per capita income was positively associated with the odds of polypharmacy, as was higher prevalence of health 
insurance among seniors. The estimates indicate that, from two individual with same personal characteristics 
living in areas that differ only by their prevalence of heath insurance, the individual living in an area where all 
seniors have health insurance would have five times greater odds (in 2006) and almost four time greater odds of 
polypharmacy (in 2010) than the individual living in an area where no seniors have health insurance. These 
findings suggest that the resources at the area level may play a significant role in determining an individual's 
likelihood of polypharmacy, in excess of an individual's personal resources. 
 
 




Multi-level generalized latent mixed regression models including random intercept at the area level (subprefecture). Models are weighted by 
inverse probability of selection. 
Model 1 includes characteristics at the individual level, identified as: enabling, predisposing, and illness level. 
Model&1 Model&2 Model&1 Model&2 Model&1 Model&2&
Individual/Level
Predisposing
Age/%10yr %1.12%(0.10) %1.13%(0.10) %1.30%(0.07)*** %1.28%(0.08)*** %1.22%(0.08)** %1.21%(0.09)**
Female %1.47%(0.15)** %1.53%(0.16)*** %1.08%(0.22) %1.07%(0.22) %0.97%(0.23) %0.96%(0.24)
Married %1.30%(0.19) %1.30%(0.19) %1.61%(0.22)** %1.59%(0.22)** %1.05%(0.24) %1.02%(0.24)
Smoking %0.84%(0.25) %0.82%(0.24) %0.99%(0.31) %0.99%(0.31) %0.95%(0.30) %0.93%(0.29)
Alcohol%use %1.03%(0.19) %1.01%(0.18) %0.73%(0.25) %0.73%(0.25) %0.77%(0.22) %0.78%(0.22)
Enabling
P.C.%Income/$%100 %1.03%(0.01)*** %1.03%(0.00)*** %1.01%(0.01) %1.01%(0.01) %1.00%(0.00) %1.00%(0.00)
Private%h.%insurance %1.31%(0.18) %1.31%(0.20) %1.77%(0.07)*** %1.78%(0.08)*** %0.77%(0.16) %0.77%(0.17)
High%care%utlization %2.15%(0.19)*** %2.11%(0.19)*** %1.19%(0.06)*** %1.18%(0.07)** %1.64%(0.19)*** %1.68%(0.21)**
Preventative%exam %1.13%(0.19) %1.12%(0.19) %1.11%(0.03)*** %1.11%(0.03)*** %1.02%(0.21) %1.00%(0.21)
Illness&Level
Nr.%Chronic%Diseases %1.85%(0.06)*** %1.88%(0.06)*** %0.82%(0.17) %0.81%(0.19) %1.74%(0.06)*** %1.73%(0.06)***
Nr.%Symptoms %1.15%(0.04)*** %1.14%(0.05)*** %1.60%(0.17)*** %1.62%(0.19)** %1.09%(0.06) %1.08%(0.06)
Nr.%ADLs%with%Disability %1.34%(0.13)** %1.07%(0.03)** %1.46%(0.17)** %1.45%(0.17)** %1.06%(0.03)* %1.06%(0.03)*
Area/Level
Enabling
Rural%area %0.97%(0.06) %1.05%(0.06) %1.19%(0.09)**
Avg.%PC.%Income%/$%100 %1.10%(0.02)*** %1.05%(0.01)*** %0.95%(0.00)***
%%health%insurance %0.54%(0.26)** %3.58%(0.34)*** %3.13%(0.26)***
%%high%care%utilizers %9.46%(0.33)*** %1.54%(0.20)** %0.31%(0.30)***
Illness&Level
Deaths%60+%/1,000%hab %1.04%(0.01)*** %1.04%(0.01)*** %0.97%(0.01)***
Model&Statistics
Constant%term %0.01%(0.34)*** %0.00%(0.43)*** %0.01%(0.32)*** %0.00%(0.61)*** %0.30%(0.47)*** %0.05%(0.40)***
N 2126 2126 1350 1350 1309 1309





Model 2 includes all individual-level characteristics, plus community characteristics divided as: enabling, illness levels. 
Estimates are odds ratios, presented with 95% confidence intervals and significance levels (p-value) 
Outcome: odds of polypharmacy, measured at the individual level 
Area-level variables: average per capita income, average rate of private insurance, average rate of high care utilizers calculated from the data 
from the SABE survey, and reflect year-specific averages for the population of 60-year olds and over in each of the geographic areas. 
Mortality among 60-year olds and over, and rural area characteristics obtained from the Ministry of Health's Vital Statistics database and the 
Brazilian Census, respectively. 
(a) Age calculated in 10-year intervals, centered at age 60. 
(b) Reference: not currently married or in a civil union. 
(c) Income measured in Brazilian Reais and presented at $100 intervals.   
(d) Chronic diseases: self-reported information on ever having been diagnosed with one or more of the following conditions: hypertension, 
diabetes, heart disease, lung disease, stroke, cancer, psychiatric conditions, joint diseases, or osteoporosis. 
(e) Reference: no private health insurance 
(f) Self-reported information on having experienced persistent chest pain, swelling of feet or ankles, dyspnea, dizziness or vertigo, tiredness 
or fatigue, nausea or vomiting, fecal or urinary incontinence in the last 12 months. 
(g) ADL: activities of daily living. Self-reported information on having difficulty performing one or more of the following activities: 
walking across a room, getting dressed, bathing, feeding, transferring to/from bed, using the toilet, preparing meals, dealing with money, 
transportation, grocery shopping, using the phone, light household chores, and heavy household chores. 
(h) Self-reported information of the number of medical visits in the last 12 months. Moderate-high utilization: more medical visits than the 
median across all areas in each year. Reference: fewer number of medical visits than the year median. 
(i) Self-report of having undergone mammogram (women) or prostate exam (men) in the last 24 months. 
(j) Reference: not currently smoking 





The present investigation explored the phenomena of polypharmacy and inappropriate polypharmacy among 
older adults in Sao Paulo, through an innovative multi-level analytical approach. Combining comprehensive 
individual- and geographic-level data, we estimated the associations between individual- and area-level factors 
and the occurrence of polypharmacy and inappropriate polypharmacy. Most importantly, we were able to 
estimate the association between area-level characteristics and polypharmacy while controlling for individual-
level characteristics.  
 
Generally, we found evidence to support that the relationships described in the Andersen framework hold for the 
use of polypharmacy in the context of Sao Paulo. In addition, our findings suggest that there may also be a role 





We found significant increases, of about two-fold, in the prevalence of polypharmacy and inappropriate 
polypharmacy over the 10-year period. We found significant geographic variation in the prevalence of 
polypharmacy and inappropriate polypharmacy across the Sao Paulo sub-prefectures. The variation across areas 
increased significantly over time. 
 
Most of the variation in the odds of polypharmacy was driven by individual characteristics. Only about 2% of 
the variation in the odds of polypharmacy across the geographic areas was explained by different propensities at 
the area level. At the individual level, polypharmacy was mostly associated with higher age, worse health status, 
and higher health care utilization. Polypharmacy was associated with higher socio-economic status and higher 
need at the area level.  
 
With the singularities of the Sao Paulo context in mind we can formulate some interpretations to our results: at 
the individual level we can hypothesize that higher socio-economic status, such as measured by higher income, 
represents higher ability to pay. Drugs represent a high percentage of medical expenditures in Brazil (Lima-
Costa et al., 2003), which could disproportionally harm low-income households. Households with higher 
incomes may have lower constraints to initiate or to maintain drug utilization, contributing to polypharmacy. 
 
In addition to higher purchasing power, higher socio-economic status at the area level may affect polypharmacy 
through higher access to care and providers. There is evidence that private services tend to be concentrated in 
areas with higher socio-economic status (Paulo & Pública, 2011). Even though access to providers is not 
necessary in order to initiate a drug or to maintain it, higher access to care may increase the likelihood of 
diagnosing underlying health conditions and may increase the number of new prescriptions. In addition, 
prescribers in areas with higher incomes may have different preferences and practice patterns than those in areas 
with lower incomes.  
 
In our study, higher incomes at the individual level had low association with polypharmacy. We believe that this 
may be because income may be an imperfect metric of socio-economic status for the senior population. Persons 




their financial support. In these cases, seniors may report zero or minimal personal income.16 Many of those 
who have an income may be retired persons reporting on their income from pensions. Because there is a cap on 
public pensions in Brazil, income from pensions may possibly flatten out differences that may have been present 
before retirement.  
 
We believe that, in our study population, the rates of private health insurance coverage may be a better marker 
of area-level socio-economic status than average income levels. Because the cost of private health insurance is 
high, having private health insurance may be a stronger marker of higher socio-economic status and ability to 
pay than income. A senior citizen who can afford private health insurance is more likely to be able to afford 
pharmaceuticals than a person who cannot afford or who chooses not to purchase private health insurance. Or, a 
senior citizen whose family can finance their private health insurance is more likely to have their drugs financed 
by family members as well. 
 
From the literature from high-income settings there is evidence that provider preferences explain much of the 
geographic variations of health care utilization, more than differences in demand or population health needs 
(Cutler et al., 2013; Fisher et al., 2003b). This could also be the case in Brazil. Provider preferences could be a 
significant underlying driver of the association that we found between higher private health insurance rates at 
the area level and polypharmacy. Provider practices may not only vary across geographic areas but also across 
time. Prescription practices, especially differences between private and public health providers, should be 
further studied and better understood.  
 
Higher age and higher rates of chronic diseases at the area level may play a role in polypharmacy by modifying 
the demand for treatments. Because drugs can be purchased over the counter, drug utilization in Brazil may be 
sensitive to individual preferences shaped by cultural and social expectations. For example, a senior individual 
who lives in an area where more people are likely to take drugs because they are older or sicker could be 
influenced to accept, or even expect, the possibility of polypharmacy more easily. In our study we did identify a 
positive association between polypharmacy and older ages at the community level. However, we identified a 
negative association with area-level rates of chronic conditions.  
                                                      
16 The SABE survey questionnaire had very broad questions covering multiple different sources of income (such as remittances, rent, 





It is unclear why higher rates of mortality in a community could lead to higher likelihood of polypharmacy and 
inappropriate polypharmacy. When we compare this association to metrics of disease morbidity, we find a 
negative association with polypharmacy, especially with levels of chronic diseases, symptoms, and disability 
levels. We hypothesize that providers may respond differently to rates of morbidity and mortality in their 
communities. 
 
There may be underlying factors that determine both higher rates of polypharmacy and higher mortality, or 
worse health status – for example, area-level patterns of exposures, especially those acting throughout the life 
course (such as education, lifelong occupation, and lifelong socio-economic status) that may predispose to 
higher occurrence of both disease and morbidity, and lower likelihood of accessing, affording, or accepting 





The main limitation of this study is that our data source, the SABE survey, was not designed to address 
questions of geographic variation. The sample size was calculated to represent the population of the entire city 
of Sao Paulo in each year. The study was not powered to look at differences across areas. Also, the number of 
geographic areas contributing level-2 information to our analyses in each year was small: 30 sub-prefectures. 
These factors may underlie some of our findings such as very large confidence intervals and changes in 
direction of the associations across the survey waves.  
 
The possibility of low power to detect differences at the area level could have biased our results towards the null 
hypothesis (type 1 error). Also, some characteristics, such as the prevalence of health insurance and the presence 
of private health services, may be correlated at the area level; therefore, there might not have been enough 
covariance patterns across the areas, and some analyses may have relied on extrapolation. This could have 
biased our results. Some approaches to mitigate this possibility, such as propensity scores and matching 





Our choice of sub-prefectures as the level -2 unit of analysis was motivated by the administrative structure of 
public services, specifically of the public health system, in Sao Paulo. This choice was not in line with the 
majority of the literature on geographic variation of health care utilization. The literature has traditionally 
utilized approaches such as hospital referral regions (HRRs), hospital service areas (HSAs) and metropolitan 
statistical areas (MSAs).   
 
It makes sense to use sub-prefectures as the unit of analysis in Sao Paulo since they correspond to administrative 
divisions involved in health care provision. At the present moment, alternative units of analysis such as HRRs 
and HSAs have not been developed in Latin America. The main advantage of using administrative divisions as 
unit of analyses is that they are easier to match with health systems and other population and community 
characteristics. Administrative divisions, however, may not reflect actual utilization patterns, since some of the 
units may lack a hospital or a pharmacy, for example.  
 
We assumed that the selected individuals who participated in the survey in each area were representative of the 
population of seniors living in that area. This assumption is does not necessarily hold, because the sampling 
process was not performed with the goal of representing the sub-prefectures. Rather, the SABE study sampling 
was performed with the goal of representing the population of 60 year-olds and over across Sao Paulo. Because 
sub-prefectures play an important role in the management of the public health system, future studies should 
consider stratifying their sampling processes by sub-prefecture, to ensure representativeness at the sub-
prefecture level. 
 
Our multi-level models assume that controlling for sub-prefecture membership completely accounts for the 
correlations that may exist between individuals living in the same sub-prefecture. The assumption is that, when 
subprefecture membership is accounted for, individuals are independent from each other. For this assumption to 
hold, however, there should be no reverse causation – i.e., people with greater propensity for polypharmacy 
would not differentially select to live in areas of high income, or higher health insurance coverage for example. 





Also, the assumption of residual confounding – i.e., that there are no characteristics missing in our models that 
affect both the outcome and the main covariates – needs to hold in order to support our interpretation of our 
results. We believe that this possibility should be further examined. We did not cover all the relevant aspects of 
access to care in the geographic areas.  There may be other health system factors – such as availability and type 
of service – that could distort our results if they remain unidentified. 
 
We provide a more detailed discussion of other relevant aspects of our methodology – especially the possible 




The present study implemented an innovative approach – a multi-level investigation – to address the occurrence 
of polypharmacy and inappropriate polypharmacy in Sao Paulo, Brazil.  
 
Multi-level investigations are highly desirable as the phenomenon of polypharmacy is multi-level by nature 
(Phillips, Morrison, Andersen, & Aday, 1998). Our empirical results corroborate that. We utilized a conceptual 
framework that has been historically employed in investigations of other forms of health care utilization, 
including polypharmacy (Aparasu, Mort, & Brandt, 2005). However, this is the first time that the behavioral 
model framework is employed in a multi-level investigation of polypharmacy. The fact that we were able to 
utilize information from a representative sample of individuals living in one of the major cities of Latin America 
is presents a significant contribution to the field.  In addition, we believe that our findings can inform further 
modifications to this framework as we found evidence of roles of illness level factors at the community level 
independently of the individual level illness levels. 
 
We found that individual characteristics such as older age, worse health, and higher use of services are the 
factors most strongly associated with higher odds of polypharmacy in Sao Paulo. We found that geographic 
factors explain only about 2% in the variation in the odds of polypharmacy. However, geographic factors such 
as higher mortality and higher socio-economic status at the community level were independently associated with 





Higher income and higher rates of private insurance in the community were more strongly associated with 
polypharmacy than income and insurance status at the individual level, indicating that area-level resources may 
be more important than the person's financial resources in determining their odds of polypharmacy.  
 
Our study does not elucidate causal pathways through which these factors may influence the odds of 
polypharmacy. However, it indicated that further investigations of factors such as provider characteristics, 
availability and quality of care at the area level, should be conducted. These hypotheses should be further 
explored, as they could help elucidate potential policy targets to improve elderly care and increase efficiency in 





5. CHAPTER V: HEALTH SYSTEMS FACTORS ASSOCIATED WITH 





Background: The growing use of pharmaceuticals worldwide may be a response to a greater prevalence of 
chronic diseases. However, not all drug utilization is driven by need. Polypharmacy that is not driven by health 
need is undesirable, because it exposes individuals to higher risk and higher spending, without corresponding 
health gains. 
 
Aims: In this study we analyze the association between polypharmacy and health systems characteristics, 
controlling for individual and community-level factors; and quantifying the contribution from individual, 
community, and health systems factors to explain geographic variation in polypharmacy. 
 
Method: We combined data from older adults living across multiple sub-prefectures of Sao Paulo, Brazil, with 
health systems information on each of the sub-prefectures. We implemented multi-level generalized latent 
mixed models to identify the associations between health systems characteristics and polypharmacy while 
controlling for individual and other area-level characteristics. 
 
Results: We found that health systems factors such as higher availability of private pharmacies, presence of 
hospitals, higher private health insurance coverage and higher enrollment in the family health program, at the 
area level, are positively associated with polypharmacy, even when controlling for multiple individual factors. 
However, they explain only a small portion of the variation in polypharmacy across individuals.  We found that 
patient characteristics accounted for 23-26% of the geographic variation in drug use; while health systems and 
community-level factors accounted for only 0.2-0.6% of the residual variation.  
 
Discussion: Our findings support the possibility that polypharmacy may exhibit a pattern of supply-sensitive 




and complexity of care. Our findings suggest that doctor's visits in the public health system, and interactions 
with private pharmacies, should be explored as potential policy targets to mitigate polypharmacy, as they may 
provide opportunities to drug revision and discontinuation. Further aspects of the health system, such as 
providers' preferences and prescribing practices, and differences across the public and private systems in Brazil, 










5.1.1 Policy Problem: Supply-Sensitive Utilization of Polypharmacy 
 
Pharmaceuticals have long been central to many different medical treatments. Some breakthroughs in disease 
treatment have come from pharmaceutical discovery. As chronic diseases have become more prevalent, 
pharmaceuticals are being used not only to treat, but also to prevent chronic conditions and their complications. 
Often pharmaceutical utilization that meets health needs is considered “effective care” (Fisher & Wennberg, 
2003) and is highly desirable, as it tends to have greater benefit than risk. However, this is not always the case. 
 
Not all drug utilization reflects effective care. Pharmaceutical utilization driven by factors other than health need 
is undesirable, because it exposes individuals to higher risk and higher spending, without corresponding health 
gains. Polypharmacy, the use of multiple pharmaceuticals per day, is a situation in which drug risks may exceed 
the clinical benefits. Polypharmacy may be clinically appropriate; however, it may also be a response to the 
preferences of patients, who often equate health care to the prescription of pharmaceuticals (Busfield, 2010). 
Polypharmacy may also reflect the preferences and practices of health providers, such as a tendency to prescribe 
pharmaceuticals to manage symptoms and signs that are not pathological, but that are part of the normal life 
cycle and aging process (Williams et al., 2011). It could also be based on clinical need if the person has multiple 
diseases. 
 
Polypharmacy has been associated with increased risk of drug-related problems such as adverse effects and drug 
interactions. The levels of risk tend to increase as the number of drugs in a pharmaceutical regimen increases. 
There is no consensus, however, among clinical communities, as to whether all cases of polypharmacy are 
necessarily and equally risky,17 and as to how many drugs are considered too many. In general, a definition of 
five or more drugs per day is accepted, because regimens above this threshold have been associated with 
increased risk of frailty, cognitive impairment, and mortality (Gnjidic et al., 2012).  
 
                                                      




In this chapter, we examine the possibility that polypharmacy may correlate with differences in the availability 
of health services in a community. We have previously demonstrated that other community characteristics – 
urban location and higher socio-economic status, for example – are associated with higher likelihood of 
polypharmacy independently from individual characteristics such as level of income and level of health need.18 
Situations of therapeutic uncertainty like polypharmacy, where there is no consensus as of which levels of 
utilization are optimal, tend to be influenced by the supply of health resources. This is sometimes called 
“supply-sensitive care” (Fisher & Wennberg, 2003). 
 
We focus our investigation on older adults living in communities across the city of Sao Paulo, Brazil. Older 
adults they tend to utilize more drugs than the rest of the population, especially polypharmacy. These 
individuals tend to be more vulnerable to drug-related risks and tend to spend greater portions of their incomes 
on drugs.  
 
Our target audience is policy-makers who may want to protect older adults from unnecessary polypharmacy and 
its associated risks and financial burden. Because public health resources are often used to provide or subsidize 
pharmaceutical treatments for the older adult population in Brazil, the management of polypharmacy also poses 
questions about appropriate allocation of public health resources in that context.  
 
5.1.2 Pharmaceutical Utilization Among Sao Paulo Older Adults 
 
The population of Sao Paulo is rapidly aging (A. Palloni et al., 2002).  There is evidence that pharmaceutical use 
is frequent, and that drug risk is a potential problem among the Sao Paulo older adult population. It is estimated 
that about one in five older adults in Sao Paulo is exposed to at least one potential drug-drug interaction, with 
various levels of clinical significance (Secoli et al., 2010).  
 
Our previous investigation found that polypharmacy doubled, from 16% to about 38%, among the Sao Paulo 
older adult population between 2000 and 2010. As the exposure to polypharmacy grew, so did the possibility of 
                                                      





drug-related risk associated with it. We estimated that inappropriate polypharmacy, the use of five or more 
drugs a day with at least one drug risk criterion, grew from about 13% to 23% in the same period (see Chapter 
3).  
 
Polypharmacy may be associated with inadequate clinical monitoring. When an individual is diagnosed with a 
drug-related condition such as drug-induced Parkinsonism, the lack of clinical follow-up may prevent the 
offending drug from being discontinued, with some patients remaining on inappropriate treatments for periods 
of up to a year (Barbosa et al., 2006).  
 
Access to medicines in Sao Paulo occurs through two main mechanisms: drugs can be purchased out-of-pocket 
in the private market, a situation that often dispenses with the need of a formal medical prescription; or drugs 
can be obtained free of cost from government pharmacies. Public distribution of drugs is limited to a national 
formulary, and it requires medical prescriptions that must be current and must be issued by a public health 
service (Secretaria de Políticas de Saúde, 2000).  
 
Private health insurance plans do not cover drugs for outpatient use in Brazil. However, private insurance allows 
for faster access to medical visits and for access to networks of private providers, which is otherwise only 
accessible out-of-pocket. Whereas requirements to access medical services (such as pre-authorization) vary by 
insurance plan, in the public health system there is a hierarchy prioritizing primary care. Primary care clinics 
and providers are the gateway to the system, which can only be bypassed by urgent care, such as in Emergency 
departments, for example (Paulo & Pública, 2011).    
 
There is a great overlap between higher socio-economic status and private health insurance coverage in Sao 
Paulo. About 70% of residents of predominantly rich areas have private health insurance, whereas a maximum 
of 30% of people have private health insurance in predominantly poor areas (Paulo & Pública, 2011). The 
distribution of private health services greatly overlaps with areas of higher socio-economic status and greater 
private health insurance coverage in the city. This is especially true for complex services such as hospitals and 





The distribution of public health services does not exhibit the same pattern. The allocation of public health 
services has been at least to some extent intended to cover underserved areas with greater population health 
needs (Paulo & Pública, 2011). Of note, the public health system provides each area with a number of family 
health teams (FHT). The FHT are part of the Family Health Program, which provides periodic home visits to 
families in the catchment area of a primary care clinic. The FHT are composed by a minimum of one doctor, 
one nurse, and one community health worker. The FHT visits provide primary care interventions such as blood 
pressure checks, weight measurement and others, including review of pharmaceutical treatments and, in some 
cases, delivery of medicines (Paulo & Pública, 2011). 
 
Most individuals who live in predominantly poor areas or in areas transitioning into middle class rely 
exclusively on the public health system to obtain their care. About half of the Sao Paulo population depends 
exclusively on the public health system to obtain care. This represents higher rates of private insurance coverage 
than the average for Brazil, which is about 25%  (Viacava et al., 2005). 
 
5.1.3 Administrative Divisions of the City of Sao Paulo 
 
Sao Paulo is unique in terms of its country-size proportions. Its population of about 12 million people is larger 
than countries like Greece and Bolivia (Factbook, 2010). The city is divided into 31 administrative areas called 
sub-prefectures, who are responsible for managing local public services, including the delivery of health 
services on the public health system. 
 
Socio-economic status and housing conditions vary significantly across the 31 Sao Paulo sub-prefectures (Table 
5.1). While the more centrally located areas are densely populated and heavily urban, there are peripheral areas 
that have almost rural characteristics. About a third of the Sao Paulo population lives in predominantly poor 
areas; a third in areas transitioning into the middle class; and a third in predominantly middle class areas; a 





Table 5.1 Socio-Demographic Characteristics of the Sao Paulo Sub-Prefectures.  
 
 
5.1.4 Evidence Linking Polypharmacy to Health Systems Characteristics  
 
Studies of health care utilization and health spending have demonstrated that not all utilization is driven by 
greater health need. The main analytical framework demonstrating this is the analysis of small area variations in 
health care utilization, or simply, geographic variation studies (J. Wennberg & Gittelsohn, 1973). The concept 
behind such analyses is that, once the characteristics of the individuals are accounted for, variations may 
correlate to characteristics occurring at the area-level, such as the supply of health services.  
 
Individual-level characteristics such as health status tend to account for a small proportion of the variation in 
health care utilization observed across geographic areas: among older adults in the United States health status 
















Aricanduva/Formosa/Carrão !!!!!!!!21.50! 266,838! 13.22% 5.38% 9.72!!!!!!!!! 814.19 3 9
Butantã !!!!!!!!56.10! 377,576! 9.18% 6.68% 9.63!!!!!!!!! 2042.10 9 14
Campo,Limpo !!!!!!!!36.70! 505,969! 4.95% 9.85% 14.73!!!!!!! 1208.88 1 22
Capela,do,Socorro !!!!!134.20! 563,922! 5.15% 9.54% 16.55!!!!!!! 876.03 3 15
Casa,Verde/,Cachoeirinha !!!!!!!!26.70! 313,323! 9.70% 7.31% 8.71!!!!!!!!! 1929.41 3 12
Cidade,Ademar !!!!!!!!30.70! 370,797! 5.94% 9.60% 11.67!!!!!!! 932.35 0 17
Cidade,Tiradentes !!!!!!!!15.00! 190,657! 3.31% 9.90% 1.11!!!!!!!!! 793.21 0 12
Ermelino,Matarazzo !!!!!!!!15.10! 204,951! 8.31% 7.26% 7.11!!!!!!!!! 1294.65 4 11
Freguesia,do,Ó/Brasilandia !!!!!!!!31.50! 392,251! 7.74% 8.57% 8.45!!!!!!!!! 1030.76 1 15
Guaianases !!!!!!!!17.80! 256,319! 4.78% 10.88% 0.82!!!!!!!!! 591.61 2 15
Ipiranga !!!!!!!!37.50! 429,235! 11.74% 6.20% 3.99!!!!!!!!! 3363.73 8 17
Itaim,Paulista !!!!!!!!21.70! 359,215! 5.32% 9.99% 6.04!!!!!!!!! 1525.29 2 16
Itaquera !!!!!!!!54.30! 489,502! 6.37% 7.74% 13.98!!!!!!! 2640.48 4 21
Jabaquara !!!!!!!!14.10! 214,095! 10.15% 6.67% 7.99!!!!!!!!! 510.80 6 5
Jaçanã/Trem !!!!!!!!64.10! 255,612! 8.64% 8.14% 13.09!!!!!!! 985.12 4 11
Lapa !!!!!!!!40.10! 270,656! 15.73% 3.91% 0.92!!!!!!!!! 1352.66 8 10
M'Boi,Mirim !!!!!!!!62.10! 484,966! 4.47% 10.24% 1.61!!!!!!!!! 543.95 2 32
Mooca !!!!!!!!35.20! 308,161! 17.64% 3.77% 2.83!!!!!!!!! 1380.77 14 11
Parelheiros !!!!!353.50! 111,240! 4.01% 11.94% – 999.03 0 8
Penha !!!!!!!!42.80! 475,879! 11.45% 5.74% 3.72!!!!!!!!! 949.46 3 18
Perus !!!!!!!!57.20! 109,116! 4.64% 10.09% – 2667.29 0 6
Pinheiros !!!!!!!!31.70! 272,574! 18.99% 1.81% 5.76!!!!!!!!! 1817.78 12 6
Pirituba !!!!!!!!54.70! 390,530! 7.77% 7.07% 9.57!!!!!!!!! 825.82 5 17
Santana/Tucuruvi !!!!!!!!34.70! 327,135! 14.01% 3.73% 2.69!!!!!!!!! 2198.82 10 7
Santo,Amaro !!!!!!!!37.50! 218,558! 14.10% 3.36% 2.60!!!!!!!!! 2753.12 10 6
São,Mateus !!!!!!!!45.80! 381,718! 5.64% 9.29% 3.42!!!!!!!!! 1599.22 4 22
São,Miguel !!!!!!!!24.30! 378,438! 6.23% 10.20% 13.26!!!!!!! 1496.74 5 14
Sé !!!!!!!!26.20! 373,914! 15.71% 3.40% 3.06!!!!!!!!! 1649.14 30 7
Vila,Maria/,Vila,Guilherme !!!!!!!!26.40! 304,393! 12.01% 7.13% 7.44!!!!!!!!! 1740.71 5 13
Vila,Mariana !!!!!!!!26.50! 313,036! 16.76% 2.04% 1.05!!!!!!!!! 732.57 29 7





Another study found that patient characteristics such as income and health explained 12% of the variation in 
spending while patient preferences explained an additional 5% (Baker et al., 2014).  
 
Supply-side characteristics have been demonstrated to explain the majority of the variation in health care 
utilization (Cutler et al., 2013; Medicine, 2013; J. E. Wennberg, 2014; J. Wennberg & Gittelsohn, 1973). In the 
case of pharmaceuticals, supply-side characteristics explained up to 50-60% of the variation in use (King & 
Essick, 2013).  
 
In the case of polypharmacy, the peer-reviewed literature suggests that some of the supply-side factors that 
could influence its utilization are: 
 
• Therapeutic guidelines and medical evidence may not provide a consensus as to what an optimal level 
of utilization would be, allowing providers to interpret and apply them with different interpretations 
(Cutler et al., 2013) 
• Physicians may have different preferences and beliefs regarding pharmaceutical treatments, motivating 
them to be more "aggressive" in their prescribing practices than others (Cutler et al., 2013) 
• Marketing practices by the pharmaceutical industry may target geographic areas with different 
intensity, influencing provider behavior (de Bakker, Coffie, Heerdink, van Dijk, & Groenewegen, 
2007; King & Essick, 2013) 
• Prescribing preferences may vary by physician specialty and may reflect the "provider mix" of 
specialties in a given area (Fisher & Wennberg, 2003; J. Wennberg & Gittelsohn, 1973) 
• Higher rates of insurance coverage in an area may lead to higher access to physicians, facilitating the 
prescription of drugs (King & Essick, 2013) 
• Higher availability of services and doctors may lead to greater number of prescriptions (Fisher, 2000) 
 
The relative importance of supply- and demand- factors in explaining variation in health care utilization varies 
across countries and settings. It has been consistently demonstrated, however, that is no correlation between 
levels of health services utilization and health outcomes (Medicine, 2013). In addition, there tends to be no 
correlation between the availability of health services and underlying population health needs (J. Wennberg & 





So far, no geographic variation analyses of health care utilization have been conducted in the Sao Paulo context. 
Such analyses could provide important insights to policy-makers, especially those who are in charge of 




The main aim of this study is to identify supply-side health systems factors associated with polypharmacy in the 
Sao Paulo older adult population. Specifically, we aim to: analyze the association between polypharmacy and 
health systems characteristics, controlling for individual and community-level factors; and to quantify the extent 
to which health systems factors contribute to explaining geographic variations in polypharmacy in addition to 
the variation explained by individual- and community-level factors. 
 
5.3 HYPOTHESES  
 
If polypharmacy were utilized mainly in response to underlying health needs, such as greater number of chronic 
diseases, this would be associated with "effective care" (Fisher & Wennberg, 2003). If “effective care’ was 
responsible for most of the utilization differences then we would expect that the occurrence of polypharmacy 
would be mostly explained by the presence and number of chronic diseases, and the level of symptoms and of 
disability, at the individual level. 
 
If polypharmacy were utilized mainly in response to the availability of services and providers at the community 
level, this would represent "supply-sensitive care" (Fisher & Wennberg, 2003).  We would expect that the 
characteristics at the individual level would less of the variation in the use of polypharmacy; instead, we would 
expect polypharmacy to be correlated with characteristics at the health system level, such as the availability of 





A third case would be if polypharmacy reflected trade-offs in care subject to preferences of patients- reflecting 
"preference-sensitive care" (Fisher & Wennberg, 2003). That case might be undistinguishable from either of the 
cases above, given the information that we have. Patients often delegate decisions to doctors and preference-






We combined individual information from a household survey of older adults living in Sao Paulo with 
information on health system characteristics of the corresponding areas where individuals lived obtained from 
publicly available government databases in Sao Paulo.  
 
The survey – the SABE study (Health, Wellbeing and Aging) – examined older adults 60 years old and over 
living in the community in Sao Paulo in the years 2000, 2006, and 2010. The survey had a census-based multi-
stage sampling process that is described in greater detail in Chapter II and in other academic publications 
(Lebrao & Duarte, 2003; A. Palloni et al., 2002). When weighted by the inverse probability of selection the 
SABE sample was representative of the population of non-institutionalized older adults in Sao Paulo in each of 
the survey years.   
 
The survey collected extensive health, demographic and socio-economic information of participants, including 
the use of medicines. The survey recorded information on all types of pharmaceutical products, including 
nutritional supplements, herbal and homeopathic medicines, and compounded substances. Because of the coding 
used for data entry, which followed the World Health Organization's Anatomical Therapeutic Chemical 
classification (WHO-ATC), we were only able to examine prescription and over-the-counter drugs in our 
analyses. We defined polypharmacy as the use of five or more prescription or over-the-counter drugs per day. 





We collected information on health systems variables from several publicly available government databases 
from the Health Secretariat and Urban Development Secretariat of the Sao Paulo Municipality (Secretaria 
Municipal de Saúde e Secretaria Municipal de Desenvolvimento Urbano), the Sao Paulo State Data Analysis 
Foundation (SEADE: Fundação Sistema Estadual de Análise de Dados), and the Brazilian National Institute for 
Geography and Statistics (Instituto Brasileiro de Geografia e Estatística), which conducts the Brazilian Census. 
Most of the data obtained from the Sao Paulo offices was linked to the DATASUS online database from the 
Brazilian Ministry of Health. 
 
The unit of the geographic variation characteristics was the sub-prefecture level. All information obtained from 
the official government sources was provided either at the level of sub-prefecture (higher level) or at the level of 
district (lower level). There is a strict correspondence between district and sub-prefecture. Each of the sub-
prefectures contains from one to seven districts, which are fixed. When we were only able to obtain district-level 
data, we aggregated it at the sub-prefecture level.  We linked all individual information with geographic area 
information using the sub-prefecture where the individuals lived.  
 
Table 5.2 displays the health systems indicators collected, the years available, and the sources. We transformed 
all count variables ("nr. of physicians", etc.) in numbers per 100,000 inhabitants, using information from the 
Brazilian Census.  
 
As can be seen from the Table 5.2, some community and health systems characteristics were not available for 
the years corresponding to the SABE study. When there was no information, we did not include the data on our 
analyses. The only exception was the availability of private pharmacies. We could not obtain historical 
information on number of private pharmacies per area. The licensing of private pharmacies is performed 
simultaneously by all sub-prefectures, plus the Sao Paulo main municipal administration, and there was not a 
unified list that was available for reference. We obtained the information for the year 2016 from a commercial 
online search tool.  We aggregated information by neighborhoods to obtain the sub-prefecture data. The 
geographic limits of neighborhoods are less precise than districts. The correspondence between neighborhoods 
and sub-prefectures can be imprecise, because there are a few neighborhoods that belong to two different sub-
prefectures. We expected that would be significant measurement error in this indicator, because of the year 




minimize the impact of these limitations, we calculated quintiles of concentrations of private pharmacies per 
area, and we assumed that an area belonged to the same quintile in 2000, 2006, and 2010, as it belonged in 
2016. As a data quality check, we used information on public-private pharmacies, a short-lived government 
program, which we had from 2013; we compared the private pharmacy quintiles against the quintiles of the 
public-private pharmacies, with significant overlap.  
 
In the case where the information was available for a different year than those of the SABE study, we proceeded 
in a case-by-case basis with each of the variables. The numbers of doctors were only available starting in 2008. 
Even though this year did not correspond to the SABE study (2008 versus 2006), we assumed it was constant 
and so we used the 2008 information in our analyses. We did not use any information for 2000. We used the 
information on percentage of C-sections and percentage of pregnancies with full antenatal care from 2007 as a 
proxy for 2006, and we did not use any information in 2000. Lastly, the information on hospital admissions for 








Table 5.2 Health Systems Characteristics – Data Availability and Sources 
Indicator Year Source 
Reference Year 2000 2006 2010 2010  
Health Professionals1 
    
  
























CE info online database 
Health Facilities 
    
  
Nr. Primary care clinics1 2000 2006 2010 
 
Infocidade online database 
Nr. Pharmacies2 
   
2016 Apontador.com 
Nr. Hospitals3 2000 2006 2010 
 
CE info online database 
Nr. Hospital beds3 2000 2006 2010 
 
CE info online database 
Health Services Utilization1 
    
  




CE info online database 
Total Nr. Hospitalizations 2003 2006 2010 
 
CE info online database 




SEADE online database 




SEADE online database 




SEADE online database 




SEADE online database 




SEADE online database 
 
Notes: 1Public health system only. 2Private health System only. 3 Available for both public and private health systems. 4Family health 
program. All count variables ("Nr. Of physicians", etc.), were transformed in numbers per 100,000 inhabitants using information from the 
Brazilian Census. IBGE: Brazilian National Institute for Geography and Statistics (Instituto Brasileiro de Geografia e Estatística), SEADE: 
Sao Paulo State Data Analysis Foundation (Fundação Sistema Estadual de Análise de Dados), Infocidade: information portal of the Urban 
Development Secretariat of the Sao Paulo Municipality (Secretaria Municipal de Desenvolvimento Urbano).  
 
In addition to the health systems characteristics, we also collected the rural/urban profile for each area from the 
Brazilian Census. Because Census information was only available for 2006 and 2010, we interpolated the rural 
area indicator for 2006 assuming that areas with same rural/urban status in 2000 and 2010 were the same in 
2006 (see more details in Chapter 4). 
 
We also calculated some of the area-level characteristics by aggregating information from the SABE 




the SABE study is displayed in Table 5.3. Of note, this information refers only to the population age 60 years 
and over.  
 
Table 5.3 Area-level information obtained from the SABE study 
Socio-Economic Status 
Income Average income in Brazilian Reais (R$) 
Health Insurance % of population with private health insurance 
Health Utilization 
Preventative exam % of the population who underwent a preventative exam in the last 24 months 
(women: mammogram; men: prostate exam). 




5.4.2 Conceptual Framework 
 
We draw from the conceptual framework of Societal and Individual Determinants of Medical Care Utilization 
developed by Andersen & Newman (Figure 5.1) (R. Andersen & Newman, 1973). In our study the main 
outcome of interest – "health service utilization" – is the use of polypharmacy.  
 
Andersen and Newman's framework envisioned health services utilization as the result of a "sequence of 
conditions". At the individual level, the framework divided these conditions as: predisposing conditions ("the 
predisposition of the individual to use services"), enabling conditions (the individual's "ability to secure 
services"), and illness level (the diagnoses, level of symptoms and disability perceived by the individual or 
ascertained by the health provider). We modified this framework to include predisposing, enabling, and illness 
levels factors at the community level as well (Figure 5.2). We addressed the individual- and the community-
level predisposing, enabling, and illness levels factors in our previous analysis (Chapter 4). We allowed 
community factors to have an independent impact with polypharmacy, when controlling for individual 
characteristics. This is displayed in the model in the form of a solid arrow (direct effect – we could measure this) 





In the current analysis we focus on a broader level, in which the Andersen model identified societal and health 
system's determinants of health utilization. Similarly to the community determinants, the model assumed that 
societal and health systems determinants affected service utilization only via individual-level characteristics. 
The possibility that societal and health systems factors might directly affect health services utilization was not 
included in the model. We assumed that health system's factors had an independent impact with polypharmacy 
when controlling for individual and community characteristics. We adapted the conceptual framework to 
identify that effect (solid arrows – Figure 5.2). 
 
We are interested in estimating the direct effect of health system determinants with polypharmacy. We assume 
that societal determinants (technology and norms) are constant across areas. Technology represents drugs - the 
drugs available in the private market, the drugs included in government formularies – as well as their prices. 
Norms represent legislation and regulation establishing the rules for drug prescription, distribution and 
commercialization. Because our sample comes from one single city, it is highly unlikely that technology and 
norms would vary significantly across the different areas. For the most part drug regulation and legislation are 
established at the national level in Brazil. Only certain governmental formularies might be defined by states and 
cities; still, the formularies would be the same across all sub-prefectures. Still, it would be possible that stock-
outs of government formulary drugs might affect some areas more than others. This might occur because of 
difficulties in transportation, logistics, or because of differences in administrative capacity in each of the areas. 
We cannot examine this possibility, however. A proxy for the availability of drugs may be area-level income 
since there is often better access to drugs in more affluent areas. 
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Figure 5.1 Andersen & Newman's societal and individual determinants of medical care utilization – Conceptual framework 
 






5.4.3 Analytical Model 
 
We model the log odds of polypharmacy using a multi-level generalized latent mixed model, as follows:  




• Log [Pr(Yij=1)/ Pr(Yij=0)] is the log odds of polypharmacy for subject j living in area i; 
• β0i, which can be decomposed as β0i = β0 + b0i, is a random intercept that represents the baseline 
propensity for polypharmacy in each geographic area; 
• Individualij is the vector of predisposing, enabling, and illness level characteristics of subject j living in 
area i; 
• Communityi is a vector enabling and illness level characteristics of area i;  
• HealthSysi is a vector of health systems characteristics of area i;  
• β1, β2 and β3 represent log odds ratios for a change in the response variable associated with a 1-unit 




We assume that there is a latent (unobserved) continuous response that represents the probability of the 
observed outcome (polypharmacy or no polypharmacy) for each subject j living in area i. A positive outcome 
(polypharmacy) will be observed when the individual's underlying latent variable is greater than zero and a 
negative outcome (no polypharmacy) will be observed when the individual's underlying latent variable is equal 
to or lower than zero. 
 
We assume that there is a baseline propensity for a positive outcome (polypharmacy) that varies across areas. 
The baseline propensity of each area is captured by its random intercept b0i. Differences in the area-specific 
                                                      




baseline propensity for polypharmacy are a result of differences in both measured and unmeasured 
characteristics of each area.  
 
The model assumes that the propensity for polypharmacy for individuals j and k living in the same area is 
correlated. The model assumes that responses are independent once the baseline propensity for polypharmacy of 
an area (captured by the area-specific random intercept b0i) is taken into account.  
 
The coefficients from the multilevel model represent effects within a given geographic area. In the multilevel 
model there is a different baseline propensity for polypharmacy in each geographic area. This baseline 
propensity must be taken into consideration when interpreting the fixed effects from the various covariates in 
the multilevel model. In the multilevel model a coefficient represents the expected change in the log odds of 
polypharmacy associated with a one-unit change in a given covariate (holding all other covariates constant) for 




We ran a series of descriptive analyses in order to describe the levels of individual and geographic 
characteristics in each of the survey waves. We used inverse probability weighting in order to reconstruct the 
individual information of the non-institutionalized population of 60 year-olds and over in Sao Paulo. We 
explored the geographic characteristics using one data point per each geographic area. The descriptive analysis 
of the geographic characteristics was performed without the use of weights.  
 
For the analysis of the associations between the individual, community, and health systems characteristics and 
polypharmacy we implemented the multi-level model described above. We implemented three different versions 
of each model: Individual Models using only individual-level covariates, Community Models using individual- 
and community-level covariates, and Full Models using individual, community and health systems covariates.  
 
We ran the analytical models for each year that the survey was available (2000, 2006 and 2010). Following the 
sample design, we applied inverse-probability weights to all models in order to reconstruct the population of 




weights, the multilevel model also required the specification of area-level weights. Because the area-level 
weights had been factored in the calculation of individual weights at the time of survey design, we assumed that 
all areas had equal weights and we set all area-level weights equal to 1. In order to account for unequal 
variances we utilized robust standard errors clustered at the primary sampling units (census tracts) in all 
analytical models.  
 
5.5 RESULTS  
5.5.1 Sample Characteristics – Overview 
 
The SABE sample included a total of 2,143 individuals living in 27 areas in 2000; 1,413 individuals living in 30 
areas in 2006; and 1,333 individuals living in 30 areas in 2010 (Table 5.4). One of Sao Paulo sub-prefectures 
(Cidade Tiradentes) was not represented by participants in any of the SABE study waves. Three sub-prefectures 
(Ermelino Mattarazzo, Guaianases and Sao Mateus) had no participants in 2000 but had participants in 2006 and 
2010. Areas without participants were not included in our analyses in the corresponding year, but were included 
in the years when there were participants.  
 
Table 5.4 Overview of participants and geographic areas in the SABE study 
 
Source: SABE database. 
 
In 2000, 107.7 participants were included on average per sub-prefecture. The sample size per area ranged from 
13 to 182 in 2000. There was a tendency of decreasing sample sizes per area over time. In 2006, the average 
number of participants per area was 63.8 (range: 5 – 111) and in 2010 it was 63.8 (range: 4 – 105). Table 5 
displays each geographic area and the corresponding sample sizes per year. 
 
2000 2006 2010
Nr.$of$Areas 27 30 30
Nr.$participants 2,143 1,413 1,133
Participants.per.Area
Avg$(sd) 107.7$(48.5) 63.8$(26.2) 56.8$(21.7)




There were 4,889 observations across the three SABE survey waves. Of these observations, 2,796 (57%) 
individuals participated in only one survey wave; 1,408 (29%) individuals participated in two survey waves; and 
685 (14%) participated in all three survey waves. We utilized information from all participants who had 
available data in each year, assuming that the samples were independent. We made this assumption because, 1) 
the majority of participants contributed information to only one survey wave; 2) because those that contributed 
with three waves of data were the minority; 3) because those who contributed with two waves of data were 
distributed across multiple years, i.e., were not concentrated in the same two waves. We provide a complete 
discussion of the participants and their characteristics in Chapter 4.  
 
Table 5.5 Sub-prefectures and sample sizes in each of the survey waves 
 
Source: SABE dataset. 
 
Code Sub(Prefecture Region 2000 2006 2010
1 Perus North 16 9 8
2 Pirituba/Jaraguá North 83 48 43
3 FreguesiaBdoBÓ/Brasilândia North 78 63 44
4 CasaBVerde North 121 75 59
5 Santana/Tucuruvi North 29 17 40
6 Jaçanã/Tremembé North 13 15 25
7 VilaBMaria/VilaBGuilherme North 177 109 79
8 Lapa West(Central 30 25 20
9 Sé West(Central 128 67 41
10 Butantã West(Central 62 42 44
11 Pinheiros West(Central 56 35 21
12 VilaBMariana Southeast 120 77 65
13 Ipiranga Southeast 108 63 66
14 SantoBAmaro South 92 53 35
15 Jabaquara Southeast 53 28 40
16 CidadeBAdemar South 37 43 43
17 CampoBLimpo South 48 52 46
18 M'BoiBMirim South 66 52 59
19 CapelaBdoBSocorro South 74 44 43
20 Parelheiros South 18 5 4
21 Penha Southeast 175 111 105
22 ErmelinoBMatarazzo East . 12 10
23 SãoBMiguel East 68 62 73
24 ItaimBPaulista East 36 17 29
25 Mooca Southeast 182 80 51
26 Aricanduva Southeast 88 54 76
27 Itaquera East 75 74 69
28 Guaianases East . 7 4
29 VilaBPrudente Southeast 110 56 52




5.5.2 Geographic Variation in Polypharmacy 
 
The overall estimated prevalence of polypharmacy among individuals 60 years old and over in Sao Paulo was 
16.1% in 2000 (95% CI: 14.4% - 17.9%), and 37.6% (95% CI: 34.8 – 40.4%) in 2010, a more than two-fold 
increase in the 10-year interval.  
 
Across the geographic areas, the average of the area-level prevalence of polypharmacy was 15.1% (95% CI: 
11.5%-18.7%) in 2000 and 36.9% (95% CI: 33.5%-40.3%) in 2010. The lowest prevalence of polypharmacy in 
any given area in 2000 was 1.3% and the highest was 25.1%.  In 2010, the lowest prevalence of polypharmacy 
in a geographic area was 6.6% and the highest was 56.6% (Figure 5.3).  
 
Figure 5.3 Prevalence of Polypharmacy among Individuals 60 years and older across the Sao Paulo Geographic Areas, 
2000-2010 
 





5.5.3 Community and Health Systems Characteristics in each Geographic Area 
 
In the 10-year interval, the population across the Sao Paulo sub-prefectures, as reconstructed by the application 
of survey weights to our sample, tended to be older and sicker. The average age went from 69.6 years old to 
70.8 years old. The prevalence of chronic diseases increased from 79% to 86% of the older adult population. 
The average number of chronic diseases per person went from 1.64 to 2.01. The average levels of symptoms and 
disability also increased during this period (Table 5.6). 
 
The areas tended to be more urbanized (20% of the sub-prefectures had predominantly rural characteristics in 
2000, as opposed to 11% in 2010); have higher incomes (from average of R$ 374 in 2000 to R$ 890 in 2010); 
and higher rates of private health insurance coverage (from 42% to 45%). Of note, both the income and the 
private health insurance coverage levels reflect rates among older adults only. 
 
The availability of health resources (per 100,000 population) in an area tended to decrease in the 10-year 
interval, for all types of resources: physicians, health facilities and pharmacies. The population of Sao Paulo 
maintained a steady growth during this period, which suggests that the numbers declined because the population 
increased at a faster pace than the health resources.   
 
The average number of hospitals per 100,000 people decreased from 2.84 to 2.03 in the period; the proportion of 
hospitals that were public changed minimally, from 35% in 2000 to 34% in 2010. The average number of 
hospital beds per area decreased from 466 to 322 per 100,000 people, but the proportion of hospital beds that 
were available to the public system increased from 41% to 45%.  
 
The average number of public primary care clinics per area increased from 3.64 to 3.79 per 100,000 people from 
2000 to 2010. In this period, there was also an increase in the number of public specialized pharmacies, from 
0.64 to 0.81 per 100,000 people, but a decrease in the number of pharmacists working in the public system, from 
10.4 to 9.7 per 100,000 people. 
 
The average number of doctors per area decreased from 477 to 440 doctors per 100,000 people in the period. 




people to 91.2 per 100,000 people. Geriatricians were the minority of this group, and they decreased from 1.89 
to 1.73 per 100,000 people. Specialists composed the majority of the workforce in all years, 80% in 2000 
and79% in 2010, and their number per 100,000 people decreased from 382 to 349 in the period. 
 
Interestingly, the indicators that reflect delivered health care (health care utilization) tended to increase over 
time. Average numbers of hospitalizations among older adults obtained from government sources more than 
doubled from 4,284 to 10,144 per 100,000 people; average rates of hospitalizations among individuals in our 
sample went from 6% to 11%; the rates of preventative exam increased from 40% to 73% and the rates of 
immunization against influenza or pneumonia increased from 61% to 80% in our sample.   
 






Table 5.6 Community and health systems characteristics of each geographic area  
 
Notes: all “count” variables are presented as number per 100,000 people (Mortality, nr. Of hospitals, beds, clinics, pharmacies, doctors, and 
hospital admissions.   
 
5.5.4 Relationship between Individual and Community-Level Characteristics and Polypharmacy 
 
In our previous work (see Chapter 4), we identified that, at the individual level, polypharmacy was strongly 
associated with being older, female, being in poorer health, and utilizing physician care and preventative care 
more often. There was no association with private health insurance, and minimal association with higher income 
(about 1% greater odds of polypharmacy in 2000 and 2010 associated with a R$100 difference in income). 
2000 2006 2010 St.Diff
Predisposing/Factors
Avg.*Age 69.55*(1.48) 70.17*(3.04) 70.77*(3.34) 0.33
%*Women 0.59*(0.07) 0.60*(0.08) 0.60*(0.08) 0.11
%*Any*NCDs 0.79*(0.05) 0.86*(0.07) 0.86*(0.04) 1.12
Illness/Level
Avg.*Nr.*NCDs 1.64*(0.16) 1.99*(0.21) 2.01*(0.24) 1.27
Avg.*Nr.*Symptoms 1.49*(0.30) 1.33*(0.35) 1.57*(0.34) 0.19
Avg.*Nr.*Disabilities 1.26*(0.44) 1.69*(0.58) 1.62*(0.62) 0.48
Mortality*60+ 3919.9*(241.3) 3574.2*(294.3) 349958*(296.4) H1.1
Enabling/Factors
Rural*Areas 0.20*(0.40) 0.10*(0.30) 0.11*(0.31) H0.2
Avg.Per*Capita*Income 374.36*(211.35) 680.10*(417.64) 890.13*(588.64) 0.82
%*Private*H.*Insurance 0.42*(0.17) 0.45*(0.17) 0.45*(0.18) 0.13
Health/Resources
Nr.*Hospitals 2.84*(2.86) 2.32*(2.63) 2.03*(2.23) H0.2
%*Public*Hospitals 0.35*(0.26) 0.34*(0.24) 0.34*(0.23) H0.1
Nr.*Hosp.*Beds 466.2*(612.1) 379.9*(541.2) 322.4*(444.6) H0.2
%*Public*Beds 0.41*(0.25) 0.46*(0.32) 0.45*(0.33) 0.09
Nr.*Public*1ary*Clinics 3.64*(1.15) 3.68*(0.92) 3.79*(1.04) 0.1
Nr.*Public*Pharmacies – 0.64*(0.94) 0.81*(1.09) 0.12
Nr.*Private*Pharmacies – – 32.93*(17.73) –
Nr.*Pharmacists – 10.38*(17.64) 9.71*(14.08) H0
Nr.*Doctors – 477.6*(652.5) 440.7*(585.6) H0
Nr.*Geriatricians – 1.89*(4.77) 1.73*(3.42) H0
Nr.*Generalists – 94.84*(105.73) 91.21*(90.18) H0
Nr.*Specialists – 382.71*(555.89) 349.49*(500.81) H0
Health/Care/Utilization
1ary*Care*Appointments – – 5088.8*(1563.5) –
Specialized*Care*Appts – – 6340.1*(8336.6) –
Hosp.*admissions 4284.6*(3976.3) 15662.6*(23333.3) 10144.8*(8481.2) 0.63
%*hospitalized*last*12*mo. 0.06*(0.03) 0.10*(0.05) 0.11*(0.06) 0.79
Avg.*nr.*hospitalizations* 0.21*(0.10) 0.14*(0.08) 0.16*(0.11) H0.3
%*Preventative*exam 0.40*(0.09) 0.56*(0.08) 0.73*(0.07) 2.79
%*Immunization 0.61*(0.09) 0.74*(0.07) 0.80*(0.09) 1.45
%*Births*via*CHsection – 0.55*(0.07) 0.58*(0.08) 0.23
%*Full*antenatal*care – 0.75*(0.07) 0.78*(0.06) 0.33




Because these results were obtained from conditional models, they represent estimates for people living in the 
same geographic area (Table 5.7). 
 
Community-level characteristics were independently associated with higher likelihood of polypharmacy. The 
main community-level factor associated with polypharmacy was the health insurance coverage at the area level. 
Higher health insurance coverage was associated with over eight times higher odds of polypharmacy in 2006 
and over three times higher odds in 2010. In 2000 the association was of about 43% higher odds of 
polypharmacy, but it was not statistically significant. If a person had private health insurance, that fact was not 
significantly associated with any differences in their likelihood of polypharmacy. However, if the person lived 
in an area with greater health insurance coverage, then the person's odds of polypharmacy were expected to be 
significantly higher, and that relationship persisted after controlling for individual-level characteristics. 
 
If two people with similar characteristics lived in areas with differed in older adult mortality rates by one death 
per 1,000 individuals, the person living in the area with greater deaths would be expected to have about 5% 
higher odds of polypharmacy in 2000, or 4% higher odds of polypharmacy in 2006, and there was no significant 





Table 5.7 Relationship between individual and community-level characteristics and polypharmacy 
 
Notes: *p<0.10; **p<0.05; ***p<0.01 Per capita income measured in Brazilian Reais. Medical visits: indicator variable on having had more 
than the median number of physician health visits in the last 12 months. Preventative exam: mammogram or prostate exam in the last 24 
months.  
 
5.5.5 Relationship between Health System-Level Characteristics and Polypharmacy 
 
While controlling for all the individual and community-level factors that we discussed above, we examined the 
association between polypharmacy and each of the multiple health systems characteristics. We do so by 
implementing adjusted models, which include for all the individual and community-level factors, plus one 
health system characteristic at a time. The estimates and 95% Confidence intervals of the coefficients associated 
with each of the variables are displayed in Table 5.8.  
Individual Indiv)+)Comm Individual Indiv)+)Comm Individual Indiv)+)Comm
Individual)Characteristics
Age $$1.24** $$1.23** 1.08 1.06 $$1.38*** $$1.40***
$($1.05–$1.46) $($1.03–$1.46) $($0.89–$1.31) $($0.87–$1.29) $($1.15–$1.67) $($1.15–$1.70)
Female $$1.38* $$1.35* 0.98 0.95 0.86 0.85
$($0.98–$1.96) $($0.95–$1.92) $($0.69–$1.40) $($0.67–$1.35) $($0.60–$1.22) $($0.60–$1.22)
Married 1.11 1.11 $$1.36* $$1.35* 0.99 0.99
$($0.80–$1.53) $($0.82–$1.52) $($0.98–$1.88) $($0.97–$1.86) $($0.76–$1.30) $($0.76–$1.28)
Per$capita$Income $$1.03*** $$1.03*** 1.01 1.01 $$1.01* $$1.01**
$($1.02–$1.04) $($1.02–$1.04) $($1.00–$1.02) $($0.99–$1.02) $($1.00–$1.02) $($1.00–$1.02)
Nr.$Chronic$Dis. $$1.79*** $$1.81*** $$2.04*** $$2.05*** $$2.27*** $$2.28***
$($1.58–$2.03) $($1.60–$2.05) $($1.78–$2.35) $($1.78–$2.36) $($2.04–$2.53) $($2.04–$2.54)
Nr.$Symptoms:1K2 $$2.31*** $$2.30*** 1.25 1.23 1.05 1.03
$($1.58–$3.36) $($1.58–$3.36) $($0.81–$1.92) $($0.80–$1.88) $($0.76–$1.43) $($0.75–$1.41)
3+ $$3.12*** $$3.06*** $$1.61* $$1.64* $$1.55** $$1.49**
$($1.83–$5.31) $($1.80–$5.22) $($0.95–$2.72) $($0.97–$2.78) $($1.09–$2.21) $($1.03–$2.14)
Nr.$disabilities:1K2 1.2 1.2 1.02 1.01 0.96 0.97
$($0.83–$1.74) $($0.83–$1.72) $($0.60–$1.74) $($0.59–$1.72) $($0.73–$1.27) $($0.73–$1.30)
3+ 1.35 1.36 $$2.46*** $$2.41*** 1.26 1.3
$($0.87–$2.09) $($0.87–$2.10) $($1.55–$3.89) $($1.51–$3.86) $($0.81–$1.97) $($0.82–$2.07)
Priv.H.Insurance 1.31 1.31 1.14 1.13 0.86 0.83
$($0.87–$1.98) $($0.85–$2.02) $($0.82–$1.58) $($0.79–$1.60) $($0.62–$1.19) $($0.58–$1.21)
Medical$visits $$1.85*** $$1.84*** $$1.72*** $$1.68*** $$2.02*** $$2.00***
$($1.32–$2.59) $($1.31–$2.60) $($1.18–$2.51) $($1.13–$2.48) $($1.41–$2.91) $($1.38–$2.88)
Preventative$Exam 1.17 1.16 $$1.87*** $$1.87*** 1.13 1.14
$($0.86–$1.57) $($0.85–$1.58) $($1.33–$2.62) $($1.33–$2.63) $($0.76–$1.69) $($0.77–$1.69)
Smoking $$0.67* $$0.67* 0.71 0.7 0.78 0.79
$($0.44–$1.03) $($0.44–$1.00) $($0.36–$1.41) $($0.35–$1.40) $($0.47–$1.29) $($0.48–$1.32)
Alcohol 0.95 0.94 $$0.76* $$0.76* 0.82 0.82
$($0.64–$1.40) $($0.63–$1.41) $($0.56–$1.03) $($0.55–$1.04) $($0.61–$1.09) $($0.60–$1.13)
Community)Characteristics
Mortality$60+ $$1.05*** $$1.04*** 0.99
$($1.04–$1.07) $($1.03–$1.06) $($0.97–$1.01)
Rural$indicator $$0.84*** $$1.35*** $$0.77***
$($0.74–$0.94) $($1.20–$1.53) $($0.68–$0.89)
%$Health$Insurance 1.43 $$8.61*** $$3.61***
$($0.76–$2.69) $($4.87–15.25) $($2.27–$5.75)
Regression)Statistics
Constant$Term $$0.01*** $$0.00*** $$0.02*** $$0.00*** $$0.03*** $$0.04***
$($0.00–$0.02) $($0.00–$0.00) $($0.01–$0.03) $($0.00–$0.00) $($0.02–$0.07) $($0.02–$0.07)
N 2126 2126 1350 1350 1309 1309






The magnitude and direction of the associations depended on the type of health service examined. Primary 
health care clinics were largely not associated with polypharmacy except for 2010, when living in an area with 
one additional primary care clinic per 100,000 people was associated with 7% higher of polypharmacy. The 
number of hospitals also was only associated with polypharmacy in 2010, when each additional hospital per 
100,000 people was associated a slight decrease in odds of polypharmacy, of about 4% per cent. Because 
hospitals were concentrated in some areas, and there were many other areas without a hospital, we created a 
binary variable to identify areas with and without a hospital. When this binary indicator was used, we found 
significant higher odds of polypharmacy in areas with a hospital, of 135% in 2006 and about 62% in 2010. 
Higher number of hospital beds largely reflected the association seen between polypharmacy and hospitals, i.e., 
associated with slightly lower odds of polypharmacy, all other things being equal.  
 
Living in an area that belonged to a higher quintile of private pharmacies was associated with increased odds of 
polypharmacy of between 26% (in 2000) to 8%; public pharmacies, however, were not significantly associated 
with polypharmacy. 
 
Greater numbers of doctors per 100,000 people were associated with lower rates of polypharmacy, regardless of 
the doctor's specialty. An exception was Geriatricians - areas without Geriatricians were associated with 24-34% 
lower odds of polypharmacy in 2006 and 2010 respectively.  
 
Living in areas where greater percentage of older adults are enrolled in a family health program was positively 
associated with polypharmacy in both years, but it was statistically significant only in 2006, when it was 






Table 5.8 Health systems characteristics and their relationship with polypharmacy – adjusted for individual and community 
characteristics 
 
Notes: Number of clinics, hospitals, hospital beds, and public pharmacies presented as per 100,000 people. Number of doctors presented as 
per 1,000 people. FHT: family health teams. *p<0.10; **p<0.05; ***p<0.01 
 
Each estimate is the result of a multi-level latent variable and mixed-effects model including the variable listed, 
plus the following characteristics: Individual characteristics: age, gender, marital status, per capita income, 
private health insurance, number of chronic diseases, number of symptoms, number of activities of daily living 
with disability, number of physician visits in the last 12 months, preventative exam in the last 24 months, 
current smoking, and current alcohol use. Community characteristics: rural vs. urban indicator, average health 
insurance coverage among 60 year-olds and over, and mortality among 60 year-olds and over. 
 
5.5.6 Health System-Level Characteristics and Polypharmacy: Full Models 
 
In order to understand whether the estimates from the multiple health system factors capture similar or different 
underlying characteristics within the health system, we followed the conceptual model and we combined 
2000 2006 2010
FACILITIES Nr.$Public$1ary$Care$Clinics 0.97 1.04 ''1.07**
'('0.93–'1.01) '('0.97–'1.12) '('1.00–'1.15)
Nr.$Hospitals 1 0.99 ''0.96***
'('0.98–'1.02) '('0.95–'1.02) '('0.94–'0.98)
Area$has$a$hospital$(y/n) 1.11 ''2.37*** ''1.62***
'('0.98–'1.27) '('1.68–'3.36) '('1.30–'2.00)
Nr.$Hospital$beds$ 0.99 ''0.99* ''0.98***
'('0.98–'1.00) '('0.98–'1.00) '('0.97–'0.99)
%$Public$Hosp.$Beds ''1.21** ''1.74*** ''1.19***
'('1.02–'1.43) '('1.44–'2.10) '('1.05–'1.34)

















variables related to health facilities, health workers, pharmacies, and the mix between public and private 
systems, in a full model (Table 5.9). All the variables that we utilized, except the number of hospitals, were not 
available for the year 2000. Therefore, we run the analyses on the years 2006 and 2010 only.  
 
We selected the following variables to compose our health systems models:  
 
• Availability of tertiary care: Indicator variable for the presence of a hospital in the area: we assume it 
will capture the effect of areas that have greater access to tertiary, complex care; 
• Availability of physicians: Number of doctors per 100,000 people: we assume it will capture 
differences in the potential for delivering physician care in a given area; we believe doctors are better 
proxies than clinics because they may provide a better indication of volume of services; 
• Provider mix: percentage of doctors who are specialists. We assume this variable will capture 
differences in prescribing practices that are associated with provider preferences related to their 
specialty; 
•  Private pharmacies (quintiles): we assume this variable will capture the access to pharmaceutical sales 
outlets, which we assume are independent from the effect of physicians and hospitals in an area; 
• Presence of the public health system: percentage of seniors enrolled in a family health program in an 
area: we assume that this variable will capture difference in the mix of services in an area between the 
public and the private health systems; the distribution between the two systems correlates with area-
level socio-economic status and the levels of care predominantly offered in a geographic area, as 
follows: lower socio-economic status -> greater availability of public care relative to private care-> 
greater availability of primary care as opposed to tertiary care -> higher rates of enrollment in the 
family health program. 
 
Table 5.9 displays the findings from our full models, as well as the findings from the individual models and 
individual + community models, for comparison.  
 
When controlling for all individual and community characteristics, the presence of hospitals, presence of private 
pharmacies, and level of enrollment in the family health program were positively and statistically significantly 




statistically significantly associated with the odds of polypharmacy. Because these are conditional models, the 
estimates reflect the expected associations for an area with the average outcome (polypharmacy).  
 
 A person with the same individual characteristics, living in an area with the same rural/urban profile, same 
levels of mortality and same levels of insurance coverage as another person, would be expected to have about 
two times higher odds of polypharmacy if he/she lived in an area that had a hospital (in 2006) or about 30% 
higher odds in 2010 (not statistically significant). If the areas differed by one quintile of the distribution of 
private pharmacies, the individual living in the area with higher quintile would be expected to have about 36% 
higher odds of polypharmacy (in 2006) or 15% (in 2010).  
 
If the areas differed in number of providers, the individual living in the area with one more provider per 100,000 
people would be expected to have 3% lower odds of polypharmacy (in 2006) and 2% lower odds of 
polypharmacy in 2010. Whether these physicians were composed of a greater number of specialists did not seem 
to be associated with any statistically significant differences in the odds of polypharmacy.  
 
Lastly, if one of these individuals lived in an area with greater coverage of the family health program, they 
would be expected to have twice the odds of polypharmacy in 2006 and about 50% higher odds of 
polypharmacy in 2010. It is important to mention that a 1-unit change in a variable that is a proportion indicates 
the expected odds ratios comparing an area with 100% and another area with 0% of the variable. In this case, if 
all seniors in one area enrolled in the FHT versus if no seniors had enrolled in the FHT. 
 
The magnitude, sign, and statistical significance of between each of the health system variables and 
polypharmacy were not greatly modified by the presence of the other health system variables in the model; the 
variable that changed the most was the presence of hospitals, which decreased in magnitude, and lost the 
statistical significance in 2010. Especially the number of doctors maintained very stable estimates unaffected by 
the other variables that were added to the model. 
 
The individual-level factors estimated in our individual models did not exhibit significant modifications after the 
introduction of the community characteristics or after the introduction of the health systems characteristics. The 





The community-level characteristics, however, had their associations with polypharmacy modified after the 
introduction of the health systems variables in the models. The most remarkable case was the indicator variable 
for rural/urban profile of a geographic area. This coefficient changed magnitude, direction, and lost the 
statistical significance once the health system variables were entered into the model. It is possible that the health 
systems characteristics at the area level may be the real drivers of the differences in the odds of polypharmacy, 
which are captured by a rural/urban indicator in the absence of more specific information in the models.   
 
The large coefficients associated with higher private insurance coverage at the area level also had their 
magnitude reduced when the health systems variables were accounted for. The coefficient for private insurance 
coverage in 2006 was reduced by 32%, and the coefficient for private insurance coverage in 2010 was reduced 
by 11% in the full model, raising the possibility that at least some of the effect captured by the health insurance 
coefficient may be due to differences in the characteristics of the health services available at the area level – 
such as accessibility and availability.  
 
Remarkably, however, much of the effect of private health insurance coverage was maintained even after the 
inclusion of the full set of health systems characteristics, suggesting that there may be other sources of 
difference in the propensity for polypharmacy associated with higher rates of private insurance at the area level 
that we have not accounted for in our models.  
 
The estimates for mortality rates were also modified when the health systems variables were added to the 
models. The estimates in both years became more negative – the coefficient in 2006, which was positive, went 
towards the null hypothesis, and the coefficient in 2010, which was negative, became even more negative, and 
acquired statistical significance. Our models are not equipped to address possible mechanisms that could explain 
why these changes have occurred. Elucidating the possible role of community illness levels in the occurrence of 





Table 5.9 Full models including multiple supply-side health systems factors and their comparison to individual models, and 
individual + community models 
 
Notes: Number of clinics, hospitals, hospital beds, and public pharmacies presented as per 100,000 people. 
Number of doctors presented as per 1,000 people. 
*p<0.10; **p<0.05; ***p<0.01 
 
 
Each estimate is the result of a multi-level latent variable and mixed-effects model including the variable listed, 
plus the following characteristics: Individual characteristics: age, gender, marital status, per capita income, 
private health insurance, number of chronic diseases, number of symptoms, number of activities of daily living 
with disability, number of physician visits in the last 12 months, preventative exam in the last 24 months, 
Individual Indiv)+)Comm Ind+Com+Hsys Individual Indiv)+)Comm Ind+Com+Hsys
Individual)Characteristics
Age 1.08 1.06 1.05 **1.38*** **1.40*** **1.38***
*(*0.89–*1.31) *(*0.87–*1.29) *(*0.85–*1.28) *(*1.15–*1.67) *(*1.15–*1.70) *(*1.14–*1.67)
Female 0.98 0.95 0.99 0.86 0.85 0.87
*(*0.69–*1.40) *(*0.67–*1.35) *(*0.69–*1.42) *(*0.60–*1.22) *(*0.60–*1.22) *(*0.61–*1.23)
Married **1.36* **1.35* **1.35* 0.99 0.99 0.97
*(*0.98–*1.88) *(*0.97–*1.86) *(*0.97–*1.88) *(*0.76–*1.30) *(*0.76–*1.28) *(*0.74–*1.26)
Per*capita*Income 1.01 1.01 1.01 **1.01* **1.01** **1.01*
*(*1.00–*1.02) *(*0.99–*1.02) *(*0.99–*1.02) *(*1.00–*1.02) *(*1.00–*1.02) *(*1.00–*1.01)
Nr.*Chronic*Dis. **2.04*** **2.05*** **2.05*** **2.27*** **2.28*** **2.26***
*(*1.78–*2.35) *(*1.78–*2.36) *(*1.78–*2.35) *(*2.04–*2.53) *(*2.04–*2.54) *(*2.03–*2.52)
Nr.*Symptoms:1K2 1.25 1.23 1.19 1.05 1.03 1.02
*(*0.81–*1.92) *(*0.80–*1.88) *(*0.77–*1.84) *(*0.76–*1.43) *(*0.75–*1.41) *(*0.74–*1.41)
3+ **1.61* **1.64* **1.59* **1.55** **1.49** **1.50**
*(*0.95–*2.72) *(*0.97–*2.78) *(*0.94–*2.69) *(*1.09–*2.21) *(*1.03–*2.14) *(*1.03–*2.18)
Nr.*disabilities:1K2 1.02 1.01 1.03 0.96 0.97 0.97
*(*0.60–*1.74) *(*0.59–*1.72) *(*0.60–*1.76) *(*0.73–*1.27) *(*0.73–*1.30) *(*0.73–*1.31)
3+ **2.46*** **2.41*** **2.30*** 1.26 1.3 1.27
*(*1.55–*3.89) *(*1.51–*3.86) *(*1.44–*3.70) *(*0.81–*1.97) *(*0.82–*2.07) *(*0.80–*2.02)
Priv.H.Insurance 1.14 1.13 1.11 0.86 0.83 0.83
*(*0.82–*1.58) *(*0.79–*1.60) *(*0.78–*1.58) *(*0.62–*1.19) *(*0.58–*1.21) *(*0.57–*1.20)
Medical*visits **1.72*** **1.68*** **1.66** **2.02*** **2.00*** **2.01***
*(*1.18–*2.51) *(*1.13–*2.48) *(*1.13–*2.44) *(*1.41–*2.91) *(*1.38–*2.88) *(*1.40–*2.90)
Preventative*Exam **1.87*** **1.87*** **1.92*** 1.13 1.14 1.14
*(*1.33–*2.62) *(*1.33–*2.63) *(*1.35–*2.73) *(*0.76–*1.69) *(*0.77–*1.69) *(*0.77–*1.70)
Smoking 0.71 0.7 0.72 0.78 0.79 0.81
*(*0.36–*1.41) *(*0.35–*1.40) *(*0.36–*1.44) *(*0.47–*1.29) *(*0.48–*1.32) *(*0.49–*1.36)
Alcohol **0.76* **0.76* **0.76* 0.82 0.82 0.82
*(*0.56–*1.03) *(*0.55–*1.04) *(*0.55–*1.05) *(*0.61–*1.09) *(*0.60–*1.13) *(*0.60–*1.12)
Community)Characteristics
Mortality*60+ **1.04*** 1.01 0.99 **0.98***
*(*1.03–*1.06) *(*0.99–*1.03) *(*0.97–*1.01) *(*0.96–*0.99)
Rural*indicator **1.35*** 1.07 **0.77*** 1.07
*(*1.20–*1.53) *(*0.90–*1.26) *(*0.68–*0.89) *(*0.91–*1.25)
%*Health*Insurance **8.61*** **5.90*** **3.61*** **3.18***













Constant*Term **0.02*** **0.002*** 0.002*** **0.03*** **0.04*** 0.033***
N 1350 1350 1350 1309 1309 1309





current smoking, and current alcohol use. Community characteristics: rural vs. urban indicator, average health 
insurance coverage among 60 year-olds and over, and mortality among 60 year-olds and over. 
 
These findings suggest that more complex care – as the care delivered in hospitals – may be associated with 
polypharmacy. Greater availability of commercial establishments, where individuals can purchase drugs out-of-
pocket and without a medical prescription - such as in areas with higher concentration of private pharmacies – 
may also be associated with polypharmacy. And greater accessibility of care, such as the one represented by the 
greater enrollment in the family health program, may also be associated with polypharmacy. Taken in isolation, 
these findings suggest that polypharmacy behaves like a supply-sensitive form of care. Supply-sensitive care 
tends to increase in utilization as the availability of resources increases in a given local area. 
 
In contrast to these findings, however, polypharmacy was negatively associated with availability of doctors: 
areas with more doctors tended to have lower polypharmacy, all other things being equal. The interpretation of 
this, as well as all other findings, depends on the assumptions that we make about the data. If more doctors truly 
reflect greater availability of physician care for the population, it is possible that greater number of doctors can 
provide better opportunities for monitoring of pharmaceutical treatments, and more opportunities to manage and 
reduce drug utilization.  
 
On the other hand, higher number of doctors may not reflect greater availability of physician care for the 
population. The information on number of doctors was available only for the professionals who worked in the 
public sector. If areas that have more doctors in the public sector also had less doctors in the private sector, and 
if there were too many barriers to entry for patients seeking care in the public sector, the higher number of 
doctors would effectively be a marker of less physician care to the population. We find this hypothesis unlikely, 
as we investigated another marker of the care delivered by the public health system (proportion of seniors 







5.5.7 Polypharmacy: A Form of Supply-Sensitive Care? 
 
Provider prescription practices are a significant component of the drivers of geographic variation in health care 
utilization and could not be adequately addressed in our analysis. In order to elucidate the possible mechanisms 
being captured by our findings we perform an additional descriptive analysis. We compare polypharmacy to a 
form of effective care: percentage of pregnancies with full antenatal care, and we compare polypharmacy to a 
form of supply-sensitive care typical of the Brazilian context: the very high rates of C-sections (Figure 5.4). 
Each data point represents one geographic area (sub-prefecture). Both years for which data was available - 2006 
(proxy: 2007) and 2010 - are included in the figure.  
 
Figure 5.4 Polypharmacy vs. antenatal care (effective care), and C-sections (supply-sensitive or preference-sensitive care) 
 
  
Polypharmacy had a positive and moderate correlation with both forms of health care utilization:  the correlation 
between polypharmacy and C-sections was 0.44, and the correlation between polypharmacy and full antenatal 
care was 0.36. However, polypharmacy did not exhibit a clear correspondence with either of these forms of care. 
An important caveat is that the providers who make decisions on obstetrics are not the same as those who make 
decisions regarding the care of older adults. However, these providers may interact in similar care networks and 
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The strong association between polypharmacy and the various measures of health care availability indicate that 
it may be a form of supply-sensitive care. Our study did not directly address provider preferences, which may be 
a significant driver underlying some of the results that we found, and should be the focus of future studies.  
 
5.5.8 Explaining Variation in Rates of Polypharmacy 
 
In order to quantify the variance accounted for by each of the set of predictors we implemented a sequence of 
estimations using the total number of drugs that the SABE participants were taking. While the number of 
medicines and the likelihood of polypharmacy are closely related, these are not the same metric.  
 
We first implemented null models (no predictors) of the count of drugs that a person was taking, adding only a 
random intercept for sub-prefecture. Next, we implemented a similar model with all the individual-level 
covariates (see Table 5.9). Finally, we implemented the same model adding all individual predictors as well as 
all community- and health systems- covariates. We implemented this analysis for 2006 and 2010 only, as these 
two years were the only ones with full information on all the health system covariates. 
 
We find that, in 2006, individual characteristics explained 23% of the variance in polypharmacy. The addition of 
the full set of community and health systems variables to the model explained an additional 0.6% of the variance 
in polypharmacy. In 2010, individual characteristics explained 26% of the variance in polypharmacy. The 
addition of the full set of community and health systems variables to the model explained an additional 0.2% of 
the variance in polypharmacy.  
 
It is important to mention that the proportion explained by the health system and community characteristics is 
not a percentage of the total variation in polypharmacy; rather, it is the proportion of the variance remaining 









Our study contributed to the understanding of the health systems characteristics associated with polypharmacy 
among Sao Paulo older adults. Polypharmacy was associated with presence of hospitals, higher concentration of 
private pharmacies, and higher enrollment in family health programs in a given geographic area. Polypharmacy 
was inversely associated with the number of physicians in a geographic area, but was not associated with 
physician specialty mix.  We also demonstrated that some health systems characteristics may underlie the 
associations between living in rural areas and differences in health care utilization that are a frequent finding of 
health care utilization studies.  
 
We found that a significant proportion of the variation in overall drug utilization (total number of drugs per 
person) was accounted for by individual -level characteristics. Individual characteristics explained 23% of the 
variation in 2006; community and health systems characteristics explained an additional 0.2% of the remaining 
variance. In 2010, the numbers were very similar: 26% of the variation in drug utilization was explained by 
individual -level characteristics; community and health systems characteristics explained an additional 0.6% of 
the remaining variance.  
 
These numbers do not mean that the set of health systems and community characteristics are not relevant in the 
Sao Paulo context; their main message is that, proportional to individual characteristics, the specific indicators 
that we studied were not associated with enough variation in the outcome in order to explain more cases. One of 
the reasons why this could be the case is if we did not capture the correct variables.  
 
Another possibility is that there may be measurement error in the variables, such as the private pharmacy 
quintiles, that are a proxy, but do not reflect the actual levels of the factors at the time of the survey. Is it 
possible that the main contribution from the health systems variables is not their effect sizes; rather, it's the 
qualitative finding of which characteristics are linked with polypharmacy, which matters as an indication of 





Another possibility is that the low percentage of variance explained by area-level characteristics may be a 
product of the low sample sizes per area. The SABE study was not meant to capture geographic variation 
outcomes. Therefore, the sample sizes at the geographic-area level were some times very small, not having 
enough power to allow correlations to emerge. New studies using other data sources such as electronic health 
records from the Sao Paulo Health Secretariat and others may be better equipped to address these questions. 
 
Even with these limitations, our study provided a contribution to the Andersen model: by identifying the 
associations between health system's factors and polypharmacy while controlling for individual factors, we 
demonstrated that there might be direct pathways through which health system factors may influence the 
occurrence of polypharmacy independently from an individual's actions or characteristics.  The possibility of 





Although some health systems characteristics are correlated with polypharmacy, there is still a large proportion 
of the variation that remains unexplained. It is possible that polypharmacy may be a supply-sensitive form of 
health care utilization in this context. Supply-sensitive forms of health care utilization are driven in large part by 
preferences and practices of health providers, which we were not able to address in our analyses.   
 
We were also not able to address other health system factors that may be key to understand the occurrence of 
polypharmacy in the Sao Paulo context. Within the Andersen health behavior model, for example, there were 
factors that we were not able to address:  
 
Societal Factors – such as technology and norms, could influence polypharmacy. We assumed that these factors 
were fixed; we assumed there would be little variation across areas of the same city. However, technology and 
norms could vary over time. Drugs enter the market, industry invests in marketing, government formularies 
expand, cultural acceptability increases, prices fluctuate, generics and other forms become available; 




important to address these factors, as changes in technology and norms are more likely to impact changes in the 
use of polypharmacy than changes in the underlying health conditions of the population over time. Even if 
chronic diseases are increasing in prevalence, higher availability of treatments may modify patients and doctors 
preferences and perceptions, may make the drugs more desirable and acceptable, and may influence their use. 
Future studies such as interrupted time series and differences-in-differences could be implemented to analyze 
polypharmacy pre- and post- certain strategic policies. However, with 3 years this is not possible in our study. 
 
Distribution of services – our multilevel analysis implicitly incorporated the assessment of health systems 
resources distribution across areas. However, we did not know the distribution within a given geographic area. 
This is a limitation of our study that could be addressed by future geographic analyses studies using geo-location 
information on the multiple health services. 
 
Volume of resources – the level of doctors and health facilities relative to the size of the population in each area 
influences polypharmacy. We chose to use the general population (as opposed to only the population of older 
adults) because we reasoned that health resources have to attend to the demand of multiple sources in that 
setting, that spend the entire population. Even for geriatricians, who in theory would serve only older adults, 
having the general population as a denominator is relatable to policy makers and standardized, so it can be a 
more meaningful metric. However, we did not have the full set of facilities and providers from the private 
sector. This was a significant limitation of our work, as about half of the Sao Paulo population is privately 
insured. Differences in private services may be captured by the area-level health insurance effects in our 
analysis, which were very large in magnitude and remained statistically significant throughout the models.  
  
Structure – the structure component reflects "what happens to the patients after they enter the system". An 
important component of the structure of the health system is the level of integration and coordination across 
services. This is especially important in the case of polypharmacy, where close and integrated monitoring of 
treatments is important in order to avoid drug risk. We could not address this characteristic. Studies that 
examine provider networks would be more equipped to address this characteristic.  
 
Access – We believe that it is of paramount importance to understand the differences in polypharmacy across 




represent significant access differences. For example, in the public health system, access is limited by barriers 
associated with health care responsiveness; there are long queues, and multiple administrative hurdles. In the 
private health system, access is mostly limited by ability to pay. In our study, we tried to fit everything in one 
model, which may have been a limitation. There may not be one single model that explains polypharmacy for 
the entire population. Subgroup analyses in future studies could focus on investigating how the multiple 
determinants affect the population of exclusive users of the public and the private systems. 
 
Provider behavior – provider's preferences and prescribing practices could also vary across the public and 
private systems. In the public system however the providers are salaried; they do not have the same need to 
prescribe in order to maintain clientele. However, they may be overworked and may not provide adequate 
monitoring of polypharmacy regimens. In the private system providers are not restricted to a formulary, they are 
targeted by the pharmaceutical industry and can provide samples, for example. But they may be more limited by 
drug prices, and they may want to satisfy their client so that they don't lose business. It would be important to 
assess whether there are significant differences in provider prescribing behavior across the public and the private 
health system that could affect polypharmacy. Qualitative studies such as in-depth interviews with providers 
might help clarify these questions. 
 
In addition, we did not address all dimensions of access. Others have proposed that access is a combination of 
multiple disaggregated dimensions: availability, accessibility, accommodation, affordability, and acceptability 
of services . In the case of polypharmacy these relevant aspects of access to care would be represented by:  
 
•  Availability: number and type of pharmaceutical products in the private market; drug formularies and 
drug shortages in the public system.  
• Accessibility: proximity of providers and pharmacies to a person's place of residence; 
• Accommodation: barriers to accessing drugs and medical services – those would mostly apply to 
individuals who depend on the public health system to obtain medicines. For example, long queues, 
paperwork, short opening times, etc. In the private health system, the main barriers to access drugs are 
requirements put forth by the pharmaceutical regulatory agency, for example special protocols that 
have to be followed in order to purchase certain controlled substances. 




• Acceptability: cultural practices and beliefs, both from patients and providers, related to drug 
utilization.  
Because we did not have such information, we were not able to include it in this study. However, it is important 
to assess both supply and demand factors, as both of these factors interfere with the likelihood of polypharmacy 
(Peters, 2008); also, these are likely to be correlated. Patients with higher propensity to polypharmacy might 
self-select into obtaining care from providers with greater propensity to prescribe polypharmacy. More 
availability of pharmacies could increase acceptability and desirability of drugs, creating supply-induced 
demand.  
 
These factors would be a very relevant analysis and it should be pursued by future studies. For example, 
qualitative methodologies could address all these components in great detail. Qualitative studies could help 
understand how those factors interact with each other and how they affect polypharmacy. This could 
complement our study and would be especially important because of the high level of decentralization of the 
public health care system in Brazil – making the inferences from secondary data such as ours very limited. 
 
Lastly, we did not assess equity in health care utilization (equity in access). But, our results indicated that 
income at the individual level was not associated with polypharmacy. This was in opposition to several other 
studies, especially in Brazil (Coelho Filho et al., 2004), which have shown that polypharmacy is associated with 
greater socio-economic status. One of the factors that may underlie this finding is that the public health system 
may be succeeding in making pharmaceuticals more accessible to the individuals who cannot afford them. The 
question is whether the public system provides the necessary monitoring for these treatments.  
 
 
5.8 POLICY IMPLICATIONS AND FINAL CONSIDERATIONS 
Our findings support the possibility that at least some of the utilization of polypharmacy may exhibit a pattern of 
supply-sensitive care. Individual characteristics, including health need, accounted for about a quarter of the 
variation in drug use that we measured across the Sao Paulo sub-prefectures. Polypharmacy was associated to 
many health system's characteristics that are linked to availability and complexity of care. However, they 





It is likely that the ultimate occurrence of polypharmacy is a combination of patient preferences, provider 
practices, health need, and the constraints and limitations of the health system where they interact. From a 
public health perspective, understanding that not all polypharmacy is driven by need is important in order to 
devise strategies to improve monitoring and provide opportunities for review and discontinuation of treatments.  
 
Historically, Brazilian policy-makers have focused on expanding access to medicines. The current trends in 
polypharmacy, especially among older adults, indicate that it is time to focus on improving appropriateness of 
treatments – the prescription of the right drug, for the right indication, in the right dosage, and for the right 
duration – and improving opportunities for treatment monitoring. The ultimate goal is to balance the benefits 
and the risks of pharmaceutical treatments.  
 
The present study contributed to informing future policies in Sao Paulo by, first, demonstrating that health 
systems factors can be associated with polypharmacy independently on individual characteristics; this opens the 
possibility that modifications at the health systems level may influence polypharmacy at a population level. 
Second, we demonstrated that the greater availability of doctors in the public health system in Brazil is 
correlated with lower odds of polypharmacy. This finding holds for the public health system even after 
controlling for individual characteristics, and might provide a policy target to be explored. Perhaps better 
training of health professionals, better practice guidelines, or simply greater availability of physician care for the 
older adult population may provide opportunities to curb polypharmacy and its risks. Third, the strong 
association between polypharmacy and the density of private pharmacies per area indicates that private 
pharmacies may also be a potential policy target where policies to reduce polypharmacy could focus on. 
Improving regulations and seizing the pharmaceutical encounter as an opportunity to inform patients, review 
treatments and reduce risk would be a low-cost solution that may attend to patient preferences. Lastly, the 
association that we identified between polypharmacy and higher enrollment in the family health program, a 
mainstay of the public health system in Brazil, indicates that policy-makers should develop a thorough 






6. CHAPTER VI: DISCUSSION 
 
6.1 SUMMARY OF FINDINGS 
Our study contributed to the understanding of trends and determinants of polypharmacy among older adults in 
Sao Paulo, Brazil, as well as the association between polypharmacy and drug risk in this population.  
 
Our main findings were:  
 
1. Drug utilization among older adults in Sao Paulo was very frequent, and grew significantly between 
2000 and 2010 
• Use of one or more drugs per day increased from 84% to 91% 
• The average number of drugs increased from 2.5 to 3.9 drugs/day per person 
• The prevalence of polypharmacy (five or more drugs per day) went from 16% to 38%, a more than 
two-fold increase 
• The prevalence of taking ten or more drugs a day went from 0.7% to 4.5%, an almost 8-fold increase 
• The prevalence of polypharmacy with at least one drug risk criterion went from 13% to 23%, almost 
doubled 
 
2. Drug risk was very frequent and was a special concern among persons with polypharmacy 
• The risks examined were: drug-drug interactions, anticholinergic adverse effects, and potentially 
inappropriate prescribing  
• About two-thirds of people with polypharmacy were exposed to some form of drug risk, and the risk 
increased with higher numbers of drugs in use 
• The number of persons with polypharmacy with at least one risk criterion decreased over time, from 
77% to 60% 
• The Beers Criteria identified most of the risk, but it was an incomplete metric; other risk metrics 




• While the risk identified by the Beers Criteria reduced over time, the risk identified by other metrics 
increased  
• There was not a specific drug or combination underlying most of the risk associated with 
polypharmacy 
 
3. Polypharmacy was associated with having greater number of chronic diseases, being in worse health, 
using greater levels of health services, being older, and being female 
• Rates of polypharmacy grew faster among men 
• Women had lower odds of polypharmacy associated with each additional chronic disease than men 
• Inappropriate polypharmacy had same determinants 
 
4. There was significant geographic variation in polypharmacy across the 30 Sao Paulo sub-prefectures.  
• Individual characteristics helped explain the most, about 25% of geographic variation, of total number 
of drugs per day 
• Community characteristics and health systems factors together explained an additional 0.2%-0.6% of 
the variance 
• There's still significant variation unexplained 
• Main community factors associated with polypharmacy were: rural area, higher income, higher health 
insurance coverage, and higher senior mortality 
• Community factors were directly associated with polypharmacy, remained when controlling for 
individual factors 
• Having private health insurance did not change the likelihood of polypharmacy, but living in an area 
with higher health insurance coverage greatly increased the likelihood of polypharmacy 
 
5. Presence of hospitals, higher number of private pharmacies, and higher enrollment in the family health 
program were associated with greater polypharmacy. Higher number of doctors in the public system was 
associated with lower polypharmacy. 





• However, these characteristics do not explain a significant portion of the variation in the utilization of 
polypharmacy 
• Higher health insurance coverage at the area level probably indicated greater availability of private 
services or differences in providers' practices 
• Polypharmacy is likely a combination of patient preferences, provider practices, health need, and the 
constraints and limitations of the health system where they interact 
• From a public health perspective, understanding that not all polypharmacy is driven by need is 
important in order to devise strategies to improve monitoring and provide opportunities for review and 




Our study was innovative in that we utilized a multi-level model in order to simultaneously explore the 
relationships between polypharmacy and both individual and area-level characteristics, including at the health 
system's level. We demonstrated that, first, polypharmacy among older adults should be a public health concern 
in Sao Paulo. Policies to reduce drug risk should target all older adults with polypharmacy. 
 
Even though individual-level factors explained the largest part of variation in drug use, area-level and health 
systems characteristics influenced polypharmacy independently from individual factors.  
 
This finding presents an important contribution to the literature. Many studies investigate individual 
characteristics only. Individual factors do not fully explain the occurrence of polypharmacy. Future studies 
aiming to elucidate the determinants of polypharmacy in other contexts should make sure to examine area-level 
as well as individual-level characteristics.  
 
Area-level characteristics should also be part of the conceptual framework of polypharmacy utilization, and both 
area-and health systems characteristics should be allowed to have direct associations with the outcome of health 





Although our study was able to demonstrate the independent effect of area-level characteristics on the 
occurrence of polypharmacy, we were not able to elucidate the mechanisms through which these associations 
occur. Future studies should focus on clarifying these mechanisms, so that better policies can be implemented to 
protect older adults from drug risks associated with polypharmacy in Sao Paulo.  
 
Pathways through which health systems characteristics could influence polypharmacy 'directly', i.e., without 
being mediated by individual factors, would be, for example, through provider preferences. If two individuals 
access the same number of physician visits but one physician is more aggressive in their prescribing practices, 
than that will influence polypharmacy differently, for the same level of patient utilization. Qualitative 
investigations, especially those exploring patient preferences and physicians’ prescribing practices, may provide 
a significant contribution to reveal possible mechanisms through which these associations occur.  
 
We identified a decrease in the levels of drug risk associated with polypharmacy over time. This is a new 
finding that added to the existing knowledge about polypharmacy trends in Brazil. We believe that the decrease 
in the levels of drug risk associated with polypharmacy is likely to reflect changes in drug selection over time. 
The characteristics and determinants of this finding in the Sao Paulo context are yet to be fully understood and 
should be explored in future investigations. A similar finding had been previously described among older adults 
in France and was attributed to policies implemented to improve prescribing among older adults (Bongue, 
2009). 
 
Our study contributed to future investigations by demonstrating that it is important to employ multi-dimensional 
measurements of drug risk when investigating persons with polypharmacy. Temporal trends in the association 
between polypharmacy and drug risk varied markedly according to the drug risk metrics that we utilized. Uni-







6.3 LIMITATIONS  
This study has several limitations. First, the cross-sectional nature of our study did not allow us to establish 
causation between the multiple factors that we examined and the occurrence of polypharmacy. Still, we call our 
findings “determinants” of polypharmacy because there is theoretical basis to explain the possible causal 
pathways between each of the factors and polypharmacy; the conceptual framework postulates these as causal 
relationships; and there is empirical evidence from previous studies supporting causal relationships between 
these characteristics and polypharmacy.  
 
Still, we cannot rule out the possibility of bi-directionality or reverse causation in the associations that we 
identified. For example, even though the literature consistently describes worse health as leading to 
polypharmacy, we cannot rule out the possibility that polypharmacy might lead to poor health. Our study 
empirically demonstrated that polypharmacy is associated with increased risk of adverse effects and drug 
interactions. While persons with poor health may be prescribed more drugs to alleviate their conditions, it is also 
possible that persons taking more drugs might feel clinically worse-off because of adverse effects and might 
report being in worse health.  
 
Or, individuals who seek greater number of physician visits may be prescribed more drugs, resulting in 
polypharmacy. Individuals with polypharmacy might develop adverse effects, requiring more physician visits, 
which in turn may result in the prescription of more drugs.   
 
Such feedback loops have actually been demonstrated to be true in some cases, and their result – a prescribing 
cascade – is considered a serious potential complication from polypharmacy. The occurrence of prescribing 
cascade among older adults with polypharmacy in Sao Paulo should be quantified in future studies. Longitudinal 
studies would be the best way to address this phenomenon, as they allow for the sequence of events to be 
recorded over time.  
 
At the area level there is also potential for the associations that we found to be a product of reverse causation. 




hospitals and services, for example. This possibility seems unlikely, but it could be explored in future studies. 
An analytical approach that might help elucidate these relationships would be the use of instrumental variables. 
 
Also, there might be unmeasured characteristics that could have distorted our results if they affected both the 
occurrence of the factors that we examined and the likelihood of polypharmacy (residual confounding). For 
example, if prices of pharmaceuticals varied according to the availability of health services in an area. If drug 
prices were higher in rural areas, and rural areas tended to have low levels of health services, we might be 
incorrectly attributing the low rates of polypharmacy to lower availability of services, when in fact higher drug 
prices in those areas were the main explanation.  
 
We believe that the possibility of residual confounding is unlikely, however. We controlled for a wide range of 
individual- and area-level characteristics in our models; and all the areas that we examined were part of the 
same city. It would be unlikely to have substantial variations in price across areas of the city given that the sales 
tax is the same across all areas, most private pharmacies are part of commercial chains that have multiple units 
across different areas, and because people might respond to higher drug prices by purchasing medicines in more 
central areas of town, in the areas where they work, for example.  
 
Second, the source of our data was a household survey originally implemented to investigate other aspects of 
health and wellbeing, not drug utilization. However, the survey collected comprehensive information on drug 
use, both via self-report and via direct observation of medicine cabinets and pill boxes. Drugs were recorded 
using a standardized international classification that greatly contributed to data quality. All survey participants 
contributed information on drug use; there were no missing values regarding drug utilization. The survey also 
collected a very comprehensive set of individual characteristics including multiple indicators of socio-economic, 
health, behavioral and health utilization characteristics.  
 
The survey mostly relied on self-reported information. Yet, self-reported use of medications is considered 
reliable, especially when the information was objectively cross-checked by the researchers (Landry et al., 1988). 
Self-reported survey data has been successfully employed in investigations of various aspects of elderly health, 




Brazil, and are often not followed, the method of self-report was likely to reflect actual drug utilization, which 
was the object of our study. 
 
Only prescription and over the counter drugs were included in our analyses. Although the survey collected 
extensive information on other pharmaceutical products, general labels were used to specify only the category of 
other pharmaceutical products. Hence, we could not identify active ingredients of herbal, homeopathic, and 
compounded products, and we were not able to include them in our analysis.  
 
Empirically, the use of other pharmaceutical products was much less frequent than prescription and over-the-
counter drugs in our sample. The use of herbal, homeopathic, and compounded products was not different across 
persons with and without polypharmacy, and tended to decrease over time in both groups. Also, focusing on 
prescription and over-the-counter drugs was in line with most of the literature with polypharmacy, facilitating 
the comparability of our results.  
 
Our study did not have information on drug dosage and posology, preventing us from addressing issues such as 
drug toxicity and medication errors. However, most studies with polypharmacy have demonstrated that the 
higher number of drugs in a pharmaceutical regimen is a problem of its own, mostly related to drug selection 
and monitoring. The literature also indicates that drug toxicity is not a frequent source of drug burden (Edwards 
& Aronson, 2000). There was also no information regarding the duration of the treatments – whether the 
individuals were taking the reported drugs for a couple of days or for longer periods of time. Given the very 
high number of drugs reported – up to 17 – and the types of drug classes involved – mostly cardiovascular, 
neuropsychiatric, and metabolic drugs - we find it likely that these were long-term regimens.   
 
Third, the survey was not designed to test for geographic variation. The sample size was calculated to represent 
the population of the entire city of Sao Paulo in each year. The study was not powered to look at differences 
across areas. Indeed there were areas with as little as five participants in our sample. This fact could probably 
have skewed our results towards the null hypothesis (type 1 error).  Because sub-prefectures play an important 
role in the management of the public health system, future studies should consider stratifying their sampling 





Each year, there were only 30 geographic areas contributing level-2 information to our analyses (sub-
prefectures). Some characteristics, such as the prevalence of health insurance and the presence of private health 
services, may be correlated at the area level; therefore, there might not have been enough covariance patterns 
across the areas, and some analyses may have relied on extrapolation. This could have biased our results. Some 
approaches to mitigate this possibility, such as propensity scores and matching methods, might be explored in 
futures studies.  
 
Fourth, our choice of sub-prefectures as the level -2 unit of analysis was motivated by the administrative 
structure of public services, specifically of the public health system, in Sao Paulo. Our multi-level models 
assume that controlling for sub-prefecture membership completely accounts for the correlations that may exist 
between individuals living in the same sub-prefecture. The assumption is that, when subprefecture is accounted 
for, individuals are independent from each other.  
 
This assumption may not hold true, however, as more than one person was allowed to participate per household. 
Having multiple individuals per household might have posed additional correlations across the participants of 
our study that remained unaddressed in our analysis.  In order to best address this possibility, methods to 
account for correlation between individuals of the same household, such as having an additional random 
intercept for household in out analytical models, should have been conducted. Such analysis would have helped 
elucidate the degree to which the unaccounted correlation might have influenced our results. 
 
Also, it is possible that there was correlation between the participants in each of the survey waves – some 
participated in several waves of the survey. This could have introduced bias in the sense that we may credit 
some changes (e.g., taking more or less drugs) to modifications in the behavior of the population over time 
(cohort effect), while they may be actually due to the aging of the sample (aging effect). In order to clarify the 
main underlying mechanism of this finding, a new wave of the survey with only new participants could be 
conducted, or, a longitudinal analysis of the existing sample, accounting for aspects of aging and survival, could 
be performed. 
 
Fifth, the representativeness of our sample to the Sao Paulo older adult population relied on a major assumption: 




not participate. This assumption may not necessarily hold. The wealthiest individuals in the country live in Sao 
Paulo, and arguably the poorest live there as well It is possible that participation in the survey might have been 
differential across the levels of income - wealthier and healthier individuals, especially those who were still 
working, might be harder to reach (the wealthy tend to live in gated communities in Sao Paulo), and might be 
less likely to agree to participate in the survey.  Poorer and sicker individuals might be more restricted to the 
household, easier to locate, and more inclined to participate.  
 
If true, this would have skewed the study sample towards sicker and poorer individuals. This possibility was not 
a matter of great concern to us, however. We did find significant differences in income across the participants. 
Some participants reported incomes that were thousands of times larger than others. Also, the main goal of our 
study was to inform policy-making aimed at mitigating polypharmacy. It is unlikely that public policies would 
significantly influence drug utilization among the extremely rich. These individuals are less likely to use 
services from the public health system, and are less likely to be sensitive to policies such as changes in 
formularies or other drug utilization incentives. Also, it can be argued that the constitutional mission of the 
public health system in Brazil prioritizes the health of the most vulnerable and underserved populations, and our 
results would be in line with that mission.  
 
Lastly, the city of Sao Paulo has several particularities that must be pondered when considering the 
generalizability of our results to other areas in Brazil. Sao Paulo is by far the largest and most economically 
advanced city in the country. The social inequalities across its population and the heterogeneity across its 
geographic areas are striking. Its administrative division in sub-prefectures is unique. All these factors might 
compromise the generalizability of our results to other areas.  
 
Yet, we argue that major urban centers in Brazil may still find value from our results. There are seventeen cities 
with over a million inhabitants in Brazil. Even if not at the same level of magnitude, these cities share with Sao 
Paulo the presence of stark social and economic inequalities and a decentralized model of decision-making in 
the public health system. Up to 85% of the population in Brazil is concentrated in major urban centers such as 
these large cities and their surrounding metropolitan areas. We believe that, at the very least, our results provide 
a basis for future investigations of polypharmacy in other Brazilian metropolitan areas. For example, we 




individual level. Future studies of polypharmacy in other Brazilian cities should make sure to include 




Our study benefitted from a very comprehensive survey that collected a wide range of demographic, socio-
economic, health, behavioral, and health care utilization characteristics from the participants, including detailed 
information on the types of drugs in use. The survey was replicated three different times, using the same 
methodology and questionnaire, spanning a total period of 10 years. When weighted by the inverse probability 
of selection, the sample was representative of the non-institutionalized population of older adults living in Sao 
Paulo. 
 
Other sources of data on drug utilization are largely unavailable in Brazil. Private insurance does not cover 
outpatient drugs in Brazil; hence, administrative claims data are not available. Drugs are purchased out-of-
pocket, so pharmacy claims data are also not available. Many individuals obtain drugs from the public system. 
However, only drugs from a selected formulary are provided by the public health system. Any data from public 
drug provision would not capture the totality of drugs utilized by the population. Electronic health records are 
proprietary of certain health providers or insurers; they may not capture drugs that were self-prescribed or that 
were prescribed by out-of-network providers. Even if they were available, none of these sources would likely 
contain the same level of detailed patient-level information and be representative of the total population of older 
adults in Sao Paulo, which were two major strengths of our data. 
 
The richness of the individual-level characteristics, combined with the geographic distribution of the 
participants – spanning all but one of the Sao Paulo sub-prefectures - allowed us to implement multi-level 
models to investigate the association of community-and health system-characteristics with polypharmacy while 
controlling for a large set of individual level factors. This structure was a major contribution of our study to the 





Multi-level models are strongly recommended in social science research, especially to address issues of health 
care utilization, because these are multi-factorial and multi-level by nature (Phillips). In addition, multi-level 
models avoid the possibility of ecological fallacy.  
 
Ecological fallacy occurs when associations estimated at the geographic level are interpreted as reflecting 
relationships at the individual level. By losing the information that links both exposures and outcomes at the 
individual level some associations may be true at the area level but not at the individual level. It is difficult to 
obtain data sources that allow for combining geographic and individual level data for the same unit of 
analysis, and multi-level investigations of the determinants of health care utilization are especially lacking in 
Latin America.  
 
Our study provides a methodological structure that can be replicated in other Latin American cities. Similar 
surveys of older adults have been performed in major Latin American metropolitan areas (Palloni, 2002) and 
health systems in the region share some characteristics, contributing to the comparability of the findings.  
 
We chose random effects models to control for the area level correlation. We could have used fixed effects 
models, but these might have allowed area membership (the effect of area) to be correlated to the other factors 
in the model.  
 
Other strategies have been proposed in order to divide geographical areas for studies of regional variation in 
health care. In the United States, hospital referral regions, hospital service areas and metropolitan statistical 
areas have been utilized in such research and have been shown to yield similar results. In Sao Paulo it makes 
sense to use sub-prefectures as the unit of analysis, as they correspond to administrative divisions involved in 
health care provision. In addition, data on health services and population characteristics is reported at the sub-






6.5 FINAL CONSIDERATIONS 
In some contexts the challenge is getting access to essential medicines. In others the problem is excessive or 
unsafe pharmaceutical use. Our study demonstrated that pharmaceutical use that is potentially excessive or 
unsafe is frequent among older adults in Sao Paulo. This should become a matter of public health concern. 
 
We empirically demonstrated that polypharmacy is associated with greater levels of risk among this population. 
Drug-related risk can negatively affect health. When that occurs, drug risks can increase the burden of disease 
independently from the health conditions that motivated the drug use in the first place. 
 
 Public health actions to reduce the occurrence of polypharmacy in general, and riskier drug choices in 
particular, would help prevent drug-related morbidity and mortality. The benefits would not only improve the 
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 Development (CNPq), Brazil 
 
PUBLICATIONS  
Journal Articles (peer-reviewed)  
• Lavoie M, Counts C, Fracica E, Socal MP, Anderson G. Options for Restoring Competition in the 
Generic Drug Industry. Article under review by Medical Care Research and Review journal. 
• Socal MP. Patient Narratives: A Tool for Patient-Centered Health Systems Education. Article 
under review by Health Education Research journal. 
• Socal MP, Trujillo AJ. Links Between Chronic Illness and Late-Life Cognition: Evidence From 
Four Latin American Countries. J Aging Health. 2016 Nov 10. pii: 0898264316674557.  
• Biehl J, Socal MP, Amon JJ. The Judicialization of Health and the Quest for State Accountability: 
Evidence from 1,262 Lawsuits for Access to Medicines in Southern Brazil. Health Hum Rights. 
2016 Jun;18(1):209-220. 
• Biehl J, Socal MP Amon JJ. The Challenging Nature of Gathering Evidence and Analyzing the 
Judicialization of Health in Brazil. Cad Saude Publica. 2016 Jun 1;32(6). 
• Fernandes GC, Socal MP, Schuh AF, Rieder CR. Clinical and Epidemiological Factors Associated 




• Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, Wu B, Xu F, Erro R, Amboni 
M, Pappatà S, Quarantelli M, Annesi G, Quattrone A, Chien HF, Barbosa ER; International 
Parkinsonism Genetics Network, Oostra BA, Barone P, Wang J, Bonifati V. Mutation in the 
SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat. 2013 
Sep;34(9):1208-15. 
• Biehl J, Amon JJ, Socal MP, Petryna A. Between the court and the clinic: lawsuits for medicines 
and the right to health in Brazil. Health Hum Rights. 2012 Jun 15;14(1):E36-52. 
• Siebert M, Donis KC, Socal M, Rieder CR, Emmel VE, Vairo F, Michelin-Tirelli K, França M Jr, 
D'Abreu AC, Bettencourt C, Lima M, Lopes Cendes I, Saraiva-Pereira ML, Jardim LB. 
Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/ spinocerebellar 
ataxia 3. Parkinsonism Relat Disord. 2012 Feb;18(2):185-90.  
• Socal, MP. Between Policy and Justice: The Brazilian National Policy on Pharmaceuticals. 
Journal of Public and International Affairs, Fall 2010: 150-158. 
• Socal MP, Emmel VE, Rieder CR, Hilbig A, Saraiva-Pereira ML, Jardim LB. Intrafamilial 
Variability of Parkinson Phenotype in SCAs: Novel Cases Due to SCA2 and SCA3 Expansions. 
Parkinsonism and Related Disorders. 2009; 15: 374–378. 
• Socal MP, Bock H, Michelin-Tirelli K, Hilbig A, Saraiva-Pereira ML, Rieder CR, Jardim LB. 
Parkinson's Disease and the Heterozygous State for Glucocerebrosidase Mutations Among 
Brazilians. Parkinsonism and Related Disorders. 2009; 15: 76e78 
• Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, 
Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, 
Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER; 
Italian Parkinson Genetics Network, Bonifati V. ATP13A2 Missense Mutations in Juvenile 
Parkinsonism and Young Onset Parkinson Disease. Neurology. 2007 May 8;68(19):1557-62. 
• Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, Picon PD. A Double-Blind, 
Randomized, Crossover Study of Prosigne Versus Botox in Patients With Blepharospasm and 
Hemifacial Spasm. Clinical Neuropharmacology. 2007 Jan-Feb;30(1):39-42. 
• Trott A, Jardim LB, Ludwig HT, Saute JA, Artigalás O, Kieling C, Wanderley HY, Rieder CR, 
Monte TL, Socal M, Alonso I, Ferro A, Carvalho T, do Céu Moreira M, Mendonça P, Ferreirinha 
F, Silveira I, Sequeiros J, Giugliani R, Saraiva-Pereira ML.Spinocerebellar Ataxias in 114 
Brazilian Families: Clinical and Molecular Findings. Clinical Genetics. 2006 Aug; 70(2): 173-6. 
• Kowacs F, Socal MP, Ziomkowski SC, Borges-Neto VF, Toniolo DP, Francesconi CR, Chaves 
ML. Symptoms of Depression and Anxiety, and Screening for Mental Disorders in Migrainous 
Patients. Cephalalgia. 2003 Mar;23(2):79-89. 
• Cunha GB, Rotta NT, Silva AR, Dieder AL, Wolf AL, Moser C, Silva FF, Socal MP, Silva PF, 
Margis R. Prevalence of prenatal exposure to cocaine in a sample of newborns from a university 
teaching hospital. J Pediatr (Rio J). 2001 Sep-Oct;77(5):369-73. [article in Portuguese]. 
• Kowacs F, Toniolo DP, Ziomkowski SC, Francesconi CRM,Chaves MLF. Migraine and 
Psychyatry Disorders. Revista de Psiquiatria do Rio Grande do Sul, 2001; 23(1): 19-36. [article in 
Portuguese]. 
Chapters 
• Socal MP, Rieder CRM, Monte TL, Krug BC, Amaral KM. Distonias focais e Espasmo Hemifacial 
(Focal Dystonia and Hemifacial Spasm) In: Protocolos Clínicos e Diretrizes Terapêuticas (Clinical 
Protocols and Therapeutic Guidelines), 2nd Ed. Paulo Dornelles Picon & Alberto Beltrame, Eds. 
Brasília, DF, Brazil: Ministério da Saúde, 2010. 
• Finkelsztejn A, Stefani MA, Cristovam RA, Moraes GS, Teixeira LB, Schneider SB, Socal MP, 
Finkelsztejn KRP, Nogueira L. Escalas em Neurologia (Scales in Neurology). In: Rotinas em 
Neurologia e Neurocirurgia (Routines in Neurology and Neurosurgery). Márcia Lorena Fagundes 







•  Constenla D, Mirelman A, Alvaro A, Chen A, Socal M. The economic value of vaccines and 
immunization programs in low- and middle-income countries: An annotated bibliography. 
International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. 
Baltimore, MD: August, 2012 
 
• Gregory A, Kawamoto R, Lopez J, Palmer D, Petkun A, Socal M, Wong A, Woods G, Yin J. 
Implications for the Utilization of Advanced Medical Imaging: Comparative Effectiveness 












M.D. Thesis – Universidade Luterana do Brasil [in Portuguese]  
2007 
• Jean Franco Rostellato Marin, MD 
Neurological side effects of cefepime - drug-induced encephalopathy (cohort study) 
2008 
• Tiago Hermes Maeso Montes, MD  
Effects of methylphenidate on the memory of Wistar rats (experimental study) 
• Fernando Godoy Neves, MD 
Comparison between different radiologic methods and macroscopic findings of ulcerations in carotid 
plaques (cross-sectional study) 
• Marta Ryff Moreira, MD  
Comorbidity between attention deficit-hyperactivity disorder and bipolar disorder (review) 
• Letícia Machado Rosa da Silva, MD 
Risk factors for late hospital arrival in patients with acute ischemic stroke (review) 
• Ana Caroline Gazolla, MD 
Socio-demographic factors and time-to-arrival in patients with acute stroke (cross-sectional study) 
2009 
• Fernando Muratore, MD 
 Cognitive scales used in the diagnosis of Alzheimer’s disease in the Brazilian population (review) 
• Eduardo Fialho Ruschel, MD 
 Economic aspects of early- versus late-onset Parkinson’s disease (review) 
• Aline Tagliari Kurtz, MD 
 Relationship between age of onset and predominant symptoms in Parkinson’s disease (review) 
 
General Internal Medicine Residency Capstone Project – Universidade Luterana do Brasil [in Portuguese] 
2009 
• Fabíola Madalozzo da Costa, MD 
• Vanice Ferraza Zaltron, MD 
 
Final Oral Exam Participation 
M.D. Thesis Examination Committee – Universidade Luterana do Brasil [in Portuguese] 
2007 
• Thais Pletsch Schaefer. Relationship between brain information processing (as measured by evoked 
potentials) and training in computer games 





• Rodrigo Meirelles Borba. Differential diagnosis of Headache. A review 
 
Classroom Instruction (Principal Instructor)  
2015  
Johns Hopkins University – Krieger School of Arts and Sciences 




Johns Hopkins University – Krieger School of Arts and Sciences 




Universidade Luterana do Brasil – School of Medicine [in Portuguese] 




Universidade Luterana do Brasil – School of Medicine [in Portuguese] 




Universidade Luterana do Brasil – School of Speech Therapy [in Portuguese] 
Introduction to Neurology 
Students: 20 
 
Other Significant Teaching 
2016 
Johns Hopkins Bloomberg School of Public Health 
223.667.11 Chronic Diseases in Low and Middle Income Countries: Prevalence and Epidemiology 
(The Summer Institute in Tropical Medicine and Public Health) 




Johns Hopkins Bloomberg School of Public Health 
223.667.11 Chronic Diseases in Low and Middle Income Countries: Prevalence and Epidemiology 
(The Summer Institute in Tropical Medicine and Public Health) 
Lecturer in the module of brain disorders 
Students: 12 
 
Teaching Assistantship  
Johns Hopkins Bloomberg School of Public Health 
2012-2013 
140.621.01 Statistical Methods in Public Health I (4 credits) 
140.622.01 Statistical Methods in Public Health II (4 credits) 
221.647.01 Comparative Evaluation for Health Policy in International Health (3 credits) 
221.652.01 Health Financing in Low and Middle Income Countries (3 credits) 
313.632.01 Economic Evaluation III (3 credits) 
221.617.01 Behavioral Economics in Health Decisions (2 credits) 
2013-2014 
 551.607.01 Pharmaceuticals Management for Under-Served Populations (3 credits) 
 221.617.01 Behavioral Economics in Health Decisions (2 credits) 
2014-2015 
 380.756.01 Poverty, Economic Development, and Health (4 credits) 





 300.610.01 Public Health Policy (4 credits) 
 309.670.01 Comparative Health Insurance (3 credits) 
 313.793.11 Extended Exercises in Cost Effectiveness (2 credits) 
 
 
RESEARCH GRANT PARTICIPATION 
2011-2016 
NIH Grant P30 AG024361 
Princeton Center for the Demography of Aging 
An exploratory study of the occurrence of pharmaceutical-induced aging symptoms in the United States 
and in Brazil 
Principal Investigator: Joao Biehl, Princeton University 
Level of funding: US$70,000 
Responsibilities: Co-principal investigator 
 
ACADEMIC SERVICE 
Division and/or Department  
2014-2015 International Health Departmental representative, JHSPH Student Assembly 
School 
 2013-2016  Founder and President, Chronic Diseases & Aging Initiative, JHSPH Student Group 
 2016-2016  Student Representative, JHSPH Ethics Board       
2014-2015 Member, Quality of Life Committee, JHSPH Student Assembly   
       
University 
2016-present Steering Committee, Princeton University Graduate Alumni Giving  
  
2012-present  Volunteer, Princeton University Graduate Alumni Giving   
 2015-2016 Mentor, JHU Public Health Connection Program 




International Scientific Meetings  
2016 
Socal MP, Anderson G. “Health Systems Determinants of Pharmaceutical Use among Brazilian 
Eldery”. 4th Global Symposium on Health Systems Research. (Vancouver, Canada) Nov 14-18 2016 
(poster) 
2015 
 Socal MP, Trujillo A. " Chronic Illness and Late-Life Cognitive Decline". Research on Aging 
Showcase. Johns Hopkins Center on Aging and Health. (Baltimore, USA) May 15 2015 (poster) 
2013 
 Socal MP. “Access and Utilization of Medicines: The Role of Health Technology Assessment from a 
Health Systems Perspective” Pharmacogenomics: From Molecules to Medicine. (Engelberg, 
Switzerland) July 09-13 2013 (oral presentation) 
2012 
Socal MP, Uribe MV, Rao KD. “Serving all and serving well? The Brazilian universal healthcare 
system and the challenge of the equitable allocation of healthcare resources”. 2nd Global Symposium 
on Health Systems Research. (Beijing, China) 31 Oct- 3 Nov 2012 (oral presentation) 
 
Socal, MP. “Measuring The Gap Between Demand And Access To Medicines In The Brazilian Public 
Healthcare System". 9th HTAi Health Technology Assessment International Annual Meeting 2012. 
HTA in Integrated Care for a Patient-Centered System. (Bilbao, Spain) (oral presentation) 
 
Socal, MP. “Estimating Access To Health Services In Brazil Through A Market Frontier Analysis”.  
9th HTAi Health Technology Assessment International Annual Meeting 2012. HTA in Integrated Care 






Picon PD, Gonzalez RS, Picon RV, Terra CD, Gertner A, Barbosa J, Socal M, Gonçalvez J, Petryna A, 
Biehl J. “Court decisions and pharmaceutical policy in Brazil: Odds for the patients and for the state”. 
7th HTAi - Health Technology Assessment International 2010 (Dublin, Ireland) (poster) 
 
Picon PD, Gonzalez RS, Picon RV, Terra CD, Gertner A, Barbosa J, Socal M, Jardim PM, Petryna A, 
Biehl J. “The impact of plaintiff economic status on access to the legal system: Suing the state of 
medicines in Rio Grande do Sul, Brazil.” 7th HTAi - Health Technology Assessment International 
2010 (Dublin, Ireland) (poster) 
2009 
 An analysis of claims of irreparable harm in lawsuits for access to medicines in the state of Rio Grande 
do Sul, Brazil. 6th HTAi—Health Technology Assessment International 2009 (Singapore, Singapore) 
(poster) 
 
Demanding Treatment Access through Regular Administrative Pathways and through Lawsuits in 
Brazil. 6th HTAi—Health Technology Assessment International 2009 (Singapore, Singapore) (poster) 
 
Claiming the Right to Medicines in Brazil through Public and Private Doctors and Lawyers: A Pilot 
Study. 6th HTAi—Health Technology Assessment International 2009 (Singapore, Singapore) (poster) 
2008 
Peer-review of Medical Prescription of Pramipexole in the Public Health System in the South of Brazil: 
Evidence of an Irrational Use of Dopaminergic Agonists for Parkinson´s Disease. 5th HTAi—Health 
Technology Assessment International 2008 (Montréal, Canada) (poster) 
 
Progressive Multifocal Leuko-Enchephalopathy Induced by Monoclonal Antibodies—A Systematic 
Review of Literature: Preliminary Data. 5th HTAi—Health Technology Assessment International 2008 
(Montréal, Canada) (poster) 
2007  
Implementation of Brazilian Guidelines for Botulinum Toxin: A Three-Year Follow-up of a Cost-
reduction Strategy in the Public Health System of Rio Grande do Sul, Brazil. 4th HTAi - Health 
Technology Assessment International 2007 (Barcelona, Spain) (oral presentation) 
2000 
Cunha GB, Silva AR, Dieder AL, Wolf AL, Zambrano C, Silva FF, Pretto I, Oliveira J, Silva PF, Socal 
MP, Margis R, Weissheimer R, Rotta NT. Prevalence of Cocaine Prenatal Exposure Detected as 
Benzoilecgonine in Newborns VIII Congreso Anual de la Academia Iberoamericana de Neurología 
Pediátrica. (Spain) – abstract available in: Comunicaciones Revista de Neurologia, Espanha, v. 31, n. 3, 
p. 228-228, 2000. 
 
Invited Lectures and Seminars 
Johns Hopkins University 
2017 
 Course: 309.670.01 Comparative Health Insurance. Main instructor: Gerard Anderson 
 Lectures: Revenue Collection  
 Universal Coverage in Low and Middle Income Countries 
  
2016  
 Course: 309.670.01 Comparative Health Insurance. Main instructor: Gerard Anderson 
Lecture: Universal Coverage in Low and Middle Income Countries  
2015  
 Course: 309.670.01 Comparative Health Insurance. Main instructor: Gerard Anderson 
Lecture: Universal Coverage in Low and Middle Income Countries 
 
Course: 313.793.11 Extended Exercises in Cost Effectiveness (Summer Institute on Health Policy and 
Management). Main instructor: Greg De Lissovoy. 
Lectures: Framing the study; patient population; comparators; outcomes; decision tree   
Model parameters: clinical events. Data sources. Calculating event probabilities 
Measures of “effect”: natural units 






Course: Brasilia Without Borders Executive Program in Public Leadership. Main instructor: Carlos 
Castillo  
Lecture: Between Policy and Justice: Access to Medicines in Brazil 
  
Other [in Portuguese]  
2015 
Lecture: Socioeconomic Information in Parkinson's disease: How and why to Analyze.   
Scientific Meeting of Movement Disorders Researchers. Hospital de Clínicas de Porto Alegre, Brazil.  
2008  
 Lecture: Genetics of Parkinson’s disease in the south of Brazil.  
 Scientific Meeting of the Department of Medical Genetics. Hospital de Clínicas de Porto Alegre, Brazil  
 
Lecture: Neuropharmacology. 
Graduate Studies program. Hospital Moinhos de Vento, Brazil. 
 
 Lecture: Evaluation of Syncope 
 Continued Medical Education Program, Universidade Luterana do Brasil 
2007  
Lecture: Frequency of genetic Parkinsonism in Rio Grande do Sul 
 Brazilian Congress of Brain, Behaviour and Emotions. Bento Gonçalves, RS, Brazil 
 
 Lecture: Pharmacoeconomic analysis of Multiple Sclerosis treatments 
 Brazilian Congress of Brain, Behaviour and Emotions. Bento Gonçalves, RS, Brazil 
 
Lecture: Tremor and Parkinsonism.  
Clinicasul, Regional Congress of Internal Medicine, Bento Gonçalves, RS, Brazil 
 
Lecture: Medication-induced Movement Disorders 
Scientific Meeting, Department of Neurology, Hospital de Clínicas de Porto Alegre, Brazil. 
 
 Lecture: Tremor – differential diagnosis and treatment   
 Scientific Week. Universidade de Passo Fundo, Brazil. 
2006  
 Lecture: Headache 
 Continuing Medical Education Program, Universidade Luterana do Brasil 
 
ADDITIONAL INFORMATION 
Personal statement of research and practice goals, objectives and impact 
Affordable, sustainable and qualified access to medicines is a challenge to countries worldwide, especially as 
their populations get older and chronic diseases become more prevalent. The appropriate use of medicines, an 
issue that cuts across all areas of medicine and medical care, is of great public health relevance globally. This is 
also an emerging issue in developing countries, which currently compose almost half of the world's 
pharmaceutical markets. I am committed to researching ways to safeguard sustainable, affordable, and 
appropriate access to pharmaceutical treatments for aging and chronically ill populations around the world. 
 
Keywords 
Pharmaceutical policy, access to medicines, drug pricing, drug safety, treatment appropriateness, health 
systems, health insurance, chronic diseases, low- and middle-income countries. 
 
